Treatment of periodontal disease for glycaemic control in people with diabetes mellitus (Review)

Simpson TC, Weldon JC, Worthington HV, Needleman I, Wild SH, Moles DR, Stevenson B, Furness S, Iheozor-Ejiofor Z

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 11

http://www.thecochranelibrary.com

WILEY
## Table of Contents

 HEADER ................................................. 1  
 ABSTRACT .............................................. 1  
 PLAIN LANGUAGE SUMMARY ............................ 3  
 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON .................. 4  
 BACKGROUND ............................................ 6  
 OBJECTIVES ........................................... 7  
 METHODS .............................................. 7  
 RESULTS ............................................... 11  
   Figure 1. ........................................... 12  
   Figure 2. ........................................... 18  
   Figure 3. ........................................... 19  
   Figure 4. ........................................... 21  
   Figure 5. ........................................... 23  
 ADDITIONAL SUMMARY OF FINDINGS ....................... 24  
 DISCUSSION ........................................... 27  
 AUTHORS’ CONCLUSIONS ................................ 29  
 ACKNOWLEDGEMENTS .................................. 30  
 REFERENCES ........................................... 31  
 CHARACTERISTICS OF STUDIES ......................... 37  
 DATA AND ANALYSES .................................. 122  
   Analysis 1.1. Comparison 1 Periodontal therapy versus no active intervention/usual care, Outcome 1 HbA1c at 3-4 months. ..................... 123  
   Analysis 1.2. Comparison 1 Periodontal therapy versus no active intervention/usual care, Outcome 2 HbA1c at 6 months. ...................... 124  
   Analysis 2.1. Comparison 2 Periodontal therapy versus alternative periodontal therapy, Outcome 1 HbA1c at 3-4 months. ..................... 125  
   Analysis 2.2. Comparison 2 Periodontal therapy versus alternative periodontal therapy, Outcome 2 HbA1c at 6 months. ...................... 127  
 ADDITIONAL TABLES ................................ 127  
 APPENDICES ......................................... 145  
 WHAT’S NEW ........................................... 150  
 CONTRIBUTIONS OF AUTHORS ........................ 150  
 DECLARATIONS OF INTEREST .......................... 151  
 SOURCES OF SUPPORT ................................. 151  
 DIFFERENCES BETWEEN PROTOCOL AND REVIEW .............. 152  
 INDEX TERMS ......................................... 152
Treatment of periodontal disease for glycaemic control in people with diabetes mellitus

Terry C Simpson¹, Jo C Weldon², Helen V Worthington², Ian Needleman³, Sarah H Wild⁴, David R Moles⁵, Brian Stevenson⁶, Susan Furness², Zipporah Iheozor-Ejiofor²

¹Edinburgh Dental Institute, University of Edinburgh, Edinburgh, UK. ²Cochrane Oral Health Group, School of Dentistry, The University of Manchester, Manchester, UK. ³Unit of Periodontology and International Centre for Evidence-Based Oral Healthcare, UCL Eastman Dental Institute, London, UK. ⁴Centre for Public Health and Primary Care Research, Public Health Sciences, University of Edinburgh, Edinburgh, UK. ⁵Oral Health Services Research, Peninsula Dental School, Plymouth, UK. ⁶Department of Restorative Dentistry, University of Dundee Dental Hospital and School, Dundee, UK

Contact address: Jo C Weldon, Cochrane Oral Health Group, School of Dentistry, The University of Manchester, JR Moore Building, Oxford Road, Manchester, M13 9PL, UK. jo.weldon@manchester.ac.uk.

Editorial group: Cochrane Oral Health Group.

Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 11, 2015.

Review content assessed as up-to-date: 31 December 2014.


Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Glycaemic control is a key issue in the care of people with diabetes mellitus (DM). Periodontal disease is the inflammation and destruction of the underlying supporting tissues of the teeth. Some studies have suggested a bidirectional relationship between glycaemic control and periodontal disease. This review updates the previous version published in 2010.

Objectives

The objective is to investigate the effect of periodontal therapy on glycaemic control in people with diabetes mellitus.

Search methods

We searched the following electronic databases: the Cochrane Oral Health Group Trials Register (to 31 December 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library 2014, Issue 11), MEDLINE via OVID (1946 to 31 December 2014), EMBASE via OVID (1980 to 31 December 2014), LILACS via BIREME (1982 to 31 December 2014), and CINAHL via EBSCO (1937 to 31 December 2014). ZETOC (1993 to 31 December 2014) and Web of Knowledge (1990 to 31 December 2014) were searched for conference proceedings. Additionally, two periodontology journals were handsearched for completeness, Annals of Periodontology (1996 to 2003) and Periodontology 2000 (1993 to 2003). We searched the US National Institutes of Health Trials Registry (http://clinicaltrials.gov) and the WHO Clinical Trials Registry Platform for ongoing trials. No restrictions were placed on the language or date of publication when searching the electronic databases.

Selection criteria

We searched for randomised controlled trials (RCTs) of people with type 1 or type 2 DM (T1DM/T2DM) with a diagnosis of periodontitis. Interventions included periodontal treatments such as mechanical debridement, surgical treatment and antimicrobial therapy. Two broad comparisons were proposed:
1. periodontal therapy versus no active intervention/usual care;
2. periodontal therapy versus alternative periodontal therapy.

Data collection and analysis

For this review update, at least two review authors independently examined the titles and abstracts retrieved by the search, selected the included trials, extracted data from included trials and assessed included trials for risk of bias.

Our primary outcome was blood glucose levels measured as glycated (glycosylated) haemoglobin assay (HbA1c).

Our secondary outcomes included adverse effects, periodontal indices (bleeding on probing (BOP), clinical attachment level (CAL), gingival index (GI), plaque index (PI) and probing pocket depth (PPD)), cost implications and diabetic complications.

Main results

We included 35 studies (including seven from the previous version of the review), which included 2565 participants in total. All studies used a parallel RCT design, and 33 studies (94%) only targeted T2DM patients. There was variation between studies with regards to included age groups (ages 18 to 80), duration of follow-up (3 to 12 months), use of antidiabetic therapy, and included participants’ baseline HbA1c levels (from 5.5% to 13.1%).

We assessed 29 studies (83%) as being at high risk of bias, two studies (6%) as being at low risk of bias, and four studies (11%) as unclear. Thirty-four of the studies provided data suitable for analysis under one or both of the two comparisons.

Comparison 1: low quality evidence from 14 studies (1499 participants) comparing periodontal therapy with no active intervention/usual care demonstrated that mean HbA1c was 0.29% lower (95% confidence interval (CI) 0.48% to 0.10% lower) 3 to 4 months post-treatment, and 0.02% lower after 6 months (five studies, 826 participants; 95% CI 0.20% lower to 0.16% higher).

Comparison 2: 21 studies (920 participants) compared different periodontal therapies with each other. There was only very low quality evidence for the multiple head-to-head comparisons, the majority of which were unsuitable to be pooled, and provided no clear evidence of a benefit for one periodontal intervention over another. We were able to pool the specific comparison between scaling and root planing (SRP) plus antimicrobial versus SRP and there was no consistent evidence that the addition of antimicrobials to SRP was of any benefit to delivering SRP alone (mean HbA1c 0.00% lower: 12 studies, 450 participants; 95% CI 0.22% lower to 0.22% higher) at 3-4 months post-treatment, or after 6 months (mean HbA1c 0.04% lower: five studies, 206 patients; 95% CI 0.41% lower to 0.32% higher).

Less than half of the studies measured adverse effects. The evidence was insufficient to conclude whether any of the treatments were associated with harm. No other patient-reported outcomes (e.g. quality of life) were measured by the included studies, and neither were cost implications or diabetic complications.

Studies showed varying degrees of success with regards to achieving periodontal health, with some showing high levels of residual inflammation following treatment. Statistically significant improvements were shown for all periodontal indices (BOP; CAL, GI, PI and PPD) at 3-4 and 6 months in comparison 1; however, this was less clear for individual comparisons within the broad category of comparison 2.

Authors’ conclusions

There is low quality evidence that the treatment of periodontal disease by SRP does improve glycaemic control in people with diabetes, with a mean percentage reduction in HbA1c of 0.29% at 3-4 months; however, there is insufficient evidence to demonstrate that this is maintained after 4 months.

There was no evidence to support that one periodontal therapy was more effective than another in improving glycaemic control in people with diabetes mellitus.

In clinical practice, ongoing professional periodontal treatment will be required to maintain clinical improvements beyond 6 months. Further research is required to determine whether adjunctive drug therapies should be used with periodontal treatment. Future RCTs should evaluate this, provide longer follow-up periods, and consider the inclusion of a third ‘no treatment’ control arm.

Larger, well conducted and clearly reported studies are needed in order to understand the potential of periodontal treatment to improve glycaemic control among people with diabetes mellitus. In addition, it will be important in future studies that the intervention is effective in reducing periodontal inflammation and maintaining it at lowered levels throughout the period of observation.
Does treatment for gum disease help people with diabetes control blood sugar levels?

Review question

The main question addressed by this review is: how effective is gum disease treatment for controlling blood sugar levels (known as glycaemic control) in people with diabetes, compared to no active treatment or usual care?

Background

Gum disease treatment is used to reduce swelling and infection from gum disease. Keeping blood sugar levels under control is a key issue for people with diabetes, and some clinical research suggests a relationship exists between gum disease treatment and glycaemic control. As a result, it is important to discover if gum disease treatment does improve glycaemic control to encourage better use of clinical resources.

There is a broad range of gum disease treatments available for treating patients with diabetes. This review considered two types.

1. Does gum disease treatment improve blood sugar control in people with diabetes?
2. Does one type of gum disease treatment have a bigger effect than another in improving blood sugar control?

Study characteristics

This review of existing clinical trials was carried out by authors working with the Cochrane Oral Health Group and updates the previous version published in 2010. The evidence is current up to 31 December 2014.

In this review there are 35 trials (including 2565 participants), published between 1997 and 2014, where people randomly received a type of gum disease treatment (including scaling and root planing (SRP) and SRP combined with other types of treatment), or usual care/no active treatment.

The trials included in this review used SRP with, or without, an additional treatment. Additional treatments included instructions for cleaning teeth properly (known as oral hygiene instruction (OHI)), and other gum treatments (for example, antimicrobials, which are used to treat infections).

Key results

We found 35 trials that were suitable for inclusion in this review. Thirty-four of those studies provided results that could be included in at least one of the two comparisons.

1. The evidence from 14 trials (1499 participants) showed that SRP reduces blood sugar levels in diabetic patients by 0.29% up to 4 months after receiving care when compared with usual care/no active treatment. After 6 months, there was no evidence that this reduction was sustained.
2. The evidence from 21 trials (920 participants) investigating different types of gum disease treatments failed to show that one treatment was better than another.

There were not enough studies measuring side effects to be able to show if gum disease treatments cause any harm.

Quality of the evidence

Currently there is low quality evidence to support using scaling and root planing for controlling blood sugar levels up to 4 months after receiving treatment. Ongoing gum disease treatment is advised to maintain improvements in blood sugar levels.
## Summary of Findings for the Main Comparison

### Periodontal therapy versus no active intervention/usual care for glycaemic control in people with diabetes mellitus

**Patient or population:** Patients with diabetes mellitus  
**Settings:** Hospital, primary care, community  
**Intervention:** Periodontal therapy  
**Comparison:** Usual care/no active treatment

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Number of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assumed risk</td>
<td>Corresponding risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Usual care/no active treatment</td>
<td>Periodontal therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c Follow-up: 3-4 months</td>
<td>The weighted mean HbA1c at 3-4 months follow-up was 8.07%</td>
<td>Mean HbA1c in the periodontal therapy group was <strong>0.29% lower</strong> (0.48% to 0.10% lower)</td>
<td>1499 (14 studies)</td>
<td>⊕⊕⊕⊕ low¹,² The weighted mean HbA1c at 6 months follow-up in the usual care/no active treatment group was 7.58% The mean effect on HbA1c at 6 months follow-up (826 participants in 5 studies) was 0.02% lower (0.20% lower to 0.16% higher) in the periodontal therapy group</td>
</tr>
</tbody>
</table>

**Adverse effects**  
Insufficient evidence to determine whether SRP for glycaemic control is associated with any harms

---

*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  
CI: confidence interval; SRP: scaling and root planing.*
## GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect  
**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate  
**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate  
**Very low quality:** We are very uncertain about the estimate

---

1. High risk of bias, largely due to lack of blinding: quality of evidence downgraded once  
2. Moderate heterogeneity ($I^2 = 53\%$): quality of evidence downgraded once
BACKGROUND

Description of the condition

Diabetes mellitus (DM) is a chronic disease of the metabolism that is caused by the body's failure either to produce the hormone insulin or to effectively use its production of insulin. Insulin is a hormone produced by the pancreas that enables the body to direct glucose from the bloodstream to cells for energy. Without this vital hormone, glucose accumulates in the bloodstream and can result in disabling and life-threatening complications.

In 2014, the global prevalence of DM was estimated to be 8.3% among adults over 18 years old (WHO 2015). Estimates produced by the International Diabetes Federation suggest that 387 million people worldwide were affected in 2014, a number that is expected to grow to 592 million by 2035 (International Diabetes Federation 2013). In 2011, under the leadership of the World Health Organization, governments agreed a global action plan for the prevention and control of non-communicable diseases, with a target of reducing global premature deaths in the 30- to 70-year-old age group by 25% by 2025 as part of its overall strategy (WHO 2013; WHO 2014).

Glycaemic control is a key issue in the care of people with DM. Prolonged hyperglycaemia is associated with complications such as retinopathy, peripheral neuropathy, macrovascular disease (coronary heart and cerebrovascular disease), foot disease (arising from a combination of vascular and neuropathic disease) and renal failure. The United Kingdom Prospective Diabetes Study (UKPDS) and the Diabetes Control and Complications trial in the USA have demonstrated that intensive treatment of hyperglycaemia can reduce the risk of long-term complications (DCCT 1993; Stratton 2000; UKPDS 1998). Each 1% reduction in the haemoglobin A1c (HbA1c) in the UKPDS was associated with a relative risk reduction of 21% for any diabetes-related endpoint, 21% for diabetes-related deaths, 14% for myocardial infarction and 37% for microvascular complications (Stratton 2000). As part of this process, blood glucose levels may be monitored daily by the patient but also by regular haematological tests in a clinical laboratory. The HbA1c level is commonly measured to assess blood glucose levels over a period of approximately 6 to 8 weeks preceding the test and is recognised as a good indicator of glycaemic control, particularly as higher HbA1c levels are associated with an increased risk of diabetes-related complications (Bunn 1981).

Poorly controlled diabetes is also a well-recognised risk factor for developing periodontal disease (Papapanou 1996; Preshaw 2012; Seppälä 1993). There is epidemiological evidence that people with both type 1 diabetes mellitus (T1DM) and type 2 (T2DM) experience more periodontal disease, and periodontal disease of greater severity, than the general population (Firlati 1997; Sandberg 2000).

Periodontitis is defined as inflammation and destruction of the underlying supporting tissues of the teeth (the periodontium). In susceptible patients whose oral hygiene is suboptimal, a microbial biofilm (bacteria and extracellular substances) can form around the gum margin and result in inflammation and destruction of the periodontium. This complex, chronic disease requires lifelong control of the causative factors (Kornman 2014). Reduced peridontal support can lead to mobility (or drifting) of teeth, and ultimately tooth loss; this in turn may require additional treatment to restore lost function and appearance. Chronic inflammation of the periodontium may also lead to systemic inflammation more distantly.

The condition is categorised as aggressive or chronic (Armitage 1999). There is no subclass specific to DM, as it is recognised that diabetes may modify all forms of periodontal disease (Milward 2003). Disease severity is graded by measurement of clinical attachment levels (clinical attachment loss, pocket depth, or both if available). It has been estimated that the total surface area of inflamed and ulcerated epithelium of the periodontal tissues in an individual with periodontitis is at least equivalent to the surface area of the palm of the hand (Page 1998).

Observational studies have demonstrated that associations exist between socioeconomic status (SES: broadly includes ethnicity, income, social class, and education) variables and periodontal disease progression (low education and low income: Buchwald 2013), and SES (low income) and DM prevalence (Rabi 2006). Consequently, SES may confound observational studies of the association between DM and periodontal disease; however, adequate randomisation in trials of periodontal treatment will avoid such confounding.

In previous years, evidence has been published suggesting a bidirectional relationship between glycaemic levels and periodontal disease (Grossi 1998; Stewart 2001; Taylor 2001). In other words, the chronic inflammation and infection that results from periodontal disease could also have an adverse effect on glycaemic control in people with diabetes, which, in turn, could lead to worsening gum disease. Authoritative studies on DM such as DCCT 1993; Stratton 2000 and UKPDS 1998 did not collect data on periodontal disease or oral health in general.

Description of the intervention

Periodontal treatment includes a number of components of care. In many cases, oral hygiene instruction will be used to educate and motivate people to control for themselves the accumulation of causative factors, dental plaque, and bacterial biofilm. In addition, mechanical debridement (different forms of scaling, using conventional hand- or powered-instruments or both) by a dentist or hygienist is often required to remove both plaque and plaque deposits that have mineralised and hardened (calculus). These deposits can form both above and below the gingival margin. With more advanced forms of disease, surgery can be needed to lift the gingival tissues away from the tooth, facilitating access to clean away the deposits when located below the gum line. Some
of these measures require several visits. Antimicrobials (inclusive of antiseptics, antibacterials and antibiotics) have also been used as adjuncts to scaling, although without evidence of a clear benefit (Bonito 2004).

**How the intervention might work**

Any improvement in glycaemic control resulting from regular and appropriate periodontal treatment has the potential to make a significant impact on the development of diabetic complications and on quality of life for people with diabetes. We would have included evidence of cost implications of treatment if these had been available from the studies. This review aims to investigate the influence of periodontal treatment upon glycaemic control.

**Why it is important to do this review**

The Cochrane Oral Health Group undertook an extensive prioritisation exercise in 2014 to identify a core portfolio of the most clinically important titles to maintain on the Cochrane Library. This review was identified as a clinically important priority title by the periodontology expert panel (Cochrane OHG priority review portfolio). This is an update of the Cochrane review first published in 2010 (Simpson 2010).

The cost to governmental health budgets of managing people with diabetes is substantial. The global cost of diabetes care has been estimated to be USD 612 billion (International Diabetes Federation 2013). The spending on diabetes-related disease has been found to be positively associated with the gross domestic product of countries (Seuring 2015). The economic burden on the UK was estimated to be approximately GBP 9.8 billion in 2010/11 or 10% of the National Health Service (NHS) budget, with GBP 8.8 billion of this amount relating to treatment for people with T2DM, and a further projected rise to 17% of health service resources by 2035/2036 (Hex 2012). If there is a direct benefit of periodontal therapy on glycaemic control, the implications may be profound.

- Periodontal disease, which is prevalent in most populations, could be an additional confounder in studies of the effect of glycaemic control.
- Readily available treatments by dentists and auxiliary workers could have a marked effect in improving glycaemic control among people with diabetes.

**OBJECTIVES**

The objective is to investigate the effect of periodontal therapy on glycaemic control in people with diabetes mellitus.

**METHODS**

Criteria for considering studies for this review

**Types of studies**

Randomised controlled trials (RCTs) were eligible for inclusion. We excluded trials if the participants were followed up for less than 90 days after completion of the treatment course. We excluded split-mouth and cross-over studies, due to the anticipated influence of carry-over effects from treatment.

**Types of participants**

We included studies of people with diabetes mellitus and periodontal disease who were at least 16 years of age. We analysed participants as having a diagnosis of type 1 diabetes mellitus (T1DM) if, at the beginning of the study, the individual’s disease classification was juvenile-onset diabetes, type 1 or insulin-dependent DM (IDDM). If an individual was described as having adult-onset, type II or non-insulin dependent DM (NIDDM), we analysed the data as for that of a participant with type 2 diabetes mellitus (T2DM).

For periodontitis, we accepted trialist statements that participants were selected on the basis of a diagnosis of chronic or adult periodontitis and we would have investigated the effect of adequacy of diagnosis on the outcomes if sufficient data had been available. We included studies regardless of the general medical health of the participants. No restriction was placed on setting - primary care, hospital or community were all considered. We would have excluded studies if more than 10% of the study sample had been diagnosed with gestational diabetes (diabetes associated with pregnancy). We did not include studies where participants were described as having metabolic syndrome.

**Types of interventions**

Periodontal treatments (any professionally-delivered intervention designed to reduce periodontal disease) should have included one or more of the following:

- mechanical debridement (also called non-surgical periodontal treatment) - scaling, root planing, subgingival curettage;
- surgical periodontal treatment - flap surgery or gingivectomy;
- antimicrobial therapy (encompassing antibacterials and antibiotics), either locally applied (including mouthrinses, gels or dentifrices) or systemically administered;
- other drug therapy with a possible benefit of improving the periodontal condition of the participant;
- other novel interventions to manage periodontal disease.
Periodontal treatments may also have included either of the following adjuncts as part of ‘usual’ care:
- oral hygiene instruction;
- education or support sessions to improve self help or self awareness of oral hygiene.

Interventions were compared with no treatment, ‘usual care’ (for example, supragingival prophylaxis, standalone oral hygiene instruction) or placebo.

Trials that made direct comparisons between different types of periodontal treatment were also included (eg adjunctive drug therapies (including multiple versus single), rapid versus standard delivery methods etc) to identify whether providing enhanced forms of periodontal treatment is of additional benefit for improving glycaemic control.

RCTs comparing surgical against non-surgical periodontal treatment would also have been included within this review if any had been found.

Types of outcome measures

A number of different blood indices have been identified as indicators of blood glucose levels and therefore, possible prognostic markers. The glycated (glycosylated) haemoglobin assay (HbA1c) gained widespread acceptance during the 1980s as the laboratory test of choice and is still widely used. HbA1c has been measured and used as an outcome since the early 1980s. The glycated haemoglobin assay (HbA1c) is a measure of the percentage of red blood cells that contain at least one haemoglobin molecule that has been glycated by glucose over the past 8 to 12 weeks. It is considered to be a more reliable measure of long-term glycaemic control than other methods, such as fasting plasma glucose, because it is less affected by short-term fluctuations in blood glucose levels. HbA1c values were implemented globally after achieving consensus on appropriate Chemistry (IFCC) standard tests (their respective standard applications)

Treatment of periodontal disease for glycaemic control in people with diabetes mellitus (Review)

Primary outcomes

- The absolute percentage change from baseline in HbA1c - from pre-treatment for periodontal condition to at least 90 days post-treatment.

The minimum of 3-month follow-up duration, for including studies in this review, is clinically justified due to human red blood cells ordinarily having a lifespan of between 8 to 12 weeks (Franco 2012).

We excluded trials that did not measure HbA1c as an outcome (ie where HbA1c is not reported in the trial report or these data are not available from the trial authors).

Secondary outcomes

- Changes in periodontal attachment level.
- Gingival indices (inflammation or bleeding or both).
- PLAQUE indices.
- Any adverse effects of treatment.
- Quality of life indicators (eg hospital anxiety and depression scale (HADS), health-related quality of life (HRQoL)).
- Cost implications.
- Diabetic complications.

Search methods for identification of studies

Electronic searches

For the identification of studies for this review, we developed detailed search strategies for each database searched. These were based on the search strategy developed for MEDLINE but revised appropriately for each database to take account of differences in controlled vocabulary and syntax rules. The MEDLINE search strategy was linked with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials (RCTs) in MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) (Higgins 2011). The searches of EMBASE and CINAHL were linked to the Cochrane Oral Health Group filters for identifying RCTs, and the search of LILACS was linked to the Brazilian Cochrane Center filter.

We searched the following databases:
- the Cochrane Oral Health Group Trials Register (to 31 December 2014);
- Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library 2014, Issue 11);
- MEDLINE via OVID (1946 to 31 December 2014);
- EMBASE via OVID (1980 to 31 December 2014);
- CINAHL via EBSCO (1937 to 31 December 2014);
- LILACS via BIREME Virtual Health Library (1982 to 31 December 2014);
- CINAHL via EBSCO (1980 to 31 December 2014).

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
- ISI Web of Knowledge (conference proceedings) (1990 to 31 December 2014);

See Appendix 1 for details of all search strategies.

Searching other resources

We searched the following databases for ongoing trials:
- US National Institutes of Health Trials Registry (http://clinicaltrials.gov) (to 31 December 2014);
- WHO Clinical Trials Registry Platform (http://apps.who.int/trialsearch/default.aspx) (to 31 December 2014).

No restrictions were placed on the language of publication when searching the electronic databases, or reviewing reference lists in identified studies or reviews. We attempted to contact known authorities, as identified by the Cochrane Oral Health Group, in the following languages for information about publications, which might contain relevant trials: Japanese, Chinese, German, French and Spanish. In addition to this, any papers we identified by any of the database searches that were in a language other than English were translated and considered for inclusion.

We contacted authors of relevant studies for clarification regarding their own studies and for information regarding other studies of which they are aware.

Handsearching

The review authors handsearched the following journals:
- Annals of Periodontology (1996 to 2003);

We did not handsearch any medical or specialist journals relating to diabetes.

We scrutinised known papers previously published on the topic for potentially relevant references.

Data collection and analysis

Selection of studies

Two review authors screened all titles (and abstracts if available) in duplicate. We rejected only clearly irrelevant records at this stage. We retrieved and examined the full text of potentially relevant studies. Four teams of two review authors independently extracted data in duplicate. Where authors disagreed on studies for inclusion, another review author acted as arbiter. The review authors were not blinded to the authors of the studies, as this has been shown to be of dubious value, but adds a significant amount of time to completion of the process (Berlin 1997).

We maintained a detailed log of study eligibility and reasons for exclusion.

Data extraction and management

We collected data on a pre-determined and piloted form. The following characteristics of each study were recorded on the data extraction form.

- General characteristics - year of study, language of original publication, country of origin, funding.
- Trial design - sample size, method of allocation, blinding and comparative group characteristics.
- Population studied - ethnic groups, setting, social class, whether T1DM or T2DM (or both), duration of diabetes, duration of diabetic control*, other stated medical conditions, type of periodontal disease (gingivitis only, chronic/adult periodontitis, aggressive/early-onset periodontitis), smoking habits, alcohol consumption, drug therapy.
- Nature of the intervention - oral hygiene, self administered measures, type of periodontal therapy and antimicrobial/antiseptics employed, compliance.
- Primary outcomes - HbA1c at baseline, during therapy and post-therapy (and where available: test method; reference values; corresponding DCCT/IFCC standards).
- Secondary outcomes - changes in clinical attachment level (CAL), probing pocket depth (PPD), bleeding on probing (BOP), gingival index (GI) and plaque index (PI). Also diabetic complications and changes in antidiabetic therapy.

*It would be of interest to be able to narratively report the proportion of the population whose diabetes control was considered to be well controlled over a longer period of time, to provide context to the findings of this review, which is based on singular HbA1c measures (at follow-up time points).

Two review authors independently extracted numerical data into data tables and Review Manager (RevMan) software (RevMan 2014). A third review author verified the data inputted into RevMan.

Diagnostic assessment

This was assessed as:
- Diabetes mellitus diagnosis: criteria for diagnosis clearly defined (and consistent with relevant classification in use during study conduct period): adequate, inadequate, unclear.
  - Adequate: prior T1DM/T2DM diagnosis (determined by either description of clinical diagnosis in publication or information from study authors).
  - Inadequate: participants self report/identify as diabetic without clinical confirmation.
  - Unclear: no information provided about T1DM/T2DM diagnosis.
• Periodontal disease diagnosis: criteria for diagnosis clearly defined: adequate, inadequate, unclear.
  ◦ Adequate: at least two sites with probing depth of ≥5 mm with ≥2 mm loss of clinical attachment and/or alveolar bone loss of more than 4 mm.
  ◦ Inadequate: less than two sites with probing depth of ≥5 mm with ≥2 mm loss of clinical attachment and/or alveolar bone loss of more than 4 mm.
  ◦ Unclear: no criteria given.

The diagnostic methods are summarised in Additional Table 1.

Assessment of risk of bias in included studies
We assessed studies against the following risk of bias criteria, in accordance with the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (Higgins 2011):
• random sequence generation;
• allocation concealment;
• blinding of participants;
• blinding of clinical operator;
• incomplete outcome data;
• selective outcome reporting;
• other biases.

We assessed each domain as being at low, high or unclear risk of bias. ‘Unclear’ indicates either lack of information or uncertainty over the potential for bias.

Measures of treatment effect
For continuous outcomes (eg HbA1c, clinical outcomes) where studies used the same scale, we used the mean values and standard deviations (SDs) reported in the studies in order to express the estimate of effect as mean difference (MD) with 95% confidence interval (CI). If different scales had been used, we would have considered expressing the treatment effect as standardised mean difference (SMD) with 95% CI.

If there had been any dichotomous outcomes we would have expressed the estimate of effect as a risk ratio (RR) with 95% CI.

Dealing with missing data
We attempted to contact trial authors to retrieve missing data when they were not available from the trial report, or to clarify areas where data or trial design and conduct were unclear. If we received no response, we excluded the data from meta-analyses until clarified by the study authors. Where standard deviations were missing we obtained these from a study’s confidence intervals, P values or t-values where available.

Assessment of heterogeneity
We assessed statistical heterogeneity by calculation of the ‘Q’ statistic with P value set at P < 0.10. This was quantified by the calculation of the I² statistic for heterogeneity.

Assessment of reporting biases
Where there were sufficient studies (more than 10 per comparison), we assessed publication bias by graphical methods (funnel plots, which indicate potential presence of reporting biases by testing for asymmetry) and via the Begg and Mazumdar adjusted rank correlation test (Begg 1994) and the Egger et al regression asymmetry test (Egger 1997).

Data synthesis
We conducted meta-analysis where studies were judged to be sufficiently similar. We used random-effects meta-analyses to combine quantitative data, where there were at least four studies. All the data analysed were continuous. We expressed pooled outcomes as mean differences with their associated 95% confidence intervals. Where single studies provided data for two subgroups with a common control group, which were pooled, half of the study’s control group was used in each subgroup to avoid double-counting participants.

Subgroup analysis and investigation of heterogeneity
If there were sufficient studies, we would have used sensitivity analyses and meta-analysis regression (using STATA software) to explore, quantify, and control for sources of heterogeneity between studies for the following quality criteria and prognostic factors:
• study quality;
• periodontal disease severity (initial probing depth);
• T1DM and T2DM;
• DM control - through categorisation of patients into good, fair and poor (mean HbA1c 7%, between 7% and 8.5% or >8.5% on the DCCT or equivalent scale);
• DM duration (since diagnosis);
• age;
• sex;
• smoking habits;
• alcohol consumption;
• general health status;
• presence of other medical conditions;
• plaque control;
• socioeconomic status;
• drug therapy.

Sensitivity analysis
We performed sensitivity analyses (where there were sufficient studies for each outcome) by excluding studies at high and unclear risk of bias in order to ensure our conclusions were robust.
Summarising findings and assessing the quality of the evidence

We developed 'Summary of findings' tables for the primary outcomes of this review using GRADEpro software (GRADEpro). We assessed the quality of the body of evidence with reference to the overall risk of bias of the included studies, the directness of the evidence, the inconsistency of the results, the precision of the estimates, the risk of publication bias, and the magnitude of the effect. The quality of the body of evidence for each of the primary outcomes was categorised as high, moderate, low or very low (GRADEpro).

RESULTS

Description of studies

Results of the search

The literature search for this review update identified 688 records after the duplicates were removed. These 688 records were screened independently and in duplicate. After screening, we retained 74 records for further assessment and categorised 614 records as not relevant.

We tried to obtain full texts of 74 records, but only found 62 full-text articles as 12 studies were still ongoing. We also found two studies (Calbacho 2004; Singh 2008) in the bibliographies of reviews (Darré 2008; Engebretson 2013a; Sgolastra 2013).

Following our assessment of the 64 full-text articles (including Calbacho 2004 and Singh 2008) from this updated search, we excluded a total of 12 studies (12 articles) with reasons provided (Characteristics of excluded studies), and we categorised five studies (seven articles) as awaiting classification at the next update of this review once required information has been identified (Characteristics of studies awaiting classification).

We included 35 studies (a total of 45 articles, including seven already included studies from the previous version of the review), of which 34 studies (all except Madden 2008) provided useable data. Figure 1 shows the study selection process.
Figure 1. Review update: study flow diagram

2 additional studies from other sources

997 records identified through database searching

698 records after duplicates removed

698 records screened

614 records categorised as not relevant

74 records retained for further assessment

12 studies ongoing

64 full-text articles assessed for eligibility

- 12 full-text articles (12 studies) excluded
- 7 full-text articles (5 studies) awaiting classification

35 studies (45 publications) included in qualitative synthesis

34 studies included in quantitative synthesis (meta-analysis)
**Included studies**

See Characteristics of included studies table. Thirty-five studies (involving a total of 2565 participants) met our criteria for inclusion, and all studies except one (Madden 2008) reported usable results for at least one of our two comparisons.

- Does periodontal therapy improve glycaemic control in people with diabetes mellitus?
- Does one periodontal therapy have a greater effect than another on improving glycaemic control?

**Characteristics of studies**

**Setting**

The included studies were conducted in the following countries:

- Brazil (seven trials, 20%; Macedo 2014; Miranda 2014; O’Connell 2008; Rodrigues 2003; Santos 2009; Santos 2012; Santos 2013);
- USA (seven trials, 20%; Engebretson 2011; Engebretson 2013; Gay 2014; Grossi 1997; Jones 2007; Madden 2008; NCT00801164);
- China (five trials, 14%; Chen 2012; Li 2011; Sun 2011; Yun 2007; Zhang 2013);
- India (three trials, 9%; Korhiwale 2013; Pradeep 2013; Singh 2008);
- Greece (two trials, 6%; Koromantzos 2011; Tsalikis 2014);
- Iran (two trials, 6%; Haerian Ardakani 2014; Moeintaghavi 2012); and
- nine countries (totaling 26%) conducted one included study (3%) each (Chile: Calbacho 2004; Japan: Katagiri 2009; Malaysia: Raman 2014; Mexico: Rocha 2001; Poland: Gilowski 2012; Saudi Arabia: Al-Zahrani 2009; Slovenia: Skaleric 2004; Spain: Llambés 2008; Turkey: Kiran 2005).

The majority of trials (n = 24; 69%) were conducted in a hospital setting; two studies (6%) were conducted in a primary care setting (Calbacho 2004; Jones 2007); two trials (6%) were conducted in a community setting (Engebretson 2013; Li 2011), and seven trials (20%) did not report the type of setting (Chen 2012; Gilowski 2012; Grossi 1997; Macedo 2014; Madden 2008; O’Connell 2008; Rocha 2001).

Twenty-five trials (71%) were conducted from a single centre; three trials (9%) did not report how many centres they conducted their trials from (Calbacho 2004; Gilowski 2012; Madden 2008), and seven trials (20%) were multiccentred (Engebretson 2013; Jones 2007; Katagiri 2009; Li 2011; Raman 2014; Tsalikis 2014; Yun 2007).

**Design**

All studies used a parallel randomised controlled trial (RCT) design. Twenty-nine studies (83%) had a two-arm design; five studies (14%) had a three-arm design (Al-Zahrani 2009; Chen 2012; Engebretson 2011; Li 2011; Singh 2008), and one study (3%) contained five arms (Grossi 1997).

**Follow-up**

Length of follow-up varied amongst the 35 included studies, ranging from 3 to 12 months duration.

- 14 studies (40%) followed up their participants for a period of 3 months (Al-Zahrani 2009; Engebretson 2011; Gilowski 2012; Haerian Ardakani 2014; Kiran 2005; Kothiwale 2013; Llambés 2008; Macedo 2014; Moeintaghavi 2012; O’Connell 2008; Raman 2014; Rodrigues 2003; Singh 2008; Sun 2011). One study (3%) had a follow-up period of 4 months.

- 12 trials (34%) followed up their participants for 6 months.

- Six of the included studies (17%) were funded by São Paulo State Research Foundation (Macedo 2014; Miranda 2014; O’Connell 2008; Rodrigues 2003; Santos 2012; Santos 2013).

- Six studies (17%) were funded by other government sponsors (Chen 2012; Katagiri 2009; Li 2011; Rocha 2001; Sun 2011; Zhang 2013).

- Five studies (14%) were funded by universities (Al-Zahrani 2009; Gilowski 2012; Madden 2008; Moeintaghavi 2012; Raman 2014).

- Four studies (11%) were funded by research institutes (Engebretson 2013; Gay 2014; Grossi 1997; Koromantzos 2011).
• Two studies (6%) were jointly funded by universities and research institutes (Engebretson 2011; Jones 2007).
• Two studies (6%) were self funded (Llambés 2008; Singh 2008 (stating no source of support)).
• One study (3%) was fully funded by an industry award (Tsanikis 2014).
• One study (3%) was partially funded by industry (NCT00801164).
• Eight studies (23%) did not report their source of funding (Calbacho 2004; Haerian Ardakani 2014; Kiran 2005; Kothiwale 2013; Santos 2009; Skaleric 2004; Yun 2007).

Conflicts of interest
In 15 of the included studies (43%), all authors declared no conflict of interests (Al-Zahrani 2009; Chen 2012; Engebretson 2011; Gay 2014; Katagiri 2009; Koromantzos 2011; Miranda 2014; O’Connell 2008; Pradeep 2013; Raman 2014; Santos 2009; Santos 2013; Singh 2008; Sun 2011; Tsanikis 2014); in one study (3%), conflict of interest declarations were available for all authors except the lead author (Engebretson 2013); and two studies (5%) have yet to be published, therefore, no declaration of conflict of interests currently exists to report (Kothiwale 2013; NCT00801164). Declarations regarding conflict of interests were not reported in the remaining 17 (49%) included studies.

Study primary outcomes and sample size calculations
Of the 35 included studies, only 11 (31%) reported HbA1c to be their studies’ primary outcome. Of these 11 studies:
• five studies (14%) were sufficiently powered to detect a statistically significant difference (Engebretson 2013; Gay 2014; Koromantzos 2011; Raman 2014; Zhang 2013);
• two studies (6%) were underpowered, due to randomising fewer participants than their own sample size calculation required (Chen 2012; Jones 2007);
• two studies (6%) did not report their sample size calculation (Engebretson 2011; Kothiwale 2013); and
• two studies (6%) indicated a sample size calculation had been undertaken, but did not report details and may not have been calculated a priori (Llambés 2008; Madden 2008).

Of the remaining included studies:
• five studies (14%) reported probing pocket depth (PPD) to be their studies’ primary outcome (sufficiently powered: Al-Zahrani 2009; Gilowski 2012; Macedo 2014; Miranda 2014. Calculation not reported: Li 2011);
• four studies (12%) reported clinical attachment level (CAL) to be their studies’ primary outcome (sufficiently powered: Santos 2009; Santos 2012; Santos 2013; Tsanikis 2014);
• one study (3%) reported bone defect fill to be their study’s primary outcome (sufficiently powered: Pradeep 2013); and
• 14 studies (40%) did not report their primary outcome. Of these, 12 studies (34%) did not report their sample size calculation (Calbacho 2004; Grossi 1997; Haerian Ardakani 2014; Katagiri 2009; Kiran 2005; O’Connell 2008; Rocha 2001; Rodrigues 2003; Singh 2008; Skaleric 2004; Sun 2011; Yun 2007), one study (3%) has yet to be published but states a required sample size in its trial register record (NCT00801164), and the remaining study (3%) broadly based their sample size upon figures used in two previous studies (Moeintaghavi 2012 using Kiran 2005 and Rodrigues 2003).

Analysis method
Of the 35 included studies, 15 reported (43%) they had analysed their participant data using intention-to-treat (ITT) (Calbacho 2004; Engebretson 2011; Engebretson 2013; Haerian Ardakani 2014; Katagiri 2009; Kiran 2005; Koromantzos 2011; Macedo 2014; Miranda 2014; Moeintaghavi 2012; Santos 2009; Santos 2012; Santos 2013; Skaleric 2004; Yun 2007); 12 studies (34%) analysed their participant data as per protocol (Chen 2012; Gay 2014; Grossi 1997; Jones 2007; Kothiwale 2013; Llambés 2008; NCT00801164; O’Connell 2008; Raman 2014; Sun 2011; Tsanikis 2014; Zhang 2013); and the method of data analysis was not reported in eight studies (23%) (Al-Zahrani 2009; Gilowski 2012; Li 2011; Madden 2008; Pradeep 2013; Rocha 2001; Rodrigues 2003; Singh 2008).

Characteristics of participants
The largest study (Engebretson 2013) included 514 participants, accounting for 20% of the total 2565 participants included in this review. Each of the other 34 studies included in the review contained less than 200 participants each.

Thirty-two studies (91%) included only T2DM participants; one study (3%) assumed participants to all be T2DM without confirmed diagnosis (Jones 2007); and two studies (6%) only included T1DM participants (Llambés 2008; Skaleric 2004). Only 16 included studies (47%) reported HbA1c criteria for participants at study entry. There was substantial variation between these trials in both the level and range of HbA1c of participants at baseline, with consequent variation in the potential for improvement in glycaemic control as a result of the intervention. Diabetic control of participants at baseline is summarised in Additional Table 2. The breadth of included studies’ diabetic control HbA1c thresholds for participant inclusion varied greatly amongst included trials and is summarised in Additional Table 2. Included trials spanned a broad range of age groups from 18 to 80 years. Eight studies (22%) did not report an age range for inclusion in their trials (Engebretson 2011; Haerian Ardakani 2014; Jones 2007) (reported only as “military veterans”); Li 2011; Moeintaghavi 2012; O’Connell 2008; Rodrigues 2003; Yun 2007).

Twenty-five studies (71%) contained a reasonably even balance of males and females; five studies (14%) contained a two-thirds
balance of sexes (in favour of males: Kothiwale 2013; Raman 2014; in favour of females: Grossi 1997; Kothiwale 2013; Santos 2013); one study (3%) almost exclusively contained male participants (Jones 2007); and proportion of male to female participants was not reported in four studies (11%) (Haerian Ardakani 2014; Moeintaghavi 2012; Rodrigues 2003; Rodrigues 2003).

Use of antidiabetic therapy varied greatly amongst included trials and is summarised in Additional Table 3. There was also variation between trials where participants’ antidiabetic therapy was changed during the trial conduct period:
- in 11 studies (31%) there were no changes to prescribed antidiabetic therapy (Al-Zahrani 2009; Calbacho 2004; Engebretson 2011; Katagiri 2009; Kiran 2005; Kothiwale 2013; Moeintaghavi 2012; Santos 2009; Santos 2012; Santos 2013; Singh 2008);
- in 10 studies (29%) some participants’ prescribed antidiabetic therapy was changed (Engebretson 2013; Gay 2014; Grossi 1997; Jones 2007; Koromantzos 2011; Llambés 2008; Madden 2008; Raman 2014; Rodrigues 2003; Skaleric 2004); and
- for 14 studies (40%), it is unknown whether any changes were made to participants’ prescribed antidiabetic therapy (Chen 2012; Gilowski 2012; Haerian Ardakani 2014; Li 2011; Macedo 2014; Miranda 2014; NCT00801164; O’Connell 2008; Pradeep 2013; Rocha 2001; Sun 2011; Tsalikis 2014; Yun 2007; Zhang 2013).

Additional Table 4 describes the changes made to antidiabetic therapy, as reported by each included study. Included studies made a variety of participant exclusions. Most frequently reported exclusion criteria were antibiotic use (largely in prior 3 months, where reported) in 28 trials (80%), pregnancy (including breastfeeding/lactation) in 25 trials (71%) and tobacco use in 17 trials (49%). Other notable exclusions were:
- periodontal treatment (largely in prior 3 months, where reported) in 10 studies (29%);
- immunosuppressed or compromised patients in 10 studies (29%);
- systemic disease in 10 studies (29%);
- non-steroidal anti-inflammatory drugs (NSAID) use (largely in prior 3 months, where reported) in nine studies (26%);
- diabetic complications in eight studies (23%);
- orthodontic appliance use in six studies (17%);
- renal/liver dysfunction in five studies (14%);
- alcohol/drug abuse in four studies (11%);
- cardiovascular disease/events in four studies (11%).

Rheumatoid arthritis and anticoagulant use were each exclusion criteria in two studies (6%), and stroke and insulin use were each excluded from single trials (3%). Grossi 1997 did not report any exclusion criteria, and unpublished author content relating to exclusions for Calbacho 2004 was unintelligible (request for clarification was sought but no response received).

Characteristics of assessments

All included studies used adequate criteria for diagnosis of diabetes mellitus (Additional Table 1). Few trials specifically indicated whether they had used IFCC or DCCT standard test scales; however, given the recorded HbA1c values at baseline, it is likely most studies used the DCCT standard.

Diagnostic criteria for periodontal disease (also Additional Table 1) was assessed as adequate in 11 studies (31%) (Engebretson 2013; Gay 2014; Koromantzos 2011; Llambés 2008; Macedo 2014; Moeintaghavi 2012; Raman 2014; Santos 2009; Sun 2011; Tsalikis 2014; Zhang 2013), and unclear in four studies (11%) (Calbacho 2004; Grossi 1997; Kiran 2005; Li 2011) due to either not reporting this detail or offering no defined criteria. Diagnosis of periodontal disease was assessed as inadequate in 20 studies (57%) for a variety of reasons:
- insufficient indication of criteria in two trials (6%) (Kothiwale 2013; Madden 2008);
- less than two sites required in three trials (9%) (Miranda 2014; O’Connell 2008; Rodrigues 2003);
- partial criteria use in nine trials (26%) (PPD only; no CAL/ bone loss; Gilowski 2012; Haerian Ardakani 2014; Jones 2007; Katagiri 2009; Skaleric 2004; Yun 2007. CAL only; no PPD/ bone loss: Al-Zahrani 2009; Engebretson 2011; NCT00801164);
- no indication of number of sites in one trial (3%; Pradeep 2013); and
- a lower threshold was used for PPD/CAL in five trials (14%) (CAL ≥1 mm: Chen 2012; PPD ≥3 mm: Rocha 2001; PPD/CAL ≥4 mm: Santos 2012; Santos 2013; Singh 2008).

Characteristics of interventions and comparisons

Interventions compared by the included studies are shown in Additional Table 5.

All included studies assessed the use of non-surgical periodontal therapy with usual care/no active treatment and/or compared different types of periodontal therapy (periodontal therapy delivered in both arms, with intervention groups receiving more intensive treatment delivery compared to that received by control groups. Combined interventions varied across studies, and are clearly detailed in Additional Table 5 within this review). No included studies compared surgical with non-surgical periodontal interventions. Twenty-seven studies (77%) included the use of oral hygiene instruction (OHI) (treatment arm only (n = 7; 20%: Chen 2012; Kiran 2005; Kothiwale 2013; Singh 2008; Sun 2011; Yun 2007; Zhang 2013), control arm only (n = 1; 3%: Calbacho 2004), or both arms (n = 19; 54%: Al-Zahrani 2009; Engebretson 2013; Gay 2014; Gilowski 2012; Katagiri 2009; Koromantzos 2011; Llambés...
Primary outcomes
HbA1c: 33 studies (94%) reported at 3-4 months (Al-Zahrani 2009; Callacho 2004; Chen 2012; Engebretson 2011; Engebretson 2013; Gay 2014; Gilowski 2012; Grossi 1997; Haerian Ardakani 2014; Jones 2007; Katagiri 2009; Kiran 2005; Koromantzos 2011; Kothiwale 2013; Li 2011; Llambés 2008; Macedo 2014; Miranda 2014; Moeintaghavi 2012; NCT00801164; O’Connell 2008; Pradeep 2013; Raman 2014; Rodrigues 2003; Santos 2009; Santos 2012; Santos 2013; Singh 2008; Skaleric 2004; Sun 2011; Tsalikis 2014; Yun 2007; Zhang 2013), and 17 studies (49%) reported at 6 months (Chen 2012; Engebretson 2013; Grossi 1997; Katagiri 2009; Koromantzos 2011; Li 2011; Madden 2008; Miranda 2014; NCT00801164; Pradeep 2013; Rocha 2001; Santos 2009; Santos 2012; Santos 2013; Skaleric 2004; Tsalikis 2014; Zhang 2013).

Secondary outcomes
- Bleeding on probing (BOP): 15 studies (43%) reported at 3-4 months; eight studies (23%) reported at 6 months.
- Clinical attachment level (CAL): 20 studies (57%) reported at 3-4 months; 14 studies (40%) reported at 6 months.
- Gingival index (GI): nine studies (26%) reported at 3-4 months; six studies (17%) reported at 6 months.
- Plaque index (PI): 19 studies (54%) reported at 3-4 months; nine studies (26%) reported at 6 months.
- Probing pocket depth (PPD): 23 studies (66%) reported at 3-4 months; 13 studies (37%) reported at 6 months.
- Adverse effects: 15 studies (43%) reported data relating to adverse events.
- No included studies reported data relating to quality of life, cost implications or diabetic complications.

Excluded studies
After examination of full-text papers, we excluded 12 studies as they failed to meet the criteria stated in the protocol. The reasons for exclusion are detailed in the Characteristics of excluded studies tables; however, a synopsis of exclusion rationale follows:
- non-randomised design (n = 3: Munenaga 2013; Promsuddhi 2005 (patients may self select to control group in both studies); Taylor 2011 (error in MEDLINE reference, is actually a review));
- HbA1c not reported (n = 2: Albrecht 1988; Llambés 2012);
- insufficient follow-up period (n = 1: Mansouri 2006);
- not utilising a professional periodontal intervention (n = 4: Al-Mubarak 2002 (irrigation device); Cinar 2014 (empowerment “health coaching”); Gorbacheva 2010 (toothpaste); Khader 2010 (full mouth tooth extraction));
- abandoned due to recruitment issues (n = 1: NCT01255254);
- a study previously classified under Ongoing studies in the 2010 version of this review has now been excluded, as reinspection of abstract indicates inclusion of non-diabetic controls (Hagiwara 2002).

Studies awaiting classification
Five studies are awaiting classification, and are fully detailed under Characteristics of studies awaiting classification.

Ongoing studies
Twelve studies are still ongoing and detailed under Characteristics of ongoing studies.

Risk of bias in included studies
Four teams of two authors independently assessed risk of bias for each included study. For consistent rating application, two authors (Jo Weldon (JW) and Zipporah Iheozor-Ejiofor (ZIE) arbitrated these assessments in accordance with guidance from Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) (Higgins 2011). All except six of the studies were judged to be at high risk of bias. Two studies (Miranda 2014; Santos 2013) were low risk and four studies (Haerian Ardakani 2014; Li 2011; Macedo 2014; Pradeep 2013) were unclear.
A 'Risk of bias' table was completed for each included study (Characteristics of included studies). Results are presented graphically by study (Figure 2) and by domain across all studies (Figure 3).
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study

<table>
<thead>
<tr>
<th>Study</th>
<th>Random sequence generation</th>
<th>Allocation concealment</th>
<th>Blinding of participants</th>
<th>Blinding of outcome assessment</th>
<th>Incomplete outcome data (attrition bias)</th>
<th>Selective reporting</th>
<th>Other bias</th>
</tr>
</thead>
</table>
Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies

<table>
<thead>
<tr>
<th>Risk of Bias Item</th>
<th>Low risk of bias</th>
<th>Unclear risk of bias</th>
<th>High risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of participants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other bias</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Allocation**

We judged studies for selection bias based on the adequacy of random sequence generation and allocation concealment (to prevent selective enrolment).

Nine studies (Engebretson 2011; Engebretson 2013; Gilowski 2012; Jones 2007; Kiran 2005; Koromantzos 2011; Miranda 2014; Pradeep 2013; Santos 2013) reported adequate random sequence generation and allocation concealment and so were judged to be at low risk of selection bias.

Three studies (Katagiri 2009; Rocha 2001; Tsalikis 2014) were judged to be at high risk of selection bias. This was due to dentists’ knowledge of allocation (Katagiri 2009) and staff being in possession of the randomisation list (Tsalikis 2014). One study (Rocha 2001) reported insufficient information on randomisation, but was assumed to be quasi-randomised.

Twenty-three studies were judged to be at unclear risk of selection bias. This was mostly due to insufficient information about allocation concealment (Al-Zahrani 2009; Calbacho 2004; Chen 2012; Gay 2014; Macedo 2014; Madden 2008; Moeinaghavi 2012; NCT00801164; Raman 2014; Rodrigues 2003; Santos 2009; Santos 2012), randomisation (Zhang 2013) or both (Grossi 1997; Haerian Ardakani 2014; Kothiwale 2013; Li 2011; Llambés 2008; O’Connell 2008; Singh 2008; Skaleric 2004; Sun 2011; Yun 2007).

**Blinding**

**Performance bias**

We assessed studies for performance bias based on blinding of participants and clinical operators.

We judged four studies (Gilowski 2012; Miranda 2014; Santos 2013; Tsalikis 2014) to be at low risk of performance bias. Of the four studies, three studies (Gilowski 2012; Santos 2013; Tsalikis 2014) used placebo, and personnel were reported to have been blinded or unaware of treatment. One study (Miranda 2014), in addition to blinding of the participants and personnel, also reported that code breaking was only performed after the final analysis.

Nine studies (Engebretson 2011; Gay 2014; Haerian Ardakani 2014; Li 2011; Macedo 2014; NCT00801164; O’Connell 2008; Pradeep 2013; Rocha 2001) were at unclear risk of performance bias. This was either because the studies were referred to as double blinded without further details, or blinding would have been possible but was not reported.

We judged 22 studies to be at high risk of bias of performance bias. Bias was due lack of participant blinding (Chen 2012; Llambés 2008; Madden 2008; Rodrigues 2003; Skaleric 2004; Sun 2011; Yun 2007), lack of personnel blinding (Grossi 1997), or
both (Al-Zahrani 2009; Calbacho 2004; Engebretson 2013; Jones 2007; Katagiri 2009; Kiran 2005; Koromantzos 2011; Kothiwale 2013; Moeintaghavi 2012; Raman 2014; Santos 2009; Santos 2012; Singh 2008; Sun 2011; Zhang 2013). The studies at high risk of performance bias provided information indicating that blinding was not undertaken at all, was unachievable due to nature of intervention, or was attempted but broken.

Detection bias

We did not assess the studies for detection bias as HbA1c tests were carried out remotely, therefore all studies were considered to be at low risk. Blind outcome assessment for the secondary outcomes was considered to be of lesser importance so as not to detract from the primary focus of the review.

Incomplete outcome data

We judged 15 studies (Calbacho 2004; Engebretson 2013; Haerian Ardakani 2014; Katagiri 2009; Kiran 2005; Koromantzos 2011; Macedo 2014; Miranda 2014; Moeintaghavi 2012; Rocha 2001; Santos 2009; Santos 2012; Santos 2013; Skaleric 2004; Yun 2007) to be at low risk of incomplete outcome bias. This assessment was due to studies reporting 100% completion (Calbacho 2004; Haerian Ardakani 2014; Katagiri 2009; Kiran 2005; Koromantzos 2011; Macedo 2014; Miranda 2014; Moeintaghavi 2012; Santos 2009; Santos 2012; Santos 2013; Skaleric 2004; Yun 2007) to be at low risk of incomplete outcome bias. This assessment was due to studies reporting 100% completion (Calbacho 2004; Haerian Ardakani 2014; Katagiri 2009; Kiran 2005; Koromantzos 2011; Macedo 2014; Miranda 2014; Moeintaghavi 2012; Santos 2009; Santos 2012; Santos 2013; Skaleric 2004), similarly low attrition rates across groups (Engebretson 2013; Miranda 2014; Santos 2013) in addition to conducting intention-to-treat (ITT) analysis. One study (Yun 2007) did not provide sufficient information, but appears not to have had any drop-outs. Rocha 2001 was considered to be ITT due to indicated degrees of freedom reported in paired t-test.

We judged six studies to be at unclear risk of incomplete outcome bias. This judgement was based on lack of sufficient information on attrition even though ITT analysis is assumed to have been undertaken (Al-Zahrani 2009; Gilowski 2012; Pradeep 2013; Rodrigues 2003; Singh 2008). One study reported no information (Li 2011).

Fourteen studies were at high risk of incomplete outcome bias. Though ITT analysis was undertaken in one study (Engebretson 2011), the attrition rate of over 20% was still considered a source of bias. The rest of the studies (Chen 2012; Gay 2014; Grossi 1997; Jones 2007; Kothiwale 2013; Llambés 2008; Madden 2008; NCT00801164; O’Connell 2008; Raman 2014; Sun 2011; Tsalikis 2014; Zhang 2013) also reported withdrawals, but did not analyse all participants in the group to which they were randomised.

Selective reporting

We judged 11 studies (Al-Zahrani 2009; Chen 2012; Engebretson 2013; Macedo 2014; Miranda 2014; Pradeep 2013; Santos 2009; Santos 2012; Santos 2013; Skaleric 2004; Tsalikis 2014) to be at low risk of selective reporting bias as all expected outcome including adverse events were recorded and fully reported.

Seventeen studies were at unclear risk of selective reporting bias. Fourteen of these studies were judged to be unclear because there was no information on whether any adverse events had occurred or not (Gay 2014; Grossi 1997; Haerian Ardakani 2014; Katagiri 2009; Kiran 2005; Koromantzos 2011; Kothiwale 2013; Moeintaghavi 2012; O’Connell 2008; Raman 2014; Rocha 2001; Rodrigues 2003; Sun 2011; Yun 2007), and one study only partially reported adverse events (Singh 2008; for an intervention component of a single group). For the remaining two studies (Li 2011; NCT00801164), there was insufficient information to make a judgement.

We judged seven studies to be at high risk of selective reporting bias. Some studies at high risk of bias either failed to report on periodontal outcome fully (Engebretson 2011; Gilowski 2012), or did not report both periodontal outcome and adverse events (Calbacho 2004; Llambés 2008). Authors of two studies that reported HbA1c in subgroups (Madden 2008) and inconsistently (Zhang 2013) were contacted via email, but message delivery failed. One study (Jones 2007) reported on adverse events for one arm only and also did not present HbA1c data at 4-month follow-up.

Other potential sources of bias

We judged 21 studies (Al-Zahrani 2009; Chen 2012; Engebretson 2011; Gay 2014; Gilowski 2012; Katagiri 2009; Kiran 2005; Koromantzos 2011; Llambés 2008; Macedo 2014; Miranda 2014; Moeintaghavi 2012; O’Connell 2008; Pradeep 2013; Rocha 2001; Santos 2009; Santos 2012; Santos 2013; Skaleric 2004; Sun 2011; Zhang 2013) to be at low risk of other potential sources of bias. We judged 10 studies to be at unclear risk of other potential sources of bias. We were unable to verify whether there were any other apparent biases due insufficient information from data extraction components of translated (Haerian Ardakani 2014; Li 2011) and unpublished studies (Calbacho 2004; Kothiwale 2013; NCT00801164). It was not clear whether there was baseline balance since participant characteristics were not reported (Madden 2008; Rodrigues 2003; Singh 2008). In another study, conflict of interests were reported for all authors except the lead author (Engebretson 2013). One study did not report the proportion of participants in receipt of hypoglycaemic medications (Tsalkis 2014).

We judged four studies to be at high risk of other potential sources of bias. There was baseline imbalance due to the randomisation of more participants with poor metabolic control to the intervention group (Raman 2014) and a difference between groups in participant characteristics (Grossi 1997; Jones 2007). One study (Yun 2007) was judged to be at high risk of bias due to overall poor reporting and study design.
Effects of interventions

See: Summary of findings for the main comparison Periodontal therapy compared to no active intervention/usual care for glycaemic control in people with diabetes mellitus; Summary of findings 2 Periodontal therapy compared to alternative periodontal therapy for glycaemic control in people with diabetes mellitus

We investigated two comparisons in this review.

1. Does periodontal therapy improve glycaemic control in people with diabetes mellitus?
2. Does one periodontal therapy have a greater effect than another on improving glycaemic control?

Comparison 1. Periodontal therapy versus no active intervention/usual care

HbA1c: 3-4 months (Analysis 1.1)

Fourteen studies (1499 participants) compared periodontal therapy against no active intervention/usual care at 3 or 4 months. Overall, there was a benefit for periodontal therapy with a mean percentage reduction in HbA1c of -0.29 (95% confidence interval (CI) -0.48 to -0.10; effect P = 0.003). There was a moderate amount of heterogeneity (P = 0.008; $I^2 = 53\%$) (Analysis 1.1).

Two subgroups were formed for studies: scaling and root planing (SRP) (eight studies), and SRP plus antimicrobials (seven studies). One study (Singh 2008) contributed data to both subgroups. There was no statistically significant difference between the subgroups ($P = 0.25$).

A funnel plot of the 15 included studies (Figure 4: reflecting Singh 2008’s contribution to both subgroups) failed to indicate any relationship between mean percentage reduction in HbA1c and precision (related to sample size). The Egger formal test for asymmetry intercept, was not statistically significant: -0.94 (95% CI -2.40 to 0.52; P =0.19) (Egger 1997).

Figure 4. Funnel plot of comparison: 1 Periodontal therapy versus no active intervention/usual care, outcome: 1.1 HbA1c at 3-4 months
HbA1c: 6 months (Analysis 1.2)

Five studies (826 participants) compared periodontal therapy against no active intervention/usual care at 6 months. Overall, there was no benefit for periodontal therapy with mean percentage reduction in HbA1c of -0.02 (95% CI -0.20 to 0.16; effect P = 0.84). There was little evidence of heterogeneity (P = 0.69; I² = 0%).

Two subgroups were formed for studies: SRP (three studies), and SRP plus antimicrobials (two studies). There was no statistically significant difference between the subgroups (P = 0.38) (Analysis 1.2).

Comparison 2. Periodontal therapy versus alternative periodontal therapy

The different interventions being compared varied across studies, and are clearly detailed in Additional Table 5 within this review.

HbA1c: 3-4 months (Analysis 2.1)

Twenty-one studies (920 participants) compared different periodontal therapies at 3 or 4 months, with adjunctive intervention being given in one or both groups. The studies were categorised into the following detailed comparisons:
- SRP versus alternative mechanical therapy (one study)
- SRP versus alternative SRP (three studies)
- SRP plus antimicrobial versus antimicrobial (one study)
- SRP plus antimicrobial versus SRP (12 studies)
- SRP plus antimicrobial (doxycycline) versus SRP plus alternative antimicrobial (three studies)
- SRP plus combined antimicrobials versus SRP plus alternative antimicrobial (three studies)
- SRP plus statin versus SRP (one study).

We were unable to pool most of these head-to-head comparisons. We were able to pool the SRP plus antimicrobial versus SRP comparison. There was no consistent evidence that the addition of antimicrobials to SRP was of any benefit to delivering SRP alone (mean HbA1c 0.00% lower: 12 studies, 450 patients; 95% CI 0.22% lower to 0.22% higher) at 3 or 4 months post-treatment. There was little evidence of heterogeneity (P = 0.16; I² = 29%).

Sensitivity analysis

A sensitivity analysis, based on restricting the meta-analysis of the pooled SRP plus antimicrobial versus SRP subgroup to the two studies assessed as being at low risk of bias indicated that the result is robust in stating that there was no consistent evidence that the addition of antimicrobials to SRP was of any benefit to delivering SRP alone. A funnel plot of the 12 included studies in analysis 2.1.4 (Figure 5) failed to indicate any relationship between mean percentage reduction in HbA1c and precision (related to sample size). The Egger formal test for asymmetry intercept, was not statistically significant: 0.12 (95% CI -1.33 to 1.57; P =0.86) (Egger 1997).
Twelve studies (34%; 583 participants) compared periodontal therapy against an alternative periodontal therapy at 6 months, with adjunctive intervention being given in one or both groups. It was inappropriate to combine studies for estimation of an overall pooled effect across subgroups.

The studies were categorised into the following detailed comparisons:

- SRP versus alternative mechanical therapy (one study)
- SRP versus alternative SRP (three studies)
- SRP plus antimicrobial versus SRP (five studies)
- SRP plus antimicrobial (doxycycline) versus SRP plus alternative antimicrobial (one study)
- SRP plus combined antimicrobials versus SRP plus alternative antimicrobial (one study)
- SRP plus bone modifier versus SRP (one study)
- SRP plus statin versus SRP (one study).

We were unable to pool most of these head-to-head comparisons. Once again we were able to pool the SRP plus antimicrobial versus SRP comparison. There was no consistent evidence that the addition of antimicrobials to SRP was of any benefit to delivering SRP alone (mean HbA1c 0.04% lower: five studies, 206 patients; 95% CI 0.41% lower to 0.32% higher) at 6 months post-treatment. There was little evidence of heterogeneity ($P = 0.11; I^2 = 46\%$) (Analysis 2.2).

**Sensitivity analysis**
A sensitivity analysis, based on restricting the meta-analysis of the pooled SRP plus antimicrobial versus SRP comparison to the only two studies assessed as being at low risk of bias indicated that the result is robust in stating that there was no consistent evidence that the addition of antimicrobials to SRP was of any benefit to delivering SRP alone.

Secondary outcomes

Periodontal indices
To allow direct comparison of data from studies on the same scale, measurements were converted to the proportion of sites for the following secondary (periodontal parameter) outcomes: bleeding on probing (BOP) (Chen 2012; Engebretson 2013; Gilowski 2012; Katagiri 2009; Kiran 2005; Koromantzos 2011; Macedo 2014; O’Connell 2011; Rodríguez 2003; Santos 2009; Santos 2012; Santos 2013; Yu 2007), gingival index (GI) (Grossi 1997; Koromantzos 2011), and plaque index (PI) (Grossi 1997, Haerian Ardakani 2014; Macedo 2014; O’Connell 2008; Pradeep 2013; Santos 2009; Santos 2012).

Comparison 1. Periodontal therapy versus no active intervention/usual care
Additional Table 6 documents the clinical periodontal secondary outcomes for the studies included in this comparison at both 3 to 4, and 6 months. Statistically significant differences in favour of periodontal intervention were found for all periodontal indices (BOP, clinical attachment level (CAL), GI, PI, probing pocket depth (PPD)) at both 3 to 4, and 6 months follow-up.

Comparison 2. Periodontal therapy versus alternative periodontal therapy
Additional Table 7 documents the clinical periodontal secondary outcomes for the studies included in this comparison at both 3 to 4, and 6 months. The success of the periodontal interventions compared are variable across clinical indices and time points.

Adverse effects
Twenty studies (57%) did not report whether their participants experienced adverse effects from their allocated treatment (Calbacho 2004; Gay 2014; Grossi 1997; Haerian Ardakani 2014; Katagiri 2009; Kiran 2005; Koromantzos 2011; Kothiwale 2013; Li 2011; Llambés 2008; Madden 2008; Moeintaghavi 2012; NCT00801164; O’Connell 2008; Raman 2014; Rocha 2001; Rodrigues 2003; Sun 2011; Yun 2007; Zhang 2013).

- Eight studies (23%) reported that no adverse events occurred (Al-Zahrani 2009; Chen 2012; Engebretson 2011; Gilowski 2012; Macedo 2014; Pradeep 2013; Santos 2009; Santos 2012).
- One study (3%) reported that no adverse effects resulted from use of doxycycline (Singh 2008 as partial intervention component for Gp B), but failed to report whether any side effects resulted from SRP or were experienced by Gps A and C.
- Three studies (9%) reported that no major adverse events occurred (Engebretson 2013 (common SRP discomfort only); Skaleric 2004; Tsialikis 2014 (one control patient reported dizziness/swallowing difficulty)).
- Three studies (9%) reported the occurrence of minor adverse events (Jones 2007 (doxycycline: diarrhoea, pain, nausea; chlorhexidine: taste change, tooth stain, mouth irritation, swelling and breathlessness); Miranda 2014 (both groups: diarrhoea, headaches, metallic taste, nausea/vomiting); Santos 2013 (more than half in both groups reported taste perception change/dry mouth/staining)).

Quality of life
No included studies reported data relating to quality of life.

Cost implications
No included studies reported data relating to cost implications.

Diabetic complications
No included studies reported data relating to diabetic complications.
### Additional Summary of Findings

**Periodontal therapy versus alternative periodontal therapy for glycaemic control in people with diabetes mellitus**

**Patient or population:** Patients with diabetes mellitus  
**Settings:** Hospital  
**Intervention:** Periodontal therapy  
**Comparison:** Alternative periodontal therapy

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Number of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assumed risk</td>
<td>Corresponding risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alternative periodontal therapy</td>
<td>Periodontal therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c</td>
<td>SRP plus antimicrobial versus SRP</td>
<td>The weighted mean HbA1c at 3-4 months follow-up was 8.04% in the SRP group</td>
<td>Mean HbA1c in the SRP plus antimicrobial group was <strong>0.00% lower</strong> (0.22% lower to 0.22% higher)</td>
<td>450</td>
</tr>
<tr>
<td>Adverse effects</td>
<td>Insufficient evidence to determine whether more intensive periodontal therapy delivery (intervention groups receiving an additional treatment combination compared to that received by control groups) for glycaemic control is associated with any harms</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The basis for the **assumed risk** (eg the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI)  
CI: confidence interval; SRP: scaling and root planing
GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate

**Very low quality:** We are very uncertain about the estimate

---

1. Interventions varied across studies, and are clearly detailed in Additional Table 5 within this review
2. Moderate to high risk of bias across domains: quality of evidence downgraded twice
3. Downgraded once due to imprecision
4. Only two (Santos 2009; Santos 2012) of three studies were suitable to pool to produce the following effect estimate: 0.48% (95% CI - 0.54% to 1.51%)
DISCUSSION

Summary of main results
The primary objective was to investigate the effect of periodontal therapy on glycaemic control in people with diabetes. We found evidence to demonstrate that the treatment of periodontal disease does improve glycaemic control in people with diabetes, with a mean percentage reduction of 0.29% in HbA1c at 3–4 months. The quality of the body of evidence for this finding was assessed as low.

To put this in context, the epidemiological analysis of UKPDS 1998 data indicated that for every percentage point decrease in HbA1c, there was a 35% reduction in the risk of microvascular complications, which appeared to be linear; however, we acknowledge that a linear relationship may not exist at lower levels. In a general population, of whom only a minority had diabetes, a lower average HbA1c level by 0.2% was associated with a 10% lower mortality (Khaw 2001) over 2-5 years. Although the findings of this and other observational studies of people with diabetes are prone to confounding.

Glycaemic control is only one component of management of diabetes and smoking cessation, weight loss, physical activity and management of dyslipidaemia and hypertension, where appropriate, are particularly important to reduce risk of macrovascular disease. Consequently, the effect of the modest reduction (0.2%) in HbA1c seems unlikely to result in a major population-level effect, particularly as effectiveness of periodontal treatment is only estimated to 3–4 months post-treatment within this review.

There was no evidence that periodontal treatment results in a significant effect at 6 months. Due to periodontitis being a chronic condition, ongoing maintenance care by clinicians would be prudent to maintain clinical improvements beyond 6 months. Further research is still needed to determine whether or not periodontal treatment (with or without adjunctive intervention) provides further benefit with regard to glycaemic control beyond other interventions of known effectiveness including lifestyle and behavioural change and treatment intensification, and perhaps future randomised controlled trials (RCTs) could look at this. Interestingly, another systematic review’s meta-analysis (including 19 RCTs, 1431 participants) demonstrated that psychological intervention (counselling, cognitive behavioural therapy or psychodynamic therapy) results in a mean difference (MD) reduction in HbA1c of 0.54% (95% confidence interval (CI) -0.83 to -0.23) for type 2 diabetes mellitus (T2DM) patients (Alam 2009). While their review is not directly comparable (participants were not diagnosed with periodontitis, and their results pooled the effects of RCTs across a broad range of follow-up periods (4 weeks to 12 months), we highlight that future trials could potentially also consider the use of adjunctive psychological intervention as this may further improve the reduction in HbA1c of 0.29% demonstrated in this review, but that such a design will require quality of life (QoL) to be measured as an outcome within such trials. Trials may be designed to include three arms, including a no periodontal treatment control.

We also wish to highlight that due to the array of associated factors (eg QoL, diabetic complications) that have been shown to influence glycaemic control, establishing a direct relationship may be particularly difficult (Chew 2015). Future trials might attempt to address this issue by including the use of health-related QoL assessments and more thoroughly reporting the prevalence of diabetic complications from their sample population.

There was no evidence of a difference in glycaemic control demonstrated by delivery of different periodontal treatments (comparison 2 in this review).

There was some variation between studies of the effect of interventions in achieving periodontal health, with some showing high levels of residual inflammation following treatment. For the trials comparing the effect of periodontal therapy with a usual care or no active treatment control group, there was evidence of reductions for all clinical periodontal indices at both 3-4 and 6 months for patients in the periodontal therapy group. There were several head-to-head studies comparing different periodontal treatments. There was no clear evidence that one treatment was more effective than another.

Overall completeness and applicability of evidence
The review assessed a varied population with a wide age range, good gender balance and varied glycaemic control (HbA1c thresholds) who were using different forms of antidiabetic therapy; however, information about socioeconomic status (SES) and body mass index (BMI) were rarely reported, raising doubts concerning the applicability of the evidence to people of various sizes and socioeconomic backgrounds.

The studies included in the meta-analyses all provided HbA1c data, however, adverse events were seldom reported. Participation in the trials might have resulted in patients monitoring their blood sugars and taking better care of their health, by complying with their medication more than they normally would. This might have resulted in an overestimation of the benefit of periodontal interventions due to potential Hawthorne effect impact (McCambridge 2014).

Overall, we find the evidence presented in this review to be pragmatic as the results of most of the studies were analysed by intention-to-treat (ITT); however, there was some variation between studies of the effect of interventions in achieving periodontal health, with some showing high levels of residual inflammation following treatment. As the postulated effect of scaling and root planing (SRP) on glycaemic control is predicated upon reduced periodontal inflammation, reduced efficacy of the intervention may have restricted the potential to show benefit.

A recent cross-sectional survey (Kowall 2015) concluded that having pre-diabetes or well-controlled T2DM (defined in their study
as a known HbA1c level of < 7.0%) was not associated with a greater prevalence of periodontitis or edentulism; however, their paper implies an association exists for people with HbA1c levels greater than 7.0%.

Considering the implications of their findings, we highlight an RCT (Khader 2010) excluded by our own review due to its use of a non-periodontal intervention, full mouth tooth extraction (FME). This study, of 58 T2DM participants diagnosed with severe periodontitis, excluded patients with a baseline HbA1c level up to 7.0% (being considered to have well-controlled T2DM), and randomised included participants (all of whose remaining teeth were deemed to be in a hopeless condition and indicated for extraction regardless) to receive FME or no treatment (delayed FME). Khader 2010’s choice of intervention potentially addresses our hypothesis in a situation where all periodontal disease may be presumed to be eliminated by use of FME. Significant reductions in mean HbA1c were demonstrated by the intervention group (FME recipients) at both 3 months follow-up (MD -0.95%; 95% CI 1.41% lower to 0.49% lower), and 6 months follow-up also (MD -1.09%; 95% CI 1.57% lower to 0.61% lower). The improvement detected in this study suggests that the benefits of eliminating infection or inflammation associated with periodontal disease in people with T2DM are likely to be centred on those with both poor metabolic control and with the most severe presentation of periodontal disease.

### Quality of the evidence

The quality of the body of evidence was low due to high risk of bias, moderate to substantial heterogeneity and serious imprecision. All the included studies were at high risk of bias except six studies, two (6%) at low risk of bias and four (11%) at unclear risk of bias. Bias was due to inadequate randomisation/allocation concealment in four (11%) studies, selective reporting in seven (20%) studies and attrition in 14 (40%) studies. However, the main source of bias was lack of blinding of participants and clinical operator which led to performance bias in 22 (63%) studies. This occurred in studies involving interventions that were mechanical in nature, for which blinding was not possible.

There was little evidence of heterogeneity across the studies despite differences in intervention delivery and various treatment combinations. There was no indirectness nor publication bias detected. When compared to usual care/no active treatment, different periodontal treatments showed consistently significant effects at 3-4 months follow-up. This significant effect was fairly consistent regardless of intervention type and supports confidence in the estimate of effect.

### Potential biases in the review process

Concerted efforts have been made to prevent bias arising in the review process:
- by cross-checking references from existing literature to ensure previously identified studies by others were appraised for inclusion in this review in the eventuality that this review's search strategy had not highlighted them;
- by screening search result records in duplicate and having all decisions arbitrated by a third review author;
- by adherence to an agreed, standardised data extraction format, utilised by at least two review authors per included study and contents reviewed for accuracy/consistency with the original record/s by an additional author;
- by use of standard Cochrane tools to utilise as much data as possible from included studies within the two comparisons in this review (eg by combining intervention arms, or splitting control group patients, from multiarmed studies, where appropriate).

Despite these attempts to avoid bias, there were other sources of potential bias in the review process which we were unable to prevent. Data extraction and risk of bias assessment were done by different teams and may have led to inconsistent ratings; however, two review authors (Jo Weldon (JW) and Zipporah Iheozor-Ejiofor (ZIE)) arbitrated all assessments in order to maintain uniformity.

We chose not to incorporate assessment of periodontal outcome detection bias as it was not the primary focus of the review. We highlight that change scores were used in meta-analysis for the following secondary (periodontal parameter) outcomes: bleeding on probing (BOP) (Engebretson 2013), clinical attachment level (CAL) (Grossi 1997; Li 2011), gingival index (GI) (Engebretson 2013), plaque index (PI) (Li 2011), and probing pocket depth (PPD) (Li 2011); however, this is indicated in the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) (Higgins 2011: section 9.4.5.2) as an acceptable method and consequently is not a concern for bias.

We imputed standard deviations (SDs) from reported means for BOP, CAL, GI and PPD (derived from reported CIs) by using standard Cochrane tools for Engebretson 2013.

Where we were unable to contact study authors to verify information, we will reattempt contact at the next update to ensure inclusion/accurate reporting of as many relevant studies as possible.

### Agreements and disagreements with other studies or reviews

Three other recent systematic reviews (Engebretson 2013a; Sgolastra 2013; Tceuw 2010) evaluated the effect of periodontal...
treatment with no treatment (Comparison 1 in this review) in reducing HbA1c for patients with diabetes. After 3 months, Teeuw 2010 (five included studies, 371 participants) estimated weighted mean HbA1c was lower by 0.40% (95% CI -0.77 to -0.04%; P = 0.03), Sgolastra 2013 (five included studies, 315 participants) estimated weighted mean HbA1c was lower by 0.65% (95% CI 0.43 to 0.88; P < 0.05), and Engebretson 2013a (nine included studies, 719 participants) found HbA1c was reduced by 0.36% (95% CI -0.54 to -0.19; P < 0.0001). This review’s relevant meta-analysis (14 included studies, 1499 participants) estimates weighted mean HbA1c to be 0.29% lower (95% CI -0.48 to -0.10; P = 0.003) after 3-4 months.

As would be expected with an increased number of included studies and participants, the treatment effect estimate range has narrowed from previous reviews.

We concur with author reported limitations from Engebretson 2013a; Sgolastra 2013 and Teeuw 2010 that intervention variety, small sample size of included studies/lack of large-scale RCTs, and an inherent high risk of bias (owed largely to the impossibility of blinding patients and operators to group allocation for many interventions) may impact the estimation of accurate treatment effects from periodontal intervention when compared with no active treatment; however, we must acknowledge that the inclusion of Engebretson 2013 (accounting for 34% of participants in comparison 1) significantly increased the sample size available for analysis.

Due to the large number of participants contributed by Engebretson 2013, it is appropriate to address some specific concerns about the trial raised in other literature (Borgnakke 2014) regarding included patients’ HbA1c range being close to optimal levels, the decision to include patients above and below protocol-specified thresholds and high BMI. Having considered these concerns, we believe that the inclusion of such patients reflects the breadth of population likely to be seen in clinical practice, and the inclusion of the trial enhances estimation of the true effect of periodontal treatment for glycaemic control in diabetic patients.

A further criticism of Engebretson 2013 made by Borgnakke 2014 is that the trial’s periodontal outcomes indicate that the accepted standard of care was not met by the periodontal therapy provided to trial participants; however, in meta-analysis to derive treatment effect estimates for periodontal indices, Engebretson 2013’s outcomes were consistent at both time points for all reported outcomes with the other included studies. Consequently, we are satisfied that Engebretson 2013’s clinical conduct is not of sufficient concern to warrant post-hoc sensitivity analyses excluding its contribution, and have confidence in its findings being consistent with those of other included studies.

**Implications for practice**

There is low quality evidence that the treatment of periodontal disease by scaling and root planing does improve glycaemic control in people with diabetes, with a mean percentage reduction in HbA1c of 0.29% at 3-4 months; however, there is insufficient evidence to demonstrate that this is maintained after 4 months.

There was no evidence to support that one periodontal therapy was more effective than another in improving glycaemic control in people with diabetes.

In clinical practice, ongoing professional periodontal treatment will be required to maintain clinical improvements beyond 6 months. Further research is required to determine whether adjunctive drug therapies should be used with periodontal treatment. Future randomised controlled trials (RCTs) should evaluate this, provide longer follow-up periods, and consider the inclusion of a third ‘no treatment’ control arm.

Larger, well conducted and clearly reported studies are needed in order to understand the potential of periodontal treatment to improve glycaemic control among people with diabetes. In addition, it will be important in future studies that the intervention is effective in reducing periodontal inflammation and maintaining it at lowered levels throughout the period of observation.

**Implications for research**

Further studies to confirm or refute these findings should be viewed as a public health priority in view of the prevalence of both periodontal disease and diabetes, and the potential impact of impaired diabetes management on morbidity, mortality and quality of life. We suggest a two-phase approach to investigating the importance of periodontal disease treatment on diabetes.

Firstly, a limited number of additional RCTs should be conducted investigating the impact of periodontal therapy on glycaemic control, with at least 6 months follow-up after treatment completion. Withholding treatment for the control group is not ethical. This could be managed, as with some of the reported studies, by the control group continuing with ‘usual care’ for the duration of the trial (eg Jones 2007: examples might include supragingival prophylaxis, standalone oral hygiene instruction or other reasonable oral care treatments), with rescue treatment provided for progressing periodontal disease. Trials should clearly report the occurrence of adverse events, and the use of antidiabetic therapy at baseline and changes to such therapy during the study periods (treatment phase and follow-up, ideally separately).

Each trial should be large enough to have sufficient power to demonstrate a statistically significant difference if it exists. The data from the existing trials should be able to provide data for such a calculation (allowing for losses to follow-up). Definitions of periodontal disease and diabetes should be clear, and studies should use the CONSORT statement to ensure adequate and transparent...
reporting of methodology. Trialists should also use the data from this systematic review and meta-analyses to inform their own study designs, and to share the results of new/ongoing trials to update collective findings and determine the overall totality of the evidence. In view of the many potential confounders that exist with a disease such as diabetes, study designs should also include data relating to age, duration, medication, smoking, HbA1c assessment standard (Diabetes Control and Complications Trial (DCCT) or the International Federation of Clinical Chemistry (IFCC)) and recognised diabetes-related complications.

The intervention and clinical setting should be appropriate for the severity of periodontitis (eg mild to moderate severity periodontitis should be treated in a similar way to primary or community care provision capabilities, whereas severe periodontitis may require specialist skills), and additional supportive maintenance care should be provided to the intervention group (as per usual practice) for studies in excess of 3 to 4 months duration. It will be important for future studies that the intervention is effective in both reducing periodontal inflammation, and maintaining it at lowered levels throughout the period of observation. In addition, studies should investigate the impact of periodontal therapy on both people with type 1 and type 2 diabetes mellitus, tobacco consumption status/duration since smoking cessation, glycaemic control, and have sufficient included participants in each group to determine the treatment response in both groups.

Secondly, if the evidence clearly indicates a potentially clinically significant benefit, community-based trials should be conducted. Future research may involve close co-operative working between researchers with dental/periodontal and medical backgrounds. Such studies might include a variety of research designs, depending on the question to be addressed. For instance, multicentred and/or international (including high income and low- to middle-income countries) RCTs (and possibly cluster-randomised trials) should be considered for addressing the question of the impact of periodontal therapy on control of diabetes. As well as glycaemic control, trials should measure quality of life and diabetes complications. Health economic evaluation is also important. Qualitative research could be used to address questions relating to barriers/facilitators of oral health and diabetes care, and preferences and experiences of patients. Furthermore, patient involvement in the design and conduct of these studies is strongly recommended.

ACKNOWLEDGEMENTS

We thank the Cochrane Oral Health Group (Cochrane OHG) for its support in undertaking this updated review: specifically, Anne Littlewood for running the searches; Laura MacDonald, Luisa Fernandez Mauleffinch and Anne-Marie Glenny for providing editorial and methodological comments; and Luisa Fernandez Mauleffinch for copy editing this review.

Our thanks to Rahul Alam, Deborah Matthews, Didac Mauricio and Hugo Pinto for peer-refereeing the clinical content of this review.

Additionally, we recognise the contribution from Cochrane OHG’s translators: Chunjie Li (Li 2011), Andreas Neudecker (Albrecht 1988) and Farhad Shokraneh (Haerian Ardakani 2014; Mansouri 2006).

Particular thanks are due to the trial authors who provided unpublished information that allowed more thorough appraisal of studies: Mohammed Al-Zahrani (Al-Zahrani 2009), Mary Cullinan (ACTRN12605000260628; ACTRN12605000340639), Poliana Mendes Duarte (Miranda 2014; Santos 2009; Santos 2012), Elena Firkova (Yun 2007), Cristiane Miranda França (NCT01964833), Łukasz Gilowski (Gilowski 2012), Sara Grossi (Grossi 1997), Judith Jones (Jones 2007), Sayaka Katagiri (Katagiri 2009), Panagiotis Koromantzos (Koromantzos 2011), Shaila Patil Kothiwal (Kothiwal 2013), Fernando Llambés (Llambés 2008), Thomas Oates (NCT00801164), Rok Schara (Skaleric 2004), Jean Suvan (ISRCTN83229304), Mario Tabo (Rodrigues 2003), Elif Unsal (Kiran 2005), and Jean-Noel Vergnes (Calbacho 2004; Mansouri 2006; ISRCTN15334496).

We would also like to acknowledge the contributions of Edward Mills to the original published review.

Finally, particular thanks are expressed by Terry Simpson to Richard Ibbetson for his personal support and guidance during this review’s initial conception.
REFERENCES

References to studies included in this review

Al-Zahrani 2009 [published and unpublished data]

Callbacho 2004 [published and unpublished data]

Chen 2012 [published data only]


Engebretson 2011 [published data only]

Engebretson 2013 [published data only]


Gay 2014 [published data only]

Gilowski 2012 [published and unpublished data]

Grossi 1997 [published and unpublished data]

Kiran 2005 [published and unpublished data]
Treatment of periodontal disease for glycaemic control in people with diabetes mellitus (Review)

Koromantzos 2011 [published and unpublished data]

Madden 2008 [published data only]

Moeintaghavi 2012 [published data only]

NCT00801164 [published and unpublished data]

O’Connell 2008 [published data only]

Pradeep 2013 [published data only]

Raman 2014 [published data only]

Rocha 2001 [published data only]

Rodrigues 2003 [published and unpublished data]

Santos 2009 [published and unpublished data]

Santos 2012 [published and unpublished data]
References to studies excluded from this review

Albrecht 1988 [published data only]

Al-Mubarak 2002 [published data only]

Santos 2013 [published data only]

Singh 2008 [published data only]

Skaleric 2004 [published and unpublished data]

Sun 2011 [published data only]

Tsaliikis 2014 [published data only]

Yun 2007 [published and unpublished data]

Zhang 2013 [published data only]

References to studies awaiting assessment

Cinar 2014 [published data only]

Gorbacheva 2010 [published data only]

Hagiwara 2002 [published and unpublished data]

Khader 2010 [published data only]

Llambés 2012 [published data only]

Mansouri 2006 [published and unpublished data]

Munenaga 2013 [published data only]

NCT01255254 [published data only]

Promsudthi 2005 [published data only]

Taylor 2011 [published data only]

References to studies awaiting assessment
Al-Mubarak 2010 {published data only}


Botero 2013 {published data only}


Chee 2006 {published data only}


Lin 2012 {published and unpublished data}


Nassar 2014 {published data only}


References to ongoing studies

ACTRN12605000260628 {published and unpublished data}


ACTRN12605000340639 {published and unpublished data}


IRCT2014082417587N7 {published data only}


ISRCTN15334496 {published and unpublished data}


ISRCTN83229304 {published and unpublished data}


NCT0016835 {published data only}


NCT01291875 {published data only}


NCT01881074 {published data only}


NCT01901926 {published data only}


NCT01904422 {published data only}


NCT01964833 {published and unpublished data}


U1111-1124-3635 {published data only}


Additional references

Alam 2009


Armitage 1999

Treatmet of periodontal disease for glycaemic control in people with diabetes mellitus (Review)

Begg 1994

Berlin 1997

Bonito 2004

Borgnakke 2014

Buchwald 2013

Bunn 1981

Chew 2015

Darré 2008

DCCT 1993

Egger 1997

Engebretson 2013a

Firlati 1997

Florkowski 2003

Franco 2012

Goldstein 2004

GRADepro
McMaster University. GRADepro. 3.6.1. McMaster University, 2014.

Grossi 1998

Hanas 2010

Hex 2012

Higgins 2011

International Diabetes Federation 2013

Khaw 2001
**Kornman 2014**
Kornman KS. Commentary: Periodontitis severity and progression are modified by various host and environmental factors. *Journal of Clinical Periodontology* 2014;45(12):1642–5.

**Kowall 2015**

**McCambridge 2014**

**Milward 2003**
Milward MR, Chapple IL. Classification of periodontal diseases: Where were we? Where are we now? Where are we going?. *Dental Update* 2003;30(1):37–44.

**Page 1998**

**Papapanou 1996**

**Peter 2007**

**Preshaw 2012**

**Rabi 2006**

**RevMan 2014**

**Sandberg 2000**

**Seppälä 1993**

**Seuring 2015**

**Sgolastra 2013**

**Stewart 2001**

**Stratton 2000**

**Taylor 2001**

**Teeuw 2010**

**UKPDS 1998**

**WHO 2013**

**WHO 2014**

**WHO 2015**

**References to other published versions of this review**

**Simpson 2004**
Simpson T, Needleman I, Wild SH, Moles DR, Mills EJ. Treatment of periodontal disease for glycaemic control in people with diabetes. *Cochrane Database*
Simpson 2010
* Indicates the major publication for the study
### Characteristics of included studies [ordered by study ID]

#### Al-Zahrani 2009

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Details</th>
</tr>
</thead>
</table>
| **Methods**     | Trial design: 3-arm, single-centre, parallel-design RCT  
|                 | Location: Saudi Arabia  
|                 | Setting: Hospital  
|                 | Number of centres: 1, King Abdulaziz University Hospital  
|                 | Recruitment period: January to November 2008  
|                 | Funding source: Supported by a grant from King Abdulaziz University |
| **Participants**| Inclusion criteria: Age >35 years, confirmed diagnosis of type 2 diabetes, generalized moderate to severe chronic periodontitis, and >20 remaining teeth. The presence of clinical attachment loss >3 mm at >30% of sites was used to define generalized moderate to severe chronic periodontitis  
|                 | Exclusion criteria: Pregnant women, patients with major diabetic complications, and patients who received periodontal treatment or antibiotic therapy 6 months before the study  
|                 | Age at baseline: Overall: mean 52.21 yrs (SD 8.35); Gp A: mean 53.14 yrs (SD 10.91); Gp B: mean 51.42 yrs (SD 6.24); Gp C: mean 51.92 yrs (SD 7.28) (P = 0.87)  
|                 | Sex (M:F): Overall: M17:F26; Gp A M7:F8; Gp B M4:F10; Gp C M6:F8 (P = 0.58)  
|                 | Tobacco use (never/ever): Overall: 33/10; Gp A: 9/6; Gp B: 13/1; Gp C: 11/3 (P = 0.28)  
|                 | Alcohol consumption: Not reported  
|                 | Diabetes type: All T2, as required by inclusion criterion  
|                 | Duration since diabetes diagnosis: Not reported  
|                 | Antidiabetic therapy: Insulin - Overall: n = 12 (28%); Gp A: n = 3 (20%); Gp B: n = 4 (29%); Gp C: n = 5 (36%)  
|                 | Oral hypoglycaemic medication - Quote: "About 72% and 28% of the participants were taking, respectively, oral hypoglycaemic medication and insulin to control their diabetes. None of the participants reported a change in the types or doses of their medications during the study period"  
|                 | Metabolic control: Poor mean HbA1c at baseline  
|                 | Mean HbA1c at baseline: Overall: 8.80% (SD 1.96); Gp A: 8.75% (SD 1.43); Gp B: 8.42% (SD 1.65); Gp C: 9.25% (SD 2.71) (P = 0.56)  
|                 | Other medical conditions: Not reported  
|                 | Other investigations: No additional investigations undertaken  
|                 | Number randomised: 45  
|                 | Number evaluated: 43 (2 lost to follow-up, allocated group not stated - possible to identify 1 each from Gps B+C - Gp A: n = 15; Gp B: n = 14; Gp C: n = 14) |
| **Interventions**| Comparison: SRP + OHI versus SRP + OHI + doxycycline versus SRP + OHI + aPDT  
|                 | Gp A (n = 15): SRP only + OHI  
|                 | Gp B (n = 14): SRP + OHI + 2x 100 mg doxycycline, then 100 mg daily for 13 days  
|                 | Gp C (n = 14): SRP + OHI + aPDT (using 0.01% methylene blue irrigator (as supplied in pre-filled syringe by manufacturer), irradiated with 670 nm non-thermal diode laser)  
|                 | All participants received individualised OHI at baseline, and SRP was performed across 4
sessions within 7 days, using ultrasonic and manual instruments under local anaesthesia if necessary

**Duration of follow-up:** 3 months

### Outcomes

**Primary:** HbA1c, recorded at baseline and 3 months

**Secondary:** PI, BOP, CAL, and PPD, recorded at baseline and 3 months

### Notes

**Sample size calculation:** A total sample size of 42 subjects (14 in each group) was required to detect a difference of 1 mm between the highest and lowest means with 80% power and an assumed common standard deviation of 0.8 at a significance level of $P < 0.05$. To compensate for any loss to follow-up, 45 patients were included

**Data analysis method:** Assumed ITT

**HbA1c assessment method:** Commercially available Dimension and Flex HA1C automated processor, Dade Behring, UK

**Adverse events:** Quote: "None of the patients reported any complications associated with the use of PDT therapy, such as burning sensations, discomfort, or pain"

**SES:** Education level attained reported

- Overall: Illiterate = 15 (M:4; F:11); elementary = 12 (M:5; F:7); >elementary = 16 (M:8; F:8)
- Gp A: Illiterate = 5; elementary = 6; >elementary = 4
- Gp B: Illiterate = 3; elementary = 4; >elementary = 7
- Gp C: Illiterate = 7; elementary = 2; >elementary = 5

**Conflict of interests:** Quote: "The authors report no conflicts of interest related to this study"

**Trial ID:** Not reported

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>A simple randomisation approach using computer-generated random numbers was employed to assign subjects to 1 of the following 3 treatment modalities</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;Allocations of subjects to their assigned groups were kept with principal investigator (Al-Zahrani) in sealed envelopes, and were given to the co-author who was performing the treatment immediately prior to the treatment schedule. The primary investigator was not involved in the immediate inclusion/exclusion of subjects and has no prior knowledge of the subjects’ periodontal findings&quot; (from correspondence with the principal author) Comment: No indication if sealed envelopes were opaque</td>
</tr>
</tbody>
</table>
### Al-Zahrani 2009 (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk Assessment</th>
<th>Risk Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Interventions different and no placebos used</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Incomplete outcome data</td>
<td>Unclear risk</td>
<td>Quote: “Two patients were lost to follow-up; one travelled outside the country, and the other one refused to return for follow-up” 2 of the original 45 randomised were lost to follow-up. Unlikely to introduce a bias. Analysis assumed to have been ITT, but not specifically reported</td>
</tr>
<tr>
<td>Selective reporting</td>
<td>Low risk</td>
<td>Planned outcomes reported in full</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other apparent biases</td>
</tr>
</tbody>
</table>

### Calbacho 2004

#### Methods
- **Trial design:** 2-arm, parallel-design RCT
- **Location:** Chile
- **Setting:** Primary care
- **Number of centres:** Not reported
- **Recruitment period:** Not reported
- **Funding source:** Not reported

#### Participants
- **Inclusion criteria:** Aged 40-60, diagnosis of T2 DM with poor metabolic control of diabetes and moderate chronic marginal periodontitis diagnosis without treatment of this disease from 1 year or more
- **Exclusion criteria:** Any other treatment or medication (except diabetes), less than 8 teeth (excluding third molars)
- **Age at baseline:** Overall: mean 50.3 yrs (SD 6.2); Gp A: mean 52.8 yrs (SD 5.4); Gp B: mean 47.8 yrs (SD 6.1). No P value reported
- **Sex (M:F):** Overall M10:F14; Gp A: M4:F8; Gp B: M6:F6. No P value reported
- **Tobacco use:** All non-smokers
- **Alcohol consumption:** Not reported
- **Diabetes type:** All T2 DM
- **Duration since diabetes diagnosis:** Both groups 10.0 yrs (SD 3.4)
- **Metabolic control:** Poor mean HbA1c at baseline
  - Mean HbA1c at baseline: Gp A: 9.70% (SD 2.90); Gp B: 10.40% (SD 2.30) (P = 0.23)
- **Antidiabetic therapy:** All in receipt of oral hypoglycaemic medication only
- **HbA1c assessment method:** High-performance liquid chromatography
- **Other clinical investigations:** Mean blood glucose levels
- **Number randomised:** 24
- **Number evaluated:** 24
Interventions | **Comparison: SRP + doxycycline versus OHI**
Gp A: (n = 12) "conventional" periodontal treatment + doxycycline 100 mg daily for 10 days
Gp B: (n = 12) OHI only

Outcomes | **Primary:** HbA1c, at baseline, 2 and 4 months
**Secondary:** PPD, PI and BOP

Notes | Only abstract published to date. Full study unpublished. Author states reason as "lack of time to prepare report and excess of work in other areas"
Author (Victor Calbacho) provided some details and numerical data via email in May 2013, but his email address is no longer valid, and other authors have been non-responsive to email requests
SES: Not reported
**Sample size calculation:** Not reported
**Data analysis method:** ITT
**HbA1c assessment method:** High-performance liquid chromatography
**Conflict of interests:** Not reported
**Adverse events:** Not reported

<table>
<thead>
<tr>
<th><strong>Bias</strong></th>
<th><strong>Authors’ judgement</strong></th>
<th><strong>Support for judgement</strong></th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk | Block randomisation - method unexplained
Quote: "12 were at random assigned to a study group and the rest to a control group"
| Allocation concealment (selection bias) | Unclear risk | Unknown |
| Blinding of participants | High risk | Not possible |
| Blinding of clinical operator | High risk | Not possible |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | All completed. ITT analysis |
| Selective reporting (reporting bias) | High risk | Secondary data only reported as P values (no means or SDs provided despite repeated email request). Also no detail of adverse events |
| Other bias | Unclear risk | Insufficient description in abstract and from author's comments to make a judgement. Full study unpublished other than as abstract, and therefore without peer-review although study lead confirms intention to |
Chen 2012

**Methods**

**Trial design:** 3-arm, single-centre, parallel-design RCT  
**Location:** Guangzhou  
**Setting:** Not reported  
**Number of centres:** 1  
**Recruitment period:** November 2008 to October 2009  
**Funding source:** 2 grants - both government sponsored: 1) Key Projects in the National Science and Technology Pillar Program (11th 5-year plan periods), Beijing, China and 2) Technology Planning Project of Guangdong Province, China (grant 2010B031600117)

**Participants**

**Inclusion criteria:** Diagnosis T2 DM <1 year; no change in TP in the previous 2 months; no major diabetic complication (e.g., CHD); diagnosis of chronic periodontal disease (AAP criteria), ≥16 teeth, ≥1 mm mean CAL; including mild, moderate and severe periodontitis  
**Exclusion criteria:** Presence of systemic disease other than diabetes that could influence the course of periodontal disease; systemic antibiotic administration in last 3 months; pregnancy or lactation; refusal of written consent; active infections other than periodontitis; periodontal treatment in last 12 months  
**Age at baseline:** Overall 60.3 yrs (SD 10.02); Gp A: mean 59.86 yrs (SD 9.48); Gp B: mean 57.91 yrs (SD 11.35); Gp C: mean 63.2 yrs (SD 8.51) (P = 0.052)  
**Sex (M:F):** Overall M66:F60; Gp A: M23:F19; Gp B: M26:F17; Gp C: M17:F24 (P = 0.2)  
**Tobacco use:** Gp A n = 7; Gp B n = 10; Gp C n = 7 (former smoker: Gp A n = 1; Gp B n = 1; Gp C n = 0) (P = 0.872)  
**Alcohol consumption:** Gp A n = 2; Gp B n = 4; Gp C n = 7 (P = 0.169)  
**Diabetes type:** All T2 DM  
**Duration since diabetes diagnosis:** Gp A mean 8.69 yrs (SD 5.25); Gp B mean 6.93 yrs (SD 4.31); Gp C mean 9.56 yrs (SD 6.02) (P = 0.066)  
**Metabolic control:** Fair mean HbA1c at baseline  
Mean HbA1c at baseline: Gp A 7.31% (SD 1.23); Gp B 7.29% (SD 1.55); Gp C 7.25% (SD 1.49) (P > 0.05)  
**Antidiabetic therapy:** All in receipt of oral hypoglycaemic medication (Gp A: 38; Gp B: 35; Gp C: 36), insulin (Gp A: 4; Gp B: 5; Gp C: 4), or diet (Gp A: 0; Gp B: 3; Gp C: 1) (P = 0.574)  
**Other clinical investigations:** Gingival recession, FPG (mmol/l), hsCRP (mg/L), TNF-α 9pg/ml), TC (mmol/l), TG (mmol/l), HDL-C (mmol/l), LDL-C (mmol/l)  
**Other medical conditions:** None  
**Number randomised:** 134  
**Number evaluated:** 126 (loss to follow-up Gp A 3, Gp B 2, Gp C 3)

**Interventions**

**Comparison:** SRP + OHI (x 3) + subgingival debridement versus SRP + OHI (x 3) + supragingival prophylaxis versus no intervention  
Gp A (n = 45): SRP (at baseline; with local anaesthetic, no antibiotics or local antimicrobials, using standard Gracey curettes and ultrasonic instrumentation, and completed in 24 hrs) + OHI (x 3: at 1.5, 3 and 6 months check-ups) + subgingival debridement (at 3 months)
Gp B (n = 45): SRP (at baseline; with local anaesthetic, no antibiotics or local antimicrobials, using standard Gracey curettes and ultrasonic instrumentation, and completed in 24 hrs) + OHI (x 3: at 1.5, 3 and 6 months check-ups) + supragingival prophylaxis (at 3 months; no intervention in deep periodontal pockets)
Gp C (n = 44): No intervention (delayed treatment until completion of study)

Duration of follow-up: 6 months with interim readings taken at 1.5 and 3 months

Outcomes

Primary: HbA1c (at baseline, month 1.5, month 3 and month 6)
Secondary: PI, BOP, mean PD, sites with PD = 4 to 5 mm, sites with PD ≥6 mm and mean CAL (all at 1.5 months, 3 months and 6 months)

Notes

Sample size calculation: A priori calculation assuming SD of 1% at 80% power - approximately 53 per group
Data analysis method: Per-protocol
HbA1c assessment method: Boronate-affinity chromatography
Conflict of interests: Authors report no conflict of interests
SES: Not reported
Adverse events: No adverse events reported by participants

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “…computer-generated list of random numbers prepared by statistician”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “Allocation concealed from researcher LC.” Allocation overseen by “independent research nurse” Sequentially numbered envelopes used 1-134 Comment: No indication whether envelopes were opaque and sealed</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Not possible due to difference in mechanical intervention</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>Unclear risk</td>
<td>Not reported. DX undertook non-surgical periodontal treatment</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>All patients accounted for with reasons provided. Per-protocol analysis: not all participants analysed in groups randomised to, regardless of intervention actually received</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>No evidence</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other apparent biases</td>
</tr>
</tbody>
</table>
### Methods
- **Trial design:** 3-arm, single-centre, parallel-design RCT
- **Location:** USA
- **Setting:** Hospital
- **Number of centres:** 1, Naomi Berrie Diabetes Centre, Columbia University Medical Center
- **Recruitment period:** Not reported
- **Funding source:** Columbia University Office of Clinical Trials Pilot Award and National Institute of Dental and Craniofacial Research Award DE 00449 (SE). Collagenex Pharmaceutical Inc. provided subantimicrobial doxycycline doses (brand name: Periostar; Gp A) and placebos (Gps B+C), and Columbia University Medical Center Research Pharmacy provided visually indistinguishable antimicrobial doxycycline doses (Gp B)

### Participants
- **Inclusion criteria:** Chronic periodontitis (CAL >5 mm in at least 1 site in each quadrant). Duration since diagnosis ≥ 6 months. Stable medication for diabetes for ≥ 3 months (insulin or OHA)
- **Exclusion criteria:** Present use of Coumadin (warfarin, anticoagulant); pregnancy or lack of birth control; chronic non-steroidal anti-inflammatory drug use or antibiotic use within 6 months; renal impairment, severe liver disease and grade 3 or 4 retinopathy
- **Age at baseline:** Overall: mean 53.8 yrs (SD 2.4); Gp A mean 53.2 yrs (SD 3); Gp B mean 54.4 yrs (SD 2); Gp C mean 53.8 yrs (SD 2) (P = 0.93)
- **Sex (M:F):** Overall: M20:F25; Gp A M7:F8; Gp B M7:F8; Gp C M6:F9 (P = 0.91)
- **Tobacco use:** Not reported
- **Alcohol consumption:** Not reported
- **Diabetes type:** Type 2 DM
- **Duration since diabetes diagnosis:** Overall mean: 9 yrs; Gp A mean 11.6 yrs (SD 13.2); Gp B mean 6.1 yrs (SD 5.1); Gp C mean 7.6 yrs (SD 4.7) (P = 0.33)
- **Metabolic control:** Fair mean HbA1c at baseline
  - Mean HbA1c at baseline: Gp A 7.9% (SD 1.9); Gp B 7.6% (SD 2.0); Gp C 8.2% (SD 2.0) (P = 0.75)
- **Antidiabetic therapy:** Inclusion criteria required stable dosage of oral hypoglycaemic agents or insulin. Study confirms use of medications remained constant during study period
- **Other clinical investigations:** Plasma glucose (mg/dL), gingival recession
- **Number randomised:** 45
- **Number evaluated:** 34 (11 losses to follow-up)

### Interventions
- **Comparison:** SRP (x 3) + subantimicrobial doxycycline (20 mg bid) versus SRP (x 3) + antimicrobial doxycycline (100 mg bid) versus SRP (x 3) + placebo
  - Gp A (n=15): SRP (x 3: at baseline, 1 month and 3-month follow-up) + subantimicrobial doxycycline (20 mg twice a day, for 3 months duration: 2 vials at baseline - AM vial 14 x 20 mg, PM vial 14 x 20 mg; 1 vial at 2-week follow-up - 28 x 20 mg; 1 vial at 1 month follow-up - 120 x 20 mg)
  - Gp B (n=15): SRP (x 3: at baseline, 1 month and 3-month follow-up) + antimicrobial dose doxycycline (100 mg daily, for 14 days: 2 vials at baseline - AM vial 14 x 100 mg, PM vial 14 x placebo tablets; 1 vial at 2-week follow-up - 28 x placebo tablets; 1 vial at 1 month follow-up - 120 x placebo tablets)
  - Gp C (n=15): SRP (x 3: at baseline, 1 month and 3-month follow-up) + placebo (twice a day, for 3 months: 2 vials at baseline - AM vial 14 x placebo tablets, PM vial 14 x placebo tablets; 1 vial at 2-week follow-up - 28 x placebo tablets; 1 vial at 1 month follow-up -
SRP for all groups including full mouth root planing, scaling with curettes and ultrasonic instrument, under local anaesthesia, lasting no longer than 2 hours

**Duration of follow-up:** 3 months

### Outcomes

**Primary:** HbA1c at baseline, 1 and 3 months (reported for baseline and 3 months: not 1 month)

**Secondary:** PPD, BOP, PI, CAL at baseline, 1 and 3 months (none reported)

### Notes

**Sample size calculation:** No a priori calculations

**Data analysis method:** ITT analysis

**SES:** Not reported

**Adverse events:** “There were no serious adverse events reported during the study. Differences in adverse events between groups were not observed, and the treatments appeared to be well tolerated”

**HbA1c assessment method:** Automated affinity chromatography system (BioRad MicroMat II, Hercules, CA)

**Conflict of interests:** “The authors disclosed no conflicts of interest”

Author emailed to 2 separate addresses for further information/missing periodontal data, but no response received

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>“Assigned by computer generated table” to either group</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Comment: Matching and indistinguishable placebo and intervention were provided by the pharmacy in vials with unique codes</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>Low risk</td>
<td>Comment: Visually indistinguishable placebo given to control group. Time intervals kept the same for each group</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>Unclear risk</td>
<td>Comment: Study stated to be double-blinded, but not explained in text</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>Large number of withdrawals (22%): 1/45 withdrew: not indicated from which arm; 10/45 lost to follow-up: Gp A: n = 6 ; Gp B: n = 1; Gp C: n = 3 ITT analysis</td>
</tr>
<tr>
<td>All outcomes</td>
<td>High risk</td>
<td>No periodontal data reported despite being recorded</td>
</tr>
</tbody>
</table>
Other bias | Low risk | No other apparent biases
--- | --- | ---

Engebretson 2013

**Methods**

**Trial design:** 2-arm, multicentre, parallel-design RCT  
**Location:** USA  
**Setting:** Community  
**Number of centres:** 5 - diabetes and dental clinics and communities associated with academic medical centres (deliberately selected for geographic diversity):  
- University of Alabama, Birmingham, Alabama;  
- University of Minnesota and Hennepin County Medical Center, Minneapolis, Minnesota;  
- University of Texas Health Science Center, San Antonio, Texas;  
- Stony Brook University, New York;  
- University of Texas Health Science Center, Houston, Texas  
**Recruitment period:** November 2009 - March 2012 (originally designed to run until May 2012)  
Enrollment stopped earlier than anticipated due to futility. Trial stopping rule based on power threshold of 40% demonstrating interim test statistic of <-0.12 t-test for HbA1c was -0.37, consequently monitoring board recommended cessation of recruitment  
**Funding source:** 2 x NIH/NIDCR grants: U01 DE018902 (awarded to S Engebretson); U01 DE018886 (awarded to L Hyman)  
No detail re: provider/manufacturer of chlorhexidine mouthrinse to compare to conflict of interests declarations

**Participants**

**Inclusion criteria:** Either sex; aged 35 or more; with physician-diagnosed type 2 diabetes (duration of >3 months); an HbA1c value between 7-<9% at screening; under care of physician for management of diabetes; diagnosed with moderate-advanced chronic periodontitis (CAL/PD >5 mm in 2 or > quadrants); minimum of 16 natural teeth; received no periodontal treatment in prior 6 months; and agreed to continue current diabetes medications (unless medically indicated otherwise); and avoid pregnancy during the trial period  
**Exclusion criteria:** Treatment required for extensive caries, abscess, or oral infection; limited life expectancy (<1 year); diabetes-related emergency in prior 30 days; NSAID use (>7 days in prior 2 months. Except low-dose aspirin: 75-325 mg/d); systemic immunosuppressant use; systemic antibiotic use (>6 days during 30 days after enrolment); receiving dialysis; increased risk of bleeding complications; heavy alcohol consumption (mean >2 drinks/day for females and >3 drinks/day for males)  
**Age at baseline:** Overall: mean 57.3 yrs (SD 10.1); Gp A: mean 56.7 yrs (SD 10.5); Gp B: mean 57.9 yrs (SD 9.6). No P value reported  
**Sex (M:F):** Overall: M277:F237; Gp A: M143:F114; Gp B: M134:F123. No P value reported  
**Tobacco use:** Gp A: Never n = 129; former n = 89; current n = 39  
Gp B: Never n = 144; former n = 86; current n = 27  
**Weight:** Gp A: mean 99.5 kg (SD 24.3); Gp B: mean 97.5 kg (SD 21.7)  
**BMI:** Gp A: 34.7 (SD 7.5); Gp B: 34.2 (SD 6.7)  
**Alcohol consumption:** Not reported
Diabetes type: All T2 DM
Duration since diabetes diagnosis: Gp A: mean 12.3 yrs (SD 8.2); Gp B: 11.3 yrs (SD 8.4)
Metabolic control: Largely fair-poor mean HbA1c at baseline
Mean HbA1c at baseline: Overall: <7.0% n = 22; >7.0%–<8.0% n = 297; >8.0%–<9.0% n = 179; >9.0%–<10.0% n = 16
Gp A: <7.0% n = 12; >7.0%–<8.0% n = 143; >8.0%–<9.0% n = 93; >9.0%–<10.0% n = 9
Gp B: <7.0% n = 10; >7.0%–<8.0% n = 154; >8.0%–<9.0% n = 86; >9.0%–<10.0% n = 7
Antidiabetic therapy: All except 11 patients (2% of 514 participants) were in receipt of oral hypoglycaemic medication, insulin, or combination treatment
Overall: No diabetes medications n = 11; oral agents only n = 244; insulin only n = 80; combination of medications n = 179
Gp A: No diabetes medications n = 7; oral agents only n = 117; insulin only n = 40; combination of medications n = 93
Gp B: No diabetes medications n = 4; oral agents only n = 127; insulin only n = 40; combination of medications n = 86
Other investigations: Change in insulin, fasting glucose levels, HOMA2 scores and diabetes medication from baseline; participants requiring periodontal/diabetes rescue therapy
Other medical conditions: Overall: Angina n = 32; myocardial infarction n = 43; stroke n = 24; hypertension n = 364; kidney disease n = 26
Gp A: Angina n = 21; myocardial infarction n = 22; stroke n = 12; hypertension n = 180; kidney disease n = 14
Gp B: Angina n = 11; myocardial infarction n = 21; stroke n = 12; hypertension n = 184; kidney disease n = 12
Number randomised: 514 (Gp A n = 257; Gp B n = 257)
Number evaluated:
ITT analysis (HbA1c outcome only):
Baseline: Gp A n = 257; Gp B n = 257
3 months: Gp A n = 257; Gp B n = 257
6 months: Gp A n = 257; Gp B n = 257
Per-protocol analysis (all outcomes - all participants with HbA1c data at 6-month visit):
Baseline: Gp A n = 240; Gp B n = 235
3 months: Gp A n = 233; Gp B n = 227 (missed 3-month visit: Gp A n = 6; Gp B n = 7). Periodontal data missing: Gp A n = 1; Gp B n = 1
6 months: Gp A n = 240; Gp B n = 233 (periodontal data missing: Gp A n = 0; Gp B n = 2)

Interventions
Comparison: SRP (x 3) + OHI (x 3) + chlorhexidine (0.5 oz bid) versus OHI (x 3)
Gp A (n = 257): SRP (at baseline, 3 and 6 months: initial SRP >160 min treatment with local anaesthesia over 2 or more sessions, and completed within 42 days of initial baseline visit; SRP at 3 and 6 months comprised of a single 1 hour session each time) + OHI and provision of 0.12% chlorhexidine gluconate oral rinse (0.5 oz twice daily for 2 weeks), toothbrush, toothpaste, and dental floss
Gp B (n = 257): OHI at baseline, 3 months and 6 months (followed by offer of SRP after 6-month visit)
Duration of follow-up: 6 months

<table>
<thead>
<tr>
<th>Outcomes</th>
</tr>
</thead>
</table>
| **Primary**: HbA1c (at baseline, 3 and 6 months)  
**Secondary**: GI, BOP, PPD and CAL (at baseline, 3 and 6 months) | 

<table>
<thead>
<tr>
<th>Notes</th>
</tr>
</thead>
</table>
| **Sample size calculation**: 468 participants required (90% power: 2-tailed, 2-sample t-test, 0.05 type I error). Accounting for attrition rate of 20%, planned sample size was 600 (300 in each arm)  
**Data analysis**: ITT (periodontal data provided per-protocol analysis; however, all periodontal parameters provided as tertiles, therefore not able to use per-protocol data in meta-analysis)  
**SEs**: Ethnicity data provided  
Overall: Black n = 146; white n = 280; Hispanic n = 166; other n = 88  
Gp A: Black n = 76; white n = 140; Hispanic n = 81; other n = 41  
Gp B: Black n = 70; white n = 140; Hispanic n = 85; other n = 47  
**Adverse events**: Quote: “No study-related serious adverse events occurred”  
Reported symptoms were consistent with common discomfort following SRP  
Diabetes rescue therapy required by 1.7% in Gp A (4/241), and 2.1% in Gp B (5/236) during the trial  
Change in medication from baseline required by 45.0% in Gp A (105/233), and 40.2% in Gp B (92/229)  
**HbA1c assessment method**: Whole-blood samples iced and analysed within 4 days by high-performance liquid chromatography (Tosoh HPLC G7 Glycohemoglobin Analyzer, Tosoh Medics Inc)  
**Conflict of interests**: No conflict declaration from lead author (Dr Engebretson), but available for others:  
Quote: “Dr Gelato reported receiving travel/meeting expenses from the Endocrine Society. Dr Seaquist reported serving as a board member and President Elect of Science and Medicine for the American Diabetes Association; serving as a consultant for AMG Medical, sanofi-aventis, SkyPharma, and Merck; receiving grants or grants pending from the American Diabetes Association, Eli Lilly, and the National Institutes of Health; and receiving payment for lectures from the Japan Diabetes Society, the American Diabetes Association, Intellyst Medical Education, Pediatric Academic Societies, the Association of Specialty Professors, and the International Society for Neurochemistry. Dr Lewis reported receiving a grant or grant pending from Novo Nordisk. Dr Katancik reported serving as a consultant for the Texas Healthy Baby Initiative 2011 and receiving a grant or grant pending, and travel/meeting expenses, from Zimmer Dental. Dr Paquette reported serving as a board member for Colgate-Palmolive; receiving a speakers honorarium from Colgate-Palmolive; and serving as a consultant for MIS Implant Technologies”  
**Trial ID**: NCT00997178 (trial referred to as Diabetes and Periodontal Therapy Trial (DPTT)) |
| Random sequence generation (selection bias) | Low risk | Quote: "Randomization was conducted centrally by the CC using a site-specific randomization assignment sequence generated prior to the start of the study. Assignments to the Treatment and Control Groups were created through a custom computer program using a permuted block randomization scheme stratified by Clinical Site using block sizes of 2, 4 or 6” |
| --- | --- | |
| Allocation concealment (selection bias) | Low risk | Quote: "Randomization assignments by individual participant were accessible in Velos eResearch only to the necessary CC personnel and the Clinical Site Coordinators. Participant IDs did not contain treatment assignment codes”  
“Once eligibility for an individual was confirmed, the CC Study Coordinator generated the randomization assignment electronically and notified the Clinic Coordinator by email or fax. The Clinic Coordinator then contacted the participant with the treatment group assignment. No other Clinical Site personnel other than the Study Therapist were informed of the assignments” |
| Blinding of participants | High risk | Quote: "Double masking would have required us to provide some type of “sham” periodontal therapy to control participants, which, to the best of our knowledge, had not been done in any previous trial in periodontology”  
“Periodontal therapy also frequently results in gingival (gum) recession and tooth sensitivity, especially to hot and cold temperatures. Treatment also removes the discolored calcified deposits that form at and just beneath the gum line. These signs and symptoms, which can be readily noticed by patients, would not be expected following some type of “sham” treatment. Thus, it is unlikely that the provision of a sham treatment would adequately mask control participants either” |
| Blinding of clinical operator | High risk | Quote: "An endpoint of treatment is the complete removal of hard and soft deposits from the tooth and root surfaces. Thus it is
Engebretson 2013  (Continued)

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Outcome</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Incomplete outcome data (attrition bias)</strong></td>
<td>All outcomes</td>
<td>Low risk</td>
</tr>
<tr>
<td><strong>Selective reporting (reporting bias)</strong></td>
<td>Low risk</td>
<td>All reported (albeit via supplementary material available online). Adverse events reported</td>
</tr>
<tr>
<td><strong>Other bias</strong></td>
<td>Unclear risk</td>
<td>Conflict of interests declaration reported for all authors except lead author</td>
</tr>
</tbody>
</table>

Gay 2014

**Methods**

| Trial design | 2-arm, single-centre, parallel-design RCT |
| Location | USA |
| Setting | Hospital |
| Number of centres | 1, University of Texas Health Science Center, Houston, Texas |
| Recruitment period | Not reported. |
| Funding source | Quote: “This study is funded by National Institutes of Health Clinical and Translational Award UL1 RR024148 and KL2 RR024149 from the National Center For Research Resources” |

**Participants**

| Inclusion criteria | >18 yrs old; diagnosed T2 DM; possessing HbA1c value >6.5% at screening (although initial values of 5.7-6.5% were included if taking hypoglycaemic medication; n = 16 (note: unsure of allocation between groups)); Hispanic; presence of local or general severe chronic periodontitis (AAP criteria) |
| Exclusion criteria | Smokers; dental treatment within prior 12 months; systemic antibiotics within 6 months of recruitment (not specified if a pre- or post-recruitment requirement) |
| Age at baseline | Overall: mean 52.8 yrs (SD 9.7); Gp A: mean 51.5 yrs (SD 9.0); Gp B: 54.0 yrs (SD 10.2). No P value reported |
| Sex (M:F) | Overall M55:F71; Gp A: M30:F36; Gp B: M25:F35. No P value reported |
| Tobacco use | Smokers were excluded from participation in the trial |
| Weight | Not reported |
| BMI | Not reported |
| Alcohol consumption | Not reported |
| Diabetes type | All T2 DM |
| Duration since diabetes diagnosis | Not reported |
| Metabolic control | Poor mean HbA1c at baseline |
| Mean HbA1c at baseline | Gp A: 9.00% (SD 2.30); Gp B: 8.40% (SD 2.00) |
| Antidiabetic therapy | All except 26 patients (21% of 126 participants) were in receipt of “diabetic treatment” without further description: Gp A: 78.8% (n = 52); Gp B: 80.0% (n = 48). Of diabetic treatment recipients, 21 patients were on insulin therapy: Gp A: 21% (n = 14); Gp B: 12% (n = 7) |
**Other investigations:** Distance from free gingival margin to cementoenamel junction (FGM-CEJ)

**Other medical conditions:** Not reported

**Number randomised:** 154 (Gp A n = 77; Gp B n = 77)

**Number evaluated:** 126 (Gp A n = 66; Gp B n = 60)

Note: All data (including baseline) only presented for evaluated patients, rather than those randomised

Attrition: Gp A: dropped out n = 2; lost to follow-up n = 8 (1 patient not accounted for); Gp B: dropped out n = 12; lost to follow-up n = 2; excluded for unreliable data n = 2 (1 patient not accounted for)

**Interventions**

**Comparison:** SRP + OHI (x 2) versus OHI

Gp A (n = 77): OHI at baseline (including modified Bass technique, interdental brush/floss use), + SRP 4-6 weeks later (ultrasonic scaler, Gracey curettes, on 2 quadrants, local anaesthetic, by 2 calibrated periodontists) when OHI repeated

Gp B (n = 77): OHI at baseline (including modified Bass technique, interdental brush/floss use), + repeat OHI 4-6 weeks later

**Duration of follow-up:** 4 months

**Outcomes**

**Primary:** HbA1c (at baseline and 4 months)

**Secondary:** BOP, PD and CAL (at baseline and 1 month)

**Notes**

**Sample size calculation:** 123 participants required (90% power; 2-sided t-test, .05 type I error). Accounting for attrition rate of 20%, planned sample size was 154 (77 in each arm)

**Data analysis:** Per-protocol

**SES:** Not reported specifically except that all participants were of Hispanic origin

**Adverse events:** Not reported

Change in medication from baseline required by Gp A: 27.3% (n = 18); Gp B: 21.7% (n = 13)

**HbA1c assessment method:** Afinion AS100 Analyzer. High value samples run in duplicate, and several other samples run in duplicate for compliance

**Conflict of interests:** Authors declare no conflict of interests

**Trial ID:** NCT01128374

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Computer-randomised sequence generation Quote: “Permuted blocks randomization with varying block sizes using Stata 11 was performed by a statistician (DT) to generate allocation sequences”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “These sequences were used by the research coordinator (AC) to recruit and blindly randomize 154 participants either</td>
</tr>
</tbody>
</table>
Gay 2014  (Continued)

<table>
<thead>
<tr>
<th>Blinding of participants</th>
<th>Unclear risk</th>
<th>Not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of clinical operator</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
</tbody>
</table>
| Incomplete outcome data (attrition bias) | High risk | All data (including baseline) only presented for evaluated (n = 126) patients, rather than those randomised (n = 154)
1 patient from each group not accounted for
Attrition: Gp A: dropped out n = 2; lost to follow-up n = 8 (1 patient not accounted for); Gp B: dropped out n = 12; lost to follow-up n = 2; excluded for unreliable data n = 2 (1 patient not accounted for)
Per-protocol analysis: not all participants analysed in groups randomised to, regardless of intervention actually received |
| Selective reporting (reporting bias) | Unclear risk | All initially stated outcomes reported on in results/tables, albeit only including those evaluated. No adverse events reported |
| Other bias | Low risk | No other apparent biases |

Gilowski 2012

Methods
- **Trial design:** 2-arm, parallel-design RCT
- **Location:** Poland
- **Setting:** Not reported
- **Number of centres:** Not reported, but assumed to be single centre due to single examiner and small sample size
- **Recruitment period:** Not reported
- **Funding source:** Medical University of Silesia, Katowice, Poland

Participants
- **Inclusion criteria:** At least 14 teeth and a clinical diagnosis of diabetes mellitus type 2 and severe or moderate, localized or generalized CP. Each patient had at least 4 non-adjacent sites with PD >= 4 mm
- **Exclusion criteria:** Previous dental prophylaxis and periodontal treatment within 6 months of the initial visit; known hypersensitivity to tetracyclines; smoking; antibiotic therapy within the 3 months of the initial visit; chronic therapy with non-steroidal anti-inflammatory drugs or immunosuppressive medications and administration of medications that can interfere with doxycycline (anticoagulants and contraceptive drugs); systemic diseases, which can have an influence on periodontal status or immunologic
Gilowski 2012  (Continued)

| Interventions | Comparison: SRP + OHI + doxycycline tablet (20 mg bid) versus SRP + OHI + placebo tablet  
Gp A (n = 17): SRP + OHI + SDD: subantimicrobial dose doxycycline 20 mg bid 3 months  
Gp B (n = 17): SRP + OHI + placebo bid 3 months  
**Duration of follow-up:** 3 months |
|---|---|

| Outcomes | **Primary:** HbA1c (at baseline and 3 months)  
**Secondary:** CAL, BOP, PPD (at baseline and 3 months) |
|---|---|

| Notes | **Sample size calculation:** “Based on previous information from a pilot study recently conducted by our research group, using data relative to the mean difference between groups and standard deviation 3 months after periodontal treatment (unpublished data). Using difference in clinical parameter (PD >= 4 mm) as primary outcome, with an expected mean difference between groups after the therapy of 0.5 mm and an expected standard deviation of 0.5 mm, it was estimated that at 80% power and a level of significance of 0.05, the sample size should be 16 subjects per group. To allow the possible drop outs, 34 patients (17 per group) were finally recruited.”  
(Note: Principal author supplied further unpublished data, including mean (SD) data)  
**Data analysis:** Assumed ITT  
**HbA1c assessment method:** Turbidometric inhibition immunoassay (Cobas Integra 400 plus; Roche Diagnostics Polska)  
**Adverse events:** No adverse effects reported by participants  
**SES:** Not reported  
**Conflict of interests:** Not reported |
|---|---|---|

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>

**Treatment of periodontal disease for glycaemic control in people with diabetes mellitus (Review)**

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Gilowski 2012 (Continued)

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Did not specify computerised <em>per se</em>, but did mention randomised blocks</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Investigators not involved in assignment of drug containers</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>Low risk</td>
<td>Quote: “indistinguishable placebo”</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>Low risk</td>
<td>All personnel blinded “indistinguishable placebo”</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Comment: Insufficient information to judge. No indication of the numbers used in each analysis Analysis assumed to have been ITT, but not specifically reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>CAL data not reported although measured</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other apparent biases</td>
</tr>
</tbody>
</table>

### Grossi 1997

**Methods**

- **Trial design:** 5-arm, single-centre, parallel-design RCT
- **Location:** USA
- **Setting:** Not reported
- **Number of centres:** 1
- **Recruitment period:** Not stated
- **Funding source:** Grants from ‘USPHS’ and National Institute of Dental Research and equipment donated by Eastman Kodak

**Participants**

- **Inclusion criteria:** Non-insulin dependent diabetics from the Gila River Indian Community, aged 25 to 65 years, with moderate to severe periodontitis
- **Exclusion criteria:** Patients on renal dialysis or presenting with diabetic complications requiring hospitalisation
- **Age at baseline:** Not reported
- **Sex (M:F):** Overall M32:F81. “...patients [...] stratified by duration of diabetes (below and above 10 years duration), insulin use, and sex and randomly assigned to one of the 5 treatment groups. Each of the groups had at least one third males”
- **Tobacco use:** Not reported
- **Alcohol consumption:** Not reported
- **Diabetes type:** T2 DM
- **Duration since diabetes diagnosis:** Not reported
- **Metabolic control:** Poor mean HbA1c at baseline
  
  Mean HbA1c at baseline: Gp A: 10.4% (SD 2.6); Gp B: 10.4% (SD 1.9); Gp C: 10.3% (SD 2.6); Gp D: 10.5% (SD 2.0); Gp E: 9.3% (SD 2.7)
  
  (Note: Means provided by study author (we requested SDs) differ from published figures)
Interventions

**Comparison:** SRP + water rinse + doxycycline versus SRP + chlorhexidine + doxycycline versus SRP + iodine + doxycycline versus SRP + chlorhexidine + placebo versus SRP + water rinse + placebo

- **Gp A (n = 18):** SRP + water rinse + doxycycline (100 mg daily for 14 days)
- **Gp B (n = 22):** SRP + chlorhexidine (0.12%) + doxycycline (100 mg daily for 14 days)
- **Gp C (n = 21):** SRP + iodine (0.05% povidone iodine) + doxycycline (100 mg daily for 14 days)
- **Gp D (n = 27):** SRP + chlorhexidine (0.12%) + placebo (daily for 14 days)
- **Gp E (n = 24):** SRP + water rinse + placebo (daily for 14 days)

All participants received ultrasonic bactericidal curettage (UBC) performed with an ultrasonic device, with continuous irrigation with an antimicrobial solution, in 2 sessions, 1 week apart at baseline (half of mouth was treated at each session).

**Duration of follow-up:** 6 months

Outcomes

**Primary:** HbA1c (at baseline, 3 and 6 months)

**Secondary:** CAL, PD, PI and GI (at baseline, 3 and 6 months)

Notes

**Sample size calculation:** Not reported

**Data analysis:** Per-protocol

**SES:** Not specifically detailed, but all participants were Native Indian residents of the Gila River Indian Community (of Pima or Pima/Papago heritage), in Arizona, USA

**Adverse events:** Not reported

**HbA1c assessment method:** Biorad high performance liquid chromatography (HPLC)

**Conflict of interests:** Not reported

Data provided by email from Bob Genco. Group ns not clearly detailed in study paper, instead derived from provided data.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “randomisation was stratified by duration of diabetes (&gt; or &lt; 10 years), insulin use, and sex.” Method of sequence generation not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>Unclear risk</td>
<td>Not reported, perhaps not possible</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>----------</td>
<td>--------------</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>Per-protocol analysis: not all participants analysed in groups randomised to, regardless of intervention actually received. Number of participants assessed in each group varies according to outcome</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>HbA1c not reported in publication, although obtained directly from authors and no estimates of variance reported for PD or plaque, numbers in each group not reported. Adverse events not reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>Imbalance of HbA1c between groups at baseline. Antidiabetic therapy use not reported</td>
</tr>
</tbody>
</table>

**Haerian Ardakani 2014**

**Methods**
- **Trial design:** 2-arm, single-centre, parallel-design RCT
- **Location:** Iran
- **Setting:** Hospital
- **Number of centres:** 1, Diabetes Research Center, Yazd City
- **Recruitment period:** Not reported
- **Funding source:** Not reported

**Participants**
- **Inclusion criteria:** Patients with type 2 diabetes and proper blood glucose control (HbA1c ≤ 7%) and chronic periodontitis with 3 regions probe depth more than 4 mm and less than 7 mm
- **Exclusion criteria:** Patients treated with anti-inflammatory agents; systemic antibiotics within 3 months before the start of study; periodontal treatment in past 6 months; smokers; acute medical conditions; less than 8 teeth in month; and pregnant or breastfeeding women
- **Age at baseline:** Not reported
- **Sex (M:F):** Not reported
- **Tobacco use:** Not reported but smoking reported as an exclusion criteria
- **Alcohol consumption:** Not reported
- **Diabetes type:** All participants had diabetes type 2
- **Duration since diabetes diagnosis:** Not reported
- **Metabolic control:** Good mean HbA1c at baseline
  Mean HbA1c at baseline: Gp A: 6.48% (SD 0.51) Gp B: 6.44% (SD 0.35)
- **Antidiabetic therapy:** Not reported.
- **Other investigations:** Cholesterol, LDL, HDL, triglyceride
- **Other medical conditions:** N/A
- **Number randomised:** 30
- **Number evaluated:** 30
### Interventions

<table>
<thead>
<tr>
<th>Group</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gp A (n = 15):</td>
<td>SRP with topically applied tetracycline gel (5%)</td>
</tr>
<tr>
<td>Gp B (n = 15):</td>
<td>SRP (standard periodontal care)</td>
</tr>
</tbody>
</table>

**Duration of follow-up:** 3 months

### Outcomes

**Primary:** HbA1c (at baseline and 3 months)<br>
**Secondary:** GI, PI, and PPD (at baseline and 3 months)

### Notes

**Sample size calculation:** Not reported<br>
**Data analysis:** ITT<br>
**HbA1c assessment method:** Not reported<br>
**Trial ID:** IRCT2013092614774N1 (www.irct.ir/searchresult.php?id=14774&number=1)<br>
**Conflict of interests:** Not reported<br>
**Adverse events:** Not reported<br>
**SES:** Not reported<br>
Study data translated by Farhad Shokraneh - January 2015

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported. (Protocol (see URL above) simply refers to an &quot;interventional randomized clinical trial&quot; &quot;randomly divided 15 patients&quot;)</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported.</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>Unclear risk</td>
<td>Not reported.</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>Unclear risk</td>
<td>Not reported.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>No losses to follow-up. ITT analysis</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>All recorded outcomes were reported on within the results section, however, no adverse events reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No way to verify if other biases exist due to translation of data extraction components</td>
</tr>
</tbody>
</table>
### Methods

**Trial design:** 2-arm, multicentre, parallel-design RCT (at 4 months)  
**Location:** USA  
**Setting:** Primary care  
**Number of centres:** 4, New England  
**Recruitment period:** Not stated  
**Funding source:** Grants from Veterans Affairs Health Services Research and Development Service and Boston University (VA HSR&D QUERI DII-99.206 and NIH K24 DE00419). Dentsply International provided ultrasonic scalers, and Colgate Oral Pharmaceuticals provided the Gluconate rinse (PerioGards)

### Participants

**Inclusion criteria:** A repeat HbA1c of 8.5% or above; a minimum of 8 natural teeth; periodontal treatment need as evidenced by the Community Periodontal Index of Treatment Need CPITN scores of 3 or 4 in at least 2 sextants on examination; and sufficient health and willingness to complete the 12-16-month study  
**Exclusion criteria:** Grave medical or psychiatric illness or severe immune compromise (eg HIV or cancer)  
**Age at baseline:** Mean 58.36 yrs. Gp A: 57.79 yrs; Gp B: 58.96 yrs. 4-month group 58.08, 12-month group 58.39  
**Sex (M:F):** Overall: M97%;F3%; Gp A: M100%;F0%; Gp B: M94%;F6%  
**Tobacco use:** Overall: 24%; Gp A: 29.5%; Gp B: 18.8%  
**Alcohol consumption:** Overall: 1.8 drinks p/wk (SD 5); Gp A: 2.2 drinks p/wk (no SD); Gp B: 1.43 drinks p/wk (no SD)  
**Diabetes type:** Assumed majority T2 DM  
**Duration since diabetes diagnosis:** Gp A 11.4 yrs; Gp B 14.1 yrs (no SDs provided by group)  
**Metabolic control:** Poor mean HbA1c at baseline  
Mean HbA1c pre-baseline: Gp A: 10.07%; Gp B: 10.29%  
**Antidiabetic therapy:** All in receipt of oral hypoglycaemic medications, insulin, or combination  
**Other medical conditions:** Many co-morbidities (co-morbidity index: Gp A: 5.95; Gp B: 6.11), high levels of hypertension, hypercholesterolaemia, obesity, atherosclerosis  
**Number randomised:** 193  
**Number evaluated:** 165 (Gp A: 82; Gp B: 83)/132 depending on outcome

### Interventions

**Comparison:** SRP + doxycycline + chlorhexidine rinse versus usual treatment  
Gp A (n = 98): SRP + doxycycline (100 mg qid for 14 days) + chlorhexidine rinse (0.12% twice daily for 4 months)  
Gp B (n = 95): Usual treatment (described only as “usual medical and dental care”)  
**Duration of follow-up:** 4 months

### Outcomes

**Primary:** Change in HbA1c (not fully reported)  
**Secondary:** GI, gingival recession

### Notes

**Sample size calculation:** Quote: “The study was designed to have 300 participants. Allowing for 33% attrition, we expected 200 patients studied, 100/group. We anticipated 80% power to detect a moderate-sized effect (ES δ= 0.40) of the intervention in 2-sided
tests at the 5% level. For the analysis at 4 months comparing the proportion of patients in Early Treatment and Usual Care groups who experienced a greater than 1% drop in their HbA1c levels, we expected similar power

**Data analysis:** Per-protocol

**Adverse events:**
- Chlorhexidine: Disturbance in taste (15%); tooth staining (13.6%); sore mouth/tongue irritation (5%); swelling of lips, face, tongue and throat also reported in a small number of participants. Also shortness of breath
- Doxycycline: Diarrhoea (7.1%); abdominal pain (3.6%); nausea (2.9%)

"Compliance with the study drug regimen was not universal. Eighty-three percent used both chlorhexidine and doxycycline, another 8% used chlorhexidine only, and 7% used doxycycline only. Thus, over 90% in the treatment group used each study drug. Among users of chlorhexidine, 17 participants reported less than daily use, 19 reported daily use, and 29 reported twice daily use. One chlorhexidine user had four bottles left, nine had two to three bottles left, 16 had one left, and 41 used all the chlorhexidine. Among doxycycline users 50 reported using all the pills, two had 10 pills left (of 14), and five had more than 10 pills left"

**SES:** Race is reported, although only as % of white participants: Overall: 97%; Gp A: 84%; Gp B: 79%

**HbA1c assessment method:** Not reported

**Conflict of interests:** Not reported

Means data for analysis provided by lead author in 2007

<table>
<thead>
<tr>
<th><strong>Risk of bias</strong></th>
<th><strong>Authors' judgement</strong></th>
<th><strong>Support for judgement</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;We used PROC PLAN in Statistical Analysis Systems (SAS) Version 8, 1, Cary, NC, USA) to obtain 12 blocks of eight, using a seed of 020348. Group assignments were put on white cards and sealed in white envelopes and numbered consecutively. Study staff took the top envelope to assign study group&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>See above</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Participants knew which group they are allocated to</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>Quote: &quot;...by seeking physicians’ concurrence, in essence we notified each participant’s primary care provider that his or her patient’s diabetes was under poor control. Because of this notification, some providers likely became more aggressive in treating these patients&quot;</td>
</tr>
</tbody>
</table>
### Jones 2007 (Continued)

<table>
<thead>
<tr>
<th>Incomplete outcome data (attrition bias)</th>
<th>High risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>All outcomes</td>
<td>193 participants recruited, 28 excluded after randomisation for reasons not related to interventions. Numbers from each group not reported. 165 in study providing baseline data then 33 withdrawals, reasons given but not by group</td>
</tr>
<tr>
<td></td>
<td>Potentially, such high drop-out rates within the short study duration may reflect the reported adverse events experienced by Gp A (relating to doxycycline and chlorhexidine)</td>
</tr>
<tr>
<td>Per-protocol analysis</td>
<td>Per-protocol analysis: not all participants analysed in groups randomised to, regardless of intervention actually received</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selective reporting (reporting bias)</th>
<th>High risk</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No mean HbA1c values at 4 months reported, only 2 dichotomous outcomes. No reporting of SD for each group, only overall reported Author supplied means and SDs in correspondence</td>
</tr>
<tr>
<td></td>
<td>Adverse events only reported for Gp A</td>
</tr>
<tr>
<td></td>
<td>All characteristics data (including baseline) only presented for evaluated patients (varies for each characteristic) (n = 154-165), rather than those randomised (n = 193)</td>
</tr>
<tr>
<td></td>
<td>1 patient from each group not accounted for</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other bias</th>
<th>High risk</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline differences with respect to smoking, history of stroke, TIAs, diabetes with nephropathy</td>
</tr>
<tr>
<td></td>
<td>Unclear what usual care could be</td>
</tr>
</tbody>
</table>

### Katagiri 2009

<table>
<thead>
<tr>
<th>Methods</th>
<th>2-arm, multicentre, parallel-design RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location</td>
<td>Japan</td>
</tr>
<tr>
<td>Setting</td>
<td>Hospital</td>
</tr>
<tr>
<td>Number of centres</td>
<td>5 diabetic clinics: Tokyo Medical and Dental University Hospital, Kagoshima University Medical and Dental Hospital, Aichi Gakunin University Dental Hospital, Tokyo Medical University Hospital and Kyoto Prefecture Medical University Hospital</td>
</tr>
<tr>
<td>Recruitment period</td>
<td>Not reported</td>
</tr>
<tr>
<td>Funding source</td>
<td>Supported by Grants-in Aid from the Ministry of Health and Welfare of Japan (H16-Iryo-020) and the Mitsui Sumitomo insurance foundation</td>
</tr>
</tbody>
</table>
### Participants

**Inclusion criteria:** Aged 39-75 years, HbA1c 6.5-10.0%; at least 11 remaining teeth, at least 2 pocket sites with probing depth 4 mm or more (indicated as mild to severe periodontitis), no periodontal treatment during the preceding 6 months

**Exclusion criteria:** Severe diabetic complications; evidence of systemic diseases other than diabetes as a risk factor for periodontitis; systemic antibiotics during the preceding 3 months; pregnancy or lactation; allergy to tetracycline; smoking; modifications in the treatment of diabetes during the preceding 2 months

**Age at baseline:** Overall: 59.7 yrs (SD 7.4); Gp A: mean 60.3 yrs (SD 9.9); Gp B: mean 59.0 yrs (SD 4.8)

**Sex (M:F):** Overall: M27:F22; Gp A: M21:F11; Gp B: M6:F11

**Tobacco use:** Non-smokers

**Alcohol consumption:** Not stated

**Diabetes type:** T2 DM

**Duration since diabetes diagnosis:** Gp A: 11.3 yrs (SD 6.4); Gp B: 8.8 yrs (SD 7.5)

**Metabolic control:** Good mean HbA1c at baseline

Mean HbA1c at baseline: Gp A: 7.2 (SD 0.9); Gp B: 6.9 (SD 0.9)

**Antidiabetic therapy:** All in receipt of oral hypoglycaemic medication, insulin, or diet

**Diet:** Overall: n = 3; Gp A: n = 1; Gp B: n = 2

**Oral hypoglycaemic medication:** Overall: n = 27; Gp A: n = 15; Gp B: n = 12

**Insulin:** Overall: n = 19; Gp A: n = 16; Gp B: n = 3

**Other medical conditions:** None reported

**Number randomised:** 49 (Gp A 32; Gp B 17)

**Number evaluated:** 49

### Interventions

**Comparison:** SRP + minocycline + OHI versus OHI

Gp A (n = 32): Mechanical debridement of the subgingival plaque and calculus was performed using piezoelectric ultrasonic scalers, and 10 mg of minocycline ointment (Periofil1, Showa Yakuhin Co., Tokyo, Japan) was administered topically in every periodontal pocket at the end of each visit. The intensive periodontal treatment was completed over the course of 4 visits within 2 months. Additional periodontal treatment including instructions for brushing, supra- and sub-gingival debridement without topical administration of antibiotics were performed, if necessary

Gp B (n = 17): Instructions for brushing their teeth, including the use of interproximal cleaning aids, such as floss and interdental brushes, depending on their individual needs After the completion of 2 months of intensive periodontal treatment, all participants visited the respective medical and dental clinics at 1, 3 and 6 months

**Duration of follow-up:** 6 months

### Outcomes

**Primary:** HbA1c at 1 month, 3 months and 6 months

**Secondary:** Change in PPD at 1 month (Delta PPD), change in BOP at 1 month (Delta BOP) and intervention of periodontal treatment on the change in HbA1c at 6 months

### Notes

**Sample size calculation:** Not reported

**Data analysis:** ITT

**HbA1c assessment method:** High-performance liquid chromatography (Kyotokagaku Co, Japan)

**Adverse events:** Not reported

**SES:** Not reported

**Conflict of interests:** Authors declare no conflict of interests
**Katagiri 2009**  (Continued)

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “randomly allocated by envelope method” - method of sequence generation not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>High risk</td>
<td>Envelope method. Dentists knew the allocations to each group (from correspondence with the author)</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>All randomised participants included in outcome evaluation. ITT analysis</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>HbA1c not reported by group but details later supplied by the lead author. Adverse events not reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other apparent biases</td>
</tr>
</tbody>
</table>

**Kiran 2005**

**Methods**
- **Trial design:** 2-arm, single-centre, parallel-design RCT
- **Location:** Turkey
- **Setting:** Hospital
- **Number of centres:** 1, Ankara University Faculty of Medicine, Department of Metabolic Diseases and Endocrinology
- **Recruitment period:** Not reported
- **Funding source:** Not reported

**Participants**
- **Inclusion criteria:** Patients with type 2 DM with glycated haemoglobin (HbA1c) values: 6%-8%; creatinine values ≤1.4 mg/dl; liver function tests not > 3 x the normal range
- **Exclusion criteria:** Major diabetic complications; systemic antibiotics administered within prior 3 months; periodontal treatment within prior 6 months
- **Sex (M:F):** Overall: M18:F26; Gp A: M10:F12; Gp B: M8:F14
- **Age at baseline:** Overall 54.39 yrs (SD 11.27); Gp A: mean 55.95 yrs (SD 11.21); Gp B: mean 52.82 yrs (SD 12.27)
- **Tobacco use (daily):** Overall: n = 7 (15.9%); Gp A n = 5 (22.7%); Gp B n = 2 (9.1%)
- **Alcohol consumption:** Not reported
- **Diabetes type:** T2 DM
- **Duration since diabetes diagnosis:** Overall mean 8.68 yrs (SD 7.18). Gp A: 9.32 yrs (SD 11.21); Gp B: 8.05 yrs (SD 5.90)
**Metabolic control:** Good-fair mean HbA1c at baseline
Mean HbA1c at baseline: Gp A: 7.31% (SD 0.74); Gp B: 7.00% (SD 0.72)

**Antidiabetic therapy:** All in receipt of oral hypoglycaemic medication (Gp A: 64%; Gp B: 72%), insulin (Gp A: 9%; Gp B: 9%), diet (Gp A: 9%; Gp B: 5%) or combination (Gp A: 18%; Gp B: 14%). No P values presented

**Other clinical investigations:** Gingival recession; fasting plasma glucose; 2-hour post-prandial glucose; total cholesterol; triglyceride; HDL-cholesterol (HDL); LDL-cholesterol (LDL); microalbuminurea

**Other medical conditions:** None reported

**Number randomised:** 44
**Number evaluated:** 44

### Interventions

**Comparison:** SRP + OHI versus no intervention

Gp A (n = 22): OHI and full mouth SRP performed under local anaesthesia
Gp B (n = 22): No periodontal treatment during study period (delayed treatment offered, if required, after conclusion of study)

**Duration of follow-up:** 3 months

### Outcomes

**Primary:** HbA1c, at baseline, at 1 month and 3 months

**Secondary:** PI, GI, PPD, CALs, and BOP were recorded at baseline, at 1 month and 3 months

### Notes

**Sample size calculation:** Not reported

**Data analysis:** ITT

**HbA1c assessment method:** Not reported

**SES:** Not reported

**Adverse events:** Not reported

**Conflict of interests:** Not reported

Clarification supplied by author

Note: teeth with periapical lesions were allocated additional treatment:
Gp A: 9 patients, 9 teeth: 4 extractions, 5 root canal treatment
Gp B: 5 patients, 5 teeth: 5 root canal treatment

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “A list was prepared in advance using random numbers. The list was transferred to a series of sealed envelopes each containing the allocation on the card” (from correspondence with a co-author)</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: “The clinician opened the envelope in the series when the patient entered the trial” (from correspondence with a co-author)</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
</tbody>
</table>
**Kiran 2005**  
(Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>ITT analysis, although subjects who had surgical treatment were excluded from statistical analysis. All participants underwent periodontal examination at baseline and 9/22 and 5/22 had periapical lesions requiring treatment prior to study start. Correspondence with co-author indicates: “HbA1c data was recorded for all 44 trial participants, 22 for test and 22 for control patients. There were no patients lost in the follow up period”</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>All outcomes reported, except adverse events</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other apparent biases</td>
</tr>
</tbody>
</table>

**Koromantzos 2011**

<table>
<thead>
<tr>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trial design</strong>: 2-arm, single-centre, parallel-design RCT</td>
</tr>
<tr>
<td><strong>Location</strong>: Greece</td>
</tr>
<tr>
<td><strong>Setting</strong>: Hospital</td>
</tr>
<tr>
<td><strong>Number of centres</strong>: 1, outpatient university diabetes clinic, Laiko Hospital, Athens</td>
</tr>
<tr>
<td><strong>Recruitment period</strong>: January 2006 to December 2008</td>
</tr>
<tr>
<td><strong>Funding source</strong>: European National Fund and National Resources (EPEAEK 2 PYTHAGORAS)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion criteria</strong>: Diabetes Type: Type 2 DM with HbA1c levels ranging from 7-10%; moderate-to-severe periodontitis; &gt; 16 teeth present; PPD with at least 8 sites ≥6 mm and CAL ≥5 mm in at least 4 sites distributed to at least 2 quadrants</td>
</tr>
<tr>
<td><strong>Exclusion criteria</strong>: Systemic antibiotic usage in last 3 months; non-surgical periodontal treatment during last 6 months; surgical periodontal treatment over last 12 months; current medication including usage of calcium channel blockers, phenytoin or cyclosporine; history of stroke or acute cardiovascular event over the past 12 months; renal dysfunction determined by creatinine levels &gt;1.5 mg/dl or liver dysfunction defined as AT/ALT levels &gt;2.5 times ULN</td>
</tr>
<tr>
<td><strong>Age at baseline</strong>: Overall: mean 59.52 yrs (SD 8.88); Gp A: mean 59.61 yrs (SD 7.95); Gp B: mean 59.4 yrs (SD 9.8)</td>
</tr>
<tr>
<td><strong>Sex (M:F)</strong>: Overall M32:F27; Gp A M17:F13; Gp B M16:F14</td>
</tr>
<tr>
<td><strong>Tobacco use</strong>: Recorded at 3 levels - current, ex and non</td>
</tr>
<tr>
<td>Gp A: 4(13.3%)/13(43.3%)/13(43.3%); Gp B: 7(23.3%)/16(53.3%)/7(23.3%)</td>
</tr>
<tr>
<td><strong>Alcohol consumption</strong>: Not recorded</td>
</tr>
<tr>
<td><strong>Duration since diabetes diagnosis</strong>: Overall 7.8 yrs (SD 5.7); Gp A 7.76 yrs (SD 4.3); Gp B 7.84 yrs (SD 6.8)</td>
</tr>
<tr>
<td><strong>Metabolic control</strong>: Fair mean HbA1c at baseline</td>
</tr>
</tbody>
</table>
| Mean HbA1c at baseline: Gp A 7.87% (SD 0.74); Gp B 7.59 (SD 0.66) (P value not
Antidiabetic therapy: Insulin Gp A 12/30 (40%), Gp B 7/30 (23.3%) (P value not reported); OHA Gp A 21/30 (70%), Gp B 27/30 (90%) (P value not reported)
Mean BMI (kg/m²): Gp A 27.76 (SD) 3.68, Gp B 27.51 (SD) 3.83 (P value not reported)
Mean remaining teeth 23.52 (SD) 3.99, 24.23 (SD) 3.78 (P value not reported)
Other clinical investigations: Total cholesterol, total triglycerides, LDL-cholesterol, HDL-cholesterol
Number randomised: 60
Number evaluated: 60 (4 lost to follow-up in Gp A, 3 in Gp B)

Interventions
Comparison: SRP + OHI versus supragingival cleaning + OHI
Gp A (n = 30): OHI (at baseline, 1 month and 3 months) + SRP (2 sessions, 1 week apart at baseline, using ultrasonic scaler and hand instruments, under local anaesthesia) + additional supportive SRP (at 1 month and 3 months) if required
Gp B (n = 30): OHI (at baseline, 1 month and 3 months) + supragingival cleaning (described as "supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler." Delayed SRP provided to all after conclusion of study)
Duration of follow-up: 6 months

Outcomes
Primary: HbA1c (recorded at baseline, 1 month, 3 and 6 months)
Secondary: CAL, PPD, BOP and GI (recorded at baseline, 1 month, 3 and 6 months)

Notes
Sample size calculation: 19 required in each arm to detect mean difference reduction in HbA1c between groups of 0.4% (90% power, 2-sided type 1 error of 5%)
HbA1c assessment method: High-performance liquid chromatography
Data analysis: ITT
SES: All Greek patients, no further details
Adverse events: Not reported
Conflict of interests: Authors declare no conflict of interests
Notes: Gp A: 2/30 had extractions at baseline

Risk of bias
<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Computer assignment undertaken by 1 author (PK) before recruitment. Sequential Quote: “The randomization sequence was generated by one author (PK) before patient recruitment. Numbers from 1 to 60 were assigned to patients according to their recruitment date (first recruited patient would be number 1 and last would be number 60). Random assignment into two groups of 30 patients each was then accomplished with the use of a computer program”</td>
</tr>
<tr>
<td>Bias Type</td>
<td>Risk</td>
<td>Details</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Allocation concealment (selection bias) | Low risk | 4 containers numbered 1-60, designated for each visit of each patient maintain masking  
Quote: “Containers (numbered 1-60, four for each visit of each patient) were designated to maintain examiner blinding” |
| Blinding of participants              | High risk | Not possible  
Quote from correspondence with author: “Every patient after the screening examination was assigned to control or treatment groups according to their rank in that sequence (first that was recruited, 2nd, 3rd etc.). The participants did not know what category they were assigned in until they received SRP or prophylaxis, they were informed that they would have treatment at the beginning or at the end of the study” |
| Blinding of clinical operator         | High risk | Quote from correspondence with author: “The periodontist that performed SRP or prophylaxis (same for all patients, P.K.) knew the allocation group of the patients, right after the baseline visit” |
| Incomplete outcome data (attrition bias) | Low risk | 100% completion. ITT analysis |
| Selective reporting (reporting bias)  | Unclear risk | No change data for triglycerides, total cholesterol, LDL-cholesterol and HDL-cholesterol. Adverse events not reported  
Quote from correspondence with author: “...in our study we divided pocket depth and CAL in 3 categories, (percentage of shallow, medium and deep pockets) and there is no available information in overall pocket depth or CAL.” Despite this, PPD and CAL data not considered to be a source of bias |
| Other bias                            | Low risk | No other apparent biases |
### Methods

<table>
<thead>
<tr>
<th>Trial design:</th>
<th>2-arm, single-centre, parallel-design RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location:</td>
<td>India</td>
</tr>
<tr>
<td>Setting:</td>
<td>Hospital</td>
</tr>
<tr>
<td>Number of centres:</td>
<td>1, Department of Periodontics, KLE VK Institute of Dental Sciences, Belgaum</td>
</tr>
<tr>
<td>Recruitment period:</td>
<td>Unknown</td>
</tr>
<tr>
<td>Funding source:</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Participants

**Inclusion criteria:** Either sex; aged 25 or older; known cases of type 2 diabetes (minimum duration of 2 years); possessing >20 natural teeth; and receiving oral hypoglycaemic medications

**Exclusion criteria:** History of smoking, haemoglobinopathies, or hypertension; receiving insulin therapy, renal dialysis or requiring hospitalisation; undergone periodontal therapy in prior 6 months; antibiotic/anti-inflammatory drugs taken in prior 3 months; have abnormal hepatic function; pregnant or lactating

**Age at baseline:**
- Gp A: mean 57.7 yrs (SD 8.61); Gp B: mean 56.4 yrs (SD 11.53)

**Sex (M:F):**
- Overall: M32:F18; Gp A: M15:F10; Gp B: M17:F8

**Tobacco use:** Excluded from participation if possess history of smoking

**Weight:** Not reported

**BMI:**
- Gp A: 23.7 (SD 1.92); Gp B: 23.85 (SD 1.65)

**Alcohol consumption:** Not reported

**Diabetes type:** All T2 DM

**Duration since diabetes diagnosis:**
- Gp A: mean 5.3 yrs (SD 2.76); Gp B: 5.2 yrs (SD 2.20)

**Metabolic control:** Fair mean HbA1c at baseline

**Mean HbA1c at baseline:**
- Gp A: 8.16 (SD 0.61); Gp B: 7.94 (SD 0.66)

**Antidiabetic therapy:** All in receipt of oral hypoglycaemic medication

**Quote:** “The oral hypoglycemic drugs for diabetes, diet and physical therapy was unchanged throughout the course of the study as monitored by the physician”

**Other investigations:** Change in periodontal status (by CPI and LOA scores)

**Other medical conditions:** Not reported

**Number randomised:** 50 (Gp A n = 25; Gp B n = 25)

**Number evaluated:** Not reported

### Interventions

**Comparison: SRP + OHI versus no treatment**

- **Gp A (n = 25):** SRP after baseline examination (by ultrasonic scaler, hand scaler and curette across varying numbers of sessions - dependent of treatment needs of individual patients), followed a further SRP session (unspecified time point) by same investigator, and provision of OHI
- **Gp B (n = 25):** No treatment (followed by SRP and OHI after end of study)

**Duration of follow-up:** 3 months

### Outcomes

**Primary:** Change in HbA1c from baseline to 3 months

**Secondary:** None

### Notes

**Sample size calculation:** Not reported

**Data analysis:** Per-protocol

**SES:** Education status data provided:
- Overall: Illiterate n = 11 (22%); primary school n = 14 (28%); high school n = 15 (30%)
<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Simply states 50 patients randomly assigned into 2 groups. No indication of method</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>Not reported, but assumed not possible as only intervention group patients would have received care</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>No patient flow provided or any drop-outs indicated, although states “After the non-surgical therapy was completed, patients were reevaluated for surgical treatment needs. The data concerning the group of patients who had surgical treatment were excluded in the statistical analysis” Per-protocol analysis: not all participants analysed in groups randomised to, regardless of intervention actually received</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Planned outcomes reported on; however no reporting of adverse events</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Unpublished data, and therefore without peer-review. Author indicated intention to publish study in full in near future</td>
</tr>
</tbody>
</table>

Adverse events: Not reported
HbA1c assessment method: High-pressure liquid chromatography (HPLC)
Conflict of interests: Not reported

Kothiwale 2013 (Continued)

; graduate n = 10 (20%)
Gp A: Illiterate n = 5 (20%); primary school n = 10 (40%); high school n = 6 (24%); graduate n = 4 (16%)
Gp B: Illiterate n = 6 (24%); primary school n = 4 (16%); high school n = 9 (36%); graduate n = 6 (24%)

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Simply states 50 patients randomly assigned into 2 groups. No indication of method</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>Not reported, but assumed not possible as only intervention group patients would have received care</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>No patient flow provided or any drop-outs indicated, although states “After the non-surgical therapy was completed, patients were reevaluated for surgical treatment needs. The data concerning the group of patients who had surgical treatment were excluded in the statistical analysis” Per-protocol analysis: not all participants analysed in groups randomised to, regardless of intervention actually received</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Planned outcomes reported on; however no reporting of adverse events</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Unpublished data, and therefore without peer-review. Author indicated intention to publish study in full in near future</td>
</tr>
</tbody>
</table>
### Methods

**Trial design:** 3-arm, multicentre, parallel-design RCT  
**Location:** Peking, China  
**Setting:** Community  
**Number of centres:** 6 community healthcare centres  
**Recruitment period:** Not reported  
**Funding source:** National Key Project of Science and Technical Supporting Programs of China, National Natural Science Foundation of China, “211” Project Foundation, Mega-projects of Science Research for the 10th Five-year Plan

### Participants

**Inclusion criteria:** Type 2 DM (the diagnostic criteria was 1999 WHO DM diagnostic criteria) with chronic periodontitis (at least 1 tooth with PD ≥ 3 mm and AL ≥ 3 mm). The number of residual teeth must have exceeded 16 and no receipt of any periodontal treatment within 1 year  
**Exclusion criteria:** Aggressive periodontitis, severe chronic or debilitating disease; long-term usage of antibiotics or steroids  
**Age at baseline:** Gp A: 60.86 yrs (SD 10.22); Gp B: 64.21 yrs (SD 5.99); Gp C: 61.64 yrs (SD 9.6)  
**Sex (M:F):** Overall M28:F38; Gp A M9:F13; Gp B M8:F11; Gp C M11:F14  
**Tobacco use:** Gp A (9.1%); Gp B (15.8%); Gp C (12%)  
**Alcohol consumption:** Not reported  
**Diabetes type (I/II):** Gp A (0/22); Gp B (0/19); Gp C (0/25)  
**Duration since diabetes diagnosis:** Gp A 6.5 (SD) 5.1 yrs; Gp B 8.84 (SD) 5.77 yrs; Gp C 7.92 (SD) 5.14 yrs  
**Metabolic control:** Fair mean HbA1c at baseline Mean HbA1c at baseline: Gp A: 7.64 (SD 1.77); Gp B: 8.15 (SD 1.97); Gp C: 8.12 (SD 1.88)  
**Antidiabetic therapy:** Gp A (oral hypoglycaemic agents: 77.3%/insulin injection: 27.3%); Gp B (78.9%/21.1%); Gp C (76%/16%)  
**Other clinical investigations:** FBG (fasting blood glucose); modified bleeding index  
**Other medical conditions:** Diabetes complications Gp A (27.3%); Gp B (21.1%); Gp C (32%)  
**Number randomised:** 66  
**Number evaluated:** Not reported

### Interventions

**Comparison:** Non-surgical periodontal treatment versus supragingival scaling versus no intervention  
**Gp A (n = 22):** Periodontal initial therapy: periodontal non-surgical treatment given by periodontists (details not given)  
**Gp B (n = 19):** Professional mechanical tooth cleaning: coronal/supragingival scaling given by oral hygienists (details not given)  
**Gp C (n = 25):** Non-clinical therapy: no active intervention  
**Duration of follow-up:** 6 months

### Outcomes

**Primary:** HbA1c (at baseline, 6 weeks, 3 and 6 months)  
**Secondary:** Probing depth, attachment loss, plaque index - change data only for periodontal parameters

### Notes

**Sample size calculation:** Not reported  
**Data analysis:** Assumed ITT
SES: Not reported
**Adverse events:** Unknown, was a stated secondary outcome in paper
**HbA1c assessment method:** Not reported
**Conflict of interests:** Not reported
Translation by Chunjie Li, May 2014

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>No information</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>No information</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>Unclear risk</td>
<td>No information</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>Unclear risk</td>
<td>No information</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>No information</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>No information</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No way to verify if other biases exist due to translation of data extraction components</td>
</tr>
</tbody>
</table>

### Llambes 2008

**Methods**

- **Trial design:** 2-arm, single-centre, parallel-design RCT
- **Location:** Spain
- **Setting:** Hospital
- **Number of centres:** 1, Dr Peset University Hospital, Valencia, Spain.
- **Recruitment period:** September 2003 to March 2004
- **Funding source:** Not reported

**Participants**

- **Inclusion criteria:** Diabetes for more than 1 year, and none of them had other major illnesses or severe diabetic complications; patients had not taken antibiotics for at least 3 months prior to baseline and did not have any active infection; a panoramic radiograph was taken to assure that neither extensive caries nor periapical lesions were present; eligible subjects had 14 or more natural teeth, of which at least 5 had a site with PPD ≥ 5 mm and CAL ≥ 3 mm i.e. moderate to severe periodontal disease
- **Exclusion criteria:** Periodontal treatment or professional cleaning of the teeth in year prior to the study; pregnant and breastfeeding women
- **Age at baseline:** Overall mean 35.3 yrs (SD 9.0); Gp A mean 36.8 yrs (SD 9.5); Gp B mean 33.8 yrs (SD 9)
- **Sex (M:F):** Overall M30:F30; Gp A M17:F13; Gp B M13:F17
- **Tobacco use:** Overall n = 22; Gp A n = 11; Gp B n = 11
<table>
<thead>
<tr>
<th>Alcohol consumption:</th>
<th>Not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes type:</td>
<td>Type 1 DM</td>
</tr>
<tr>
<td>Duration since diabetes diagnosis:</td>
<td>At least 1 year, Gp A 14 (SD 7.5), Gp B 15 (10) years</td>
</tr>
<tr>
<td>Metabolic control:</td>
<td>Fair mean HbA1c at baseline</td>
</tr>
<tr>
<td>Mean HbA1c at baseline:</td>
<td>Gp A: 7.64 (SD 1.81); Gp B: 7.51 (SD 1.36)</td>
</tr>
<tr>
<td>Antidiabetic therapy:</td>
<td>All in receipt of insulin</td>
</tr>
<tr>
<td>Other clinical investigations:</td>
<td>Fructosamine</td>
</tr>
<tr>
<td>Number randomised:</td>
<td>72</td>
</tr>
<tr>
<td>Number evaluated:</td>
<td>60</td>
</tr>
</tbody>
</table>

Interventions

Comparison: SRP + OHI + chlorhexidine rinse + systemic doxycycline versus SRP + OHI + chlorhexidine rinse
Gp A (n = 30): OHI (instruction on Bass brushing technique and interproximal cleaning) + SRP (under local anaesthesia, in 1 or 2 sessions, 1 week apart depending on periodontal disease severity and number of natural teeth) + chlorhexidine rinse (20 ml for 30 sec, twice daily for 12 weeks) + systemic doxycycline (200 mg on day 1, then 100 mg/day for 14 days)
Gp B (n = 30): As above, without systemic doxycycline
Duration of follow-up: 3 months

Outcomes

Primary: Changes in HbA1c
Secondary: PI, BOP, PPD, CAL (recorded but not presented, and not provided by authors)

Notes

Sample size calculation: Reported that “enough statistical power to detect HbA1c changes ≥0.3% with a risk of 0.05.” Possibly a post hoc calculation
Compliance with chlorhexidine rinsing reported to be same in both groups
Data analysis: Per-protocol
HbA1c assessment method: Not reported
SES: Not reported
Adverse events: Not reported
Conflict of interests: Not reported

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “The sample was randomized, allowing the subjects to self-select a coded number contained in an envelope; this number identified the group to which the patient was assigned (group 1 or 2)” Comment: Method of code generation not stated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Comment: Unclear if envelope was sealed and opaque</td>
</tr>
</tbody>
</table>
### Llambés 2008 (Continued)

<table>
<thead>
<tr>
<th>Source</th>
<th>Blinding of participants</th>
<th>Blinding of clinical operator</th>
<th>Incomplete outcome data (attrition bias)</th>
<th>Other bias</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>High risk</td>
<td>Unclear risk</td>
<td>High risk</td>
<td>Low risk</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Quote: &quot;At the end of the study, 12 sub-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>jects were dropped out because they did</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>not follow appropriately the study proto-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>col or due to active acute infections du-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ring post-treatment period&quot;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Per-protocol analysis: not all partici-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>pants analysed in groups randomised to,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>regardless of intervention actually re-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ceived</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PI, BOP, PPD, CAL recorded but not re-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ported. Adverse events also not re-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ported.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No other apparent biases</td>
<td></td>
</tr>
</tbody>
</table>
Interventions

SRP + adjunctive antimicrobial + aPDT + OHI (x 7) versus SRP + adjunctive antimicrobial + OHI (x 7)

Gp A (n = 15): SRP (using hand instruments, ultrasonic instrumentation, and local anaesthesia in 2–4 sessions within 24-36 hours by the same operator) + adjunctive doxycycline (100 mg p/d x 2 weeks, initiated 1 day prior to SRP commencing) + phenothiazine chloride photo sensitiser-induced antimicrobial photodynamic therapy (aPDT: single-episode of diode laser using 660 nm wavelength, with 10 mg/ml concentration photo sensitiser, continuously deposited in each pocket for 1 minute per tooth, followed by distilled water irrigation to remove excess). OHI delivered 14 days prior to treatment.

Gp B (n = 15): SRP (using hand instruments, ultrasonic instrumentation, and local anaesthesia in 2–4 sessions within 24-36 hours by the same operator) + adjunctive doxycycline (100 mg p/d x 2 weeks, initiated 1 day prior to SRP commencing). OHI delivered 14 days prior to treatment.

Note: All patients received supragingival professional tooth cleaning 7 days prior to treatment, OHI review every 14 days, and prophylaxis for 3 months.

Outcomes

Primary: HbA1c at baseline and 3 months
Secondary: PPD, CAL, BOP, and PI at baseline and 3 months
Duration of follow-up: 3 months

Notes

Sample size calculation: 30 participants required (76% power, .05 significance)
Data analysis: ITT
Adverse events: Quote: “Healing was uneventful on all cases. No adverse effects were reported by any of the subjects”
HbA1c assessment method: Automated immunoturbidimetric method using 15 ml samples
SES: Not reported
Conflict of interests: Not reported

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “A randomization approach using computer-generated random numbers was employed to assign subjects to one of the following two treatment modalities”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>No drop-outs, all 30 completed the trial. ITT analysis</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Macedo 2014 (Continued)

<table>
<thead>
<tr>
<th>Selective reporting (reporting bias)</th>
<th>Low risk</th>
<th>All outcomes reported, including adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other apparent biases</td>
</tr>
</tbody>
</table>

### Madden 2008

**Methods**
- **Trial design:** 2-arm, parallel-design RCT
- **Location:** USA
- **Setting:** Not reported
- **Number of centres:** Not reported
- **Recruitment period:** Not reported
- **Funding source:** Financial support from the Medical Research Foundation of Oregon (Oregon Health and Science University)

**Participants**
- **Inclusion criteria:** Mild/moderate gingivitis or periodontitis; HbA1c >7.0% - <13.11%; elevated HbA1c >1 year; >15 natural teeth; 18-80 years old
- **Exclusion criteria:** Periodontal surgery/antibiotic prophylaxis required; conditions/medications interfering with diabetic control; antibiotic/steroid/hydantoin/NSAID use; immunosuppression; rheumatoid arthritis; HIV; pregnancy; tobacco use; fixed orthodontic appliances; inability to give consent; unable/unwilling to remain enrolled for 8 months
- **Age at baseline:** Not reported
- **Sex (M:F):** Not reported specifically, only “treatment groups were balanced for gender only”
- **Tobacco use:** Specified as exclusion criteria
- **Alcohol consumption:** Not reported
- **Diabetes type:** All T2 DM
- **Duration since diabetes diagnosis:** Not reported
- **Metabolic control:** Fair-poor mean HbA1c at baseline
  - Mean HbA1c at baseline presented by 4 subgroups, without SDs, and only for the 42 completing patients:
  - Gp A: No medication change: severe Gp: 10.3% (n = 6) mild Gp: 8.0% (n = 6); medication change: severe Gp: 11.10% (n = 5) mild Gp: 7.8% (n = 4)
  - Gp B: No medication change: severe Gp: 10.0% (n = 5) mild Gp: 8.1% (n = 10); medication change: severe Gp: 10.2% (n = 2) mild Gp: 7.7% (n = 4)
- **Antidiabetic therapy:** Not reported
- **Other medical conditions:** Not reported
- **Other clinical investigations:** Calculus index
  - Number randomised: 50
  - Number evaluated: 42 (Gp A n = 21; Gp B n = 21)
  - Losses: Died (unrelated to study) n = 2; withdrawn for inclusion/exclusion violations (smoking indicated as example) n = 6

**Interventions**
- SRP (x 5) + adjunctive antibacterial rinse (chlorhexidine) (throughout) + OHI (x 5) versus SRP (x 2) + OHI (x 2)
  - Gp A (n = 25): SRP x 5 (“inflamed periodontal pockets with clinical attachment loss” only; single session (60-90 min) delivery by the same operator) + adjunctive 0.12%
chlorhexidine gluconate rinse (Peridex, Zila Pharmaceuticals: 30 seconds oral rinsing bid for duration of study) + OHI. All delivered at baseline, 2, 4, 6 and 8 months follow-up

Gp B (n = 25): SRP x 2 (inflamed periodontal pockets with clinical attachment loss only; single session (60-90 min) delivery by the same operator) + OHI x 2. Both delivered at baseline and 6-month follow-up

Outcomes

**Primary:** HbA1c at baseline, 6 and 8 months  
**Secondary:** PPD, CAL (indicated as CEJ in graph), GI, and PI at baseline, 6 and 8 months  
**Duration of follow-up:** 8 months

Notes

**Sample size calculation:** Indication calculation occurred, although not specifically reported. Quote: “Sample size presented the major flaw in this study and was exacerbated by the need to accommodate statistically for 15 subjects [Gp A: n = 9; Gp B: n = 6] undergoing changes in their diabetes medications”

**Data analysis:** Not reported  
**Adverse events:** Not reported  
**HbA1c assessment method:** Not reported  
**SES:** Not reported  
**Conflict of interests:** Not reported

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “consenting subjects were randomized (by flip of coin)”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>Unclear risk</td>
<td>Not specifically reported, and probably not possible as all treatment delivered by single operator. Quote: “All treatment provided in this protocol was delivered by the research dental hygienist”</td>
</tr>
</tbody>
</table>
| Incomplete outcome data (attrition bias)  | High risk          | Per-protocol analysis: not all participants analysed in groups randomised to, regardless of intervention actually received  
\   Rationale provided for all missing patients, although not by group |
| All outcomes                              |                    | Primary outcome data presented as subgroups (severe/mild HbA1c) and tables split by patients not requiring a change in antidiabetic therapy. All data presented |
### Madden 2008

<table>
<thead>
<tr>
<th>Other bias</th>
<th>Unclear risk</th>
<th>Adverse events also not reported. Clarification request email to authors bounced</th>
</tr>
</thead>
</table>

### Miranda 2014

#### Methods

| Trial design: 2-arm, single-centre, parallel-design RCT |
|------------|--------------------------------------------------|
| Location: Brazil |
| Setting: Hospital |
| Number of centres: 1, Periodontal Clinic of Guarulhos University, São Paulo |
| Recruitment period: Assumed 1 month, September-October 2011, as 12 month-long follow-up period. Quote: “The study was conducted between September 2011 and October 2012” |
| Funding source: São Paulo State Research Foundation (São Paulo, São Paulo, Brazil, #2011/14872-4; 2013/01072-5) |

#### Participants

| Inclusion criteria: >35 yrs; diagnosed type 2 DM >5 yrs; receiving hypoglycaemic treatment/supplementation; HbA1c level >6.5%—<11%; at least 15 teeth (excluding 3rd molars, or decayed teeth requiring extraction); >30% of sites with >4 mm PD/CAL; minimum 6 teeth with at least 1 site BOP and >5 mm PD/CAL |
|------------|--------------------------------------------------|
| Exclusion criteria: Smoker within prior 5 years; SRP in prior 12 months; antimicrobial therapies in prior 6 months; antimicrobial-containing mouthrinse use in prior 3 months; pregnancy; lactation; allergic to metronidazole or amoxicillin; systemic condition affecting periodontitis progression (including immunological disorders, osteoporosis); conditions requiring prophylactic antibiotics; orthodontic appliances; extensive prosthetic rehabilitation; major complications of DM |
| Age at baseline: Overall: mean 53.9 yrs (SD 8.1); Gp A: 54.0 yrs (SD 8.2); Gp B: 53.7 yrs (SD 8.0) |
| Tobacco use: Specified as exclusion criteria to have smoked in prior 5 years |
| Alcohol consumption: Not reported |
| Diabetes type: All type 2 |
| Duration since diabetes diagnosis: Overall 7.7 yrs (SD 3.4); Gp A: 8.0 yrs (SD 3.2); Gp B: 7.4 yrs (SD 3.6) |
| Metabolic control: Poor mean HbA1c at baseline |
| Mean HbA1c at baseline: Gp A: 8.53 (SD 1.56); Gp B: 8.99 (SD 1.63) |
| Antidiabetic therapy: Required by inclusion criteria. Quote: “all subjects included in this study reported to be under metformin or glibenclamide treatment. In addition, two subjects per group also reported to be under insulin supplementation” |
Other medical conditions: Not reported
Other investigations: Suppuration; differences between groups for disease progression (low, moderate, high risk patients); FPG
Number randomised: 58 (Gp A: n = 29; Gp B: n = 29)
Number evaluated: 56 (Gp A: n = 29; Gp B: n = 27 - 2 did not attend baseline visit)

<table>
<thead>
<tr>
<th>Interventions</th>
<th>SRP + OHI + adjunctive antimicrobial (metronidazole) versus SRP + OHI + adjunctive placebo antimicrobial</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gp A (n = 29): SRP (4-6 x 1 hour-sessions within 14 days of baseline, under local anaesthesia, using manual curettes and ultrasonic device); OHI (brushing technique and provision of toothpaste); and metronidazole (3 x 400 mg p/d for 14 days) and amoxicillin (3 x 500 mg p/d for 14 days) administered immediately after first SRP session</td>
</tr>
<tr>
<td></td>
<td>Gp B (n = 29): SRP (4-6 x 1 hour-sessions within 14 days of baseline, under local anaesthesia, using manual curettes and ultrasonic device); OHI (brushing technique and provision of toothpaste); and placebo pills (6 p/d for 14 days) administered immediately after first SRP session</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Primary: HbA1c at baseline, 3 months, 6 months, 12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Secondary: PD reduction and CAL gain; both at baseline, 3 months, 6 months, 12 months</td>
</tr>
<tr>
<td></td>
<td>Duration of follow-up: 12 months</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Notes</th>
<th>Sample size calculation: 24 participants required per group (80% power, .05 significance). Accounting for 15% attrition, 29 patients required in each arm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Data analysis: ITT</td>
</tr>
<tr>
<td></td>
<td>Adverse events: Gp A: n = 14 (48%); Gp B: n = 6 (22%) report at least 1 adverse event of antibiotic/placebo use</td>
</tr>
<tr>
<td></td>
<td>Gp A: Diarrhea n = 7 (24%); headache n = 4 (14%); metallic taste n = 4 (14%); nausea/vomiting n = 5 (17%)</td>
</tr>
<tr>
<td></td>
<td>Gp B: Diarrhea n = 3 (11%); headache n = 1 (4%); metallic taste n = 2 (7%); nausea/vomiting n = 2 (7%)</td>
</tr>
<tr>
<td></td>
<td>Quote: “All subjects stated that the medications did not cause any major disturbance in their daily routine and, therefore, they would repeat the antibiotic treatment, if necessary”</td>
</tr>
<tr>
<td></td>
<td>HbA1c assessment method: High-performance liquid chromatography</td>
</tr>
<tr>
<td></td>
<td>Conflicts of interest: Authors declare no conflict of interest. All participants received Colgate Total toothpaste (attributed to Colgate Palmolive Co., São Paulo, SP, Brazil) for use throughout trial, but it is not clear if products were donated by the company</td>
</tr>
<tr>
<td></td>
<td>Trial ID: NCT02135952</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “...each selected subject received a code number and one of the study coordinators (M.Fe.) used a computer-generated table to randomly allocate them into one of the [...] treatment groups”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&quot;...randomization was stratified to allow</td>
</tr>
</tbody>
</table>
### Allocation concealment (selection bias)

**Low risk**

Quote: “The same pharmacy (Proderma Farmacia de Manipulacao Ltda, Piracicaba, SP, Brazil) prepared the antibiotics and placebos. Identical plastic bottles containing the antibiotics or placebos were sent to one of the study coordinators (P.M.D.), who marked the code number of each subject on each bottle, according to the therapy assigned. Allocation concealment was assured by means of sequentially numbered drug containers of identical appearance. Study personnel, including the examiner (T.S.M.), the two operators, the investigator responsible for the data analysis (M. Fa.) and the participants were blinded to treatment assignment. Code breaking was performed after final statistical analysis.”

### Blinding of participants

**Low risk**

Quote: “...participants were blinded to treatment assignment. Code breaking was performed after final statistical analysis.”

### Blinding of clinical operator

**Low risk**

Quote: “Study personnel, including [...], the two operators, [...] were blinded to treatment assignment. Code breaking was performed after final statistical analysis.”

### Incomplete outcome data (attrition bias)

**Low risk**

Comment: Both arms’ attrition occurred at 6-month follow-up, due to patients being uncontactable, however still included in study’s ITT analysis

Quote: “Four subjects in the control group and two in the test group were lost during the follow up visits”

“The data were evaluated using intention-to-treat analysis with last observation carried forward”

### Selective reporting (reporting bias)

**Low risk**

All outcomes reported, although PD/CAL provided as subsets (moderate (4-6 mm; deep >7 mm) thus not usable in meta-analysis. Despite this, not considered to be a source of bias

### Other bias

**Low risk**

No other apparent biases
### Participants

**Inclusion criteria:** Mild-moderate periodontitis (AAP criteria); diagnosis of T2 DM with HbA1c >7%; no major complications of diabetes; controlled by OHA (gly-bengalamide and metformin) but not insulin administration; no periodontal treatment or antibiotic administration in last 6 months

**Exclusion criteria:** Presence of systemic diseases other than T2 DM that could influence course of periodontal disease; intake of immunosuppressive drugs, steroids, hydantoin, or NSAIDs; tobacco use; pregnancy or intention to become pregnant during study period; fixed orthodontic appliances; refusal or inability to give informed consent

**Age at baseline:** Overall: 50.29 yrs (SD 3); M 52.48 yrs (SD 3); F 48.1 yrs (SD 3) (by sex P = 0.9)

No detail of age by group allocation

**Sex (M:F):** Overall M20:F20; Gp A M9:F13; Gp B M11:F7 (P = 0.341)

**Tobacco use:** Excluded

**Alcohol consumption:** Not reported, although consumption of alcohol is illegal in Iran

**Diabetes type:** T2 DM

**Duration since diabetes diagnosis:** Not reported

**Metabolic control:** Poor mean HbA1c at baseline

Mean HbA1c at baseline: Gp A 8.15% (SD 2.22); Gp B 8.72% (SD 1.82) (P = 0.304)

**Antidiabetic therapy:** All in receipt of oral hypoglycaemic medication (no insulin)

**Other clinical investigations:** Biochemical markers TG, TC (total cholesterol), LDL, HDL, FPG

**Number randomised:** 40

**Number evaluated:** 40

### Interventions

**Comparison:** SRP versus no intervention

Gp A (n = 22): SRP (ultrasonic device, standard periodontal curettes, local anaesthetic and no limitation on time)

Gp B (n = 18): No treatment (delayed SRP provided after completion of trial)

**Duration of follow-up:** 3 months

### Outcomes

**Primary:** HbA1c (at baseline and 3 months)

**Secondary:** CAL, PPD, PI and GI (at baseline and 3 months)

### Notes

**HbA1c assessment method:** Cobas Integra 700; Roche Diagnostics, Germany

**Data analysis:** ITT

**Conflict of interests:** Not reported

**Adverse events:** Not reported

**SES:** Not reported

**Sample size calculation:** A priori calculation based on Kiran 2005 and Rodrigues 2003 of 20 per group (α = 0.05 and β = 0.2)

**Trial ID:** NCT01252082
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;Patients were randomly divided into treatment and non-treatment (control) groups by the study research assistant (KK) using a computer generated random numbers table&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Examiner (AMT) at baseline &quot;blinded to subjects' group assignment.&quot; Although 'AMT' blinded, randomisation statement relates to 'KK' and therefore unclear if allocation concealment occurred</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>ITT analysis. All patients completed the study, however several non-planned treatments occurred: Reported extractions - 1 per group Endodontic treatment to 1 in Gp A</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Age differences not reported between group but by sex instead Adverse events not reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other apparent biases</td>
</tr>
</tbody>
</table>

### NCT00801164

#### Methods
- **Trial design:** 2-arm, single-centre, parallel-design RCT
- **Location:** USA
- **Setting:** Hospital
- **Number of centres:** 1, University of Texas Health Science Center at San Antonio, Dental School, San Antonio, Texas
- **Recruitment period:** December 2008 -
- **Funding source:** Biomedical Development Corporation (manufacturer of an iodine mouthrinse product: www.biodevcorp.com/products/icleanmouths/); Methodist Healthcare Ministries of South Texas; Foundation Of Collaborative Unique Science (FOCUS)

#### Participants
- **Inclusion criteria:** Either sex; over 35 years old; self reported T2 DM (>3 months duration); HbA1c value between 7.0% and 12%; no change in diabetes-related medications during prior 3 months; at least 16 natural teeth; moderate to severe chronic periodontitis,
defined by loss of clinical attachment of >5 mm on 2 separate teeth, and no treatment within 6 months; able and willing to comply with study requirements (instructions and attendance); written informed consent; females to test negative for pregnancy, before and during the study period; use of effective birth control

**Exclusion criteria:** Evidence of chronic medical or psychiatric condition to prevent active study participation; TPOab positive; baseline serum level of TSH <0.35 or >5.5; antibiotics 3 months prior, or any other systemic condition requiring antibiotic premedication; history of thyroid disease; purported sensitivity or allergy to iodine; known sensitivity or allergy to shellfish; history of autoimmune disease, chronic infection (eg HIV or hepatitis), CVD (in prior 3 months), stroke or history/treatment for transient ischaemic attacks (in prior 3 months), or pulmonary embolus (in prior 6 months), angina pectoris, renal disease: serum creatinine exceeding 1.4 mg/dl (women) or 1.5 mg/dl (men), or currently receiving dialysis; periodontal disease, rampant caries, tissue damage created by poor oral care or treatment, soft or hard tissue tumours; mucosal tissue ulcerations, inflammation, or canker sores; orthodontic (including removable) appliances impinging on oral tissues; history of alcohol abuse or drug abuse; use of concomitant medication that, in the opinion of the investigator, might interfere with the outcome of the study (eg antibiotics, immuno-suppressants, steroids, or therapeutic doses of non-steroidal anti-inflammatory agents, phenytoin, calcium antagonists, cyclosporine or coumadin); concomitant therapy with another investigational drug or device without prior approval from the sponsor within 4 weeks prior to Visit 2 (Study Day 1); concomitant endodontic or periodontal therapy other than prophylaxis in the past 6 months; pregnant or nursing mothers, or intention to become pregnant during the study; residence in the same household as a subject already enrolled in the study (inclusion may create blinding and/or compliance issues)

**Age at baseline:** Unknown

**Sex (M:F):** Unknown

**Tobacco use:** Unknown

**Alcohol consumption:** Unknown, participants with history of alcohol abuse excluded though

**Diabetes type:** T2 DM

**Duration since diabetes diagnosis:** > 3 months

**Metabolic control:** Poor mean HbA1c at baseline
Mean HbA1c at baseline: Gp A: 8.77 (SD 0.37); Gp B: 8.48 (SD 0.38)

**Antidiabetic therapy:** Not reported

**Other clinical investigations:** Suppuration; systemic biomarkers (LPS, TNF-a, CRP, IL-6, serum insulin and glucose); staining, calculus, opportunistic Candida infection; and patient satisfaction

**Number randomised:** 30

**Number evaluated:** 27

**Interventions**

**Comparison: SRP + iodine rinse versus SRP + placebo rinse**

Gp A (n = 15): Standard periodontal therapy including SRP, Frio (Iocide) mouthrinse (molecular free iodine antibacterial rinse, 15 ml x 2 daily for 90 days)

Gp B (n = 15): Standard periodontal therapy including SRP, placebo mouthrinse (15 ml x 2 daily for 90 days)

**Duration of follow-up:** 6 months
### Outcomes

**Primary:** HbA1c (at baseline, 3 and 6 months: data provided by email)

**Secondary:** CAL, PPD, PI, GI (currently unpublished)

### Notes

**Trial ID:** NCT00801164; HSC20080508H (study title: Exploratory study of iocide oral rinse in a diabetic population)


**Adverse events:** Not reported

**Data analysis:** Per-protocol

**Conflict of interests:** Unknown

**SES:** Unknown

**Sample size calculation:** Unknown. Trial register indicates 12 patients required per arm

Contact information: Thomas W Oates (oates@uthscsa.edu)

Emailed. Response received. Full existing study report (student thesis) not available until published in a journal

Quote: “We have not published this study other than as a student’s masters thesis, I am sorry to say. However we have completed it. Here are the results for A1c - treatment was completed by 3 weeks from baseline:

<table>
<thead>
<tr>
<th>Group</th>
<th>Baseline</th>
<th>2 months</th>
<th>3 months</th>
<th>6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iocide</td>
<td>8.771 (SD 0.365)</td>
<td>8.529 (SD 0.380)</td>
<td>8.714 (SD 0.468)</td>
<td>9.136 (SD 0.468)</td>
</tr>
<tr>
<td>Placebo</td>
<td>8.477 (SD 0.379)</td>
<td>8.415 (SD 0.394)</td>
<td>8.662 (SD 0.486)</td>
<td>8.800 (SD 0.485)</td>
</tr>
</tbody>
</table>

There were no significant differences between groups or time points

This was a randomized study using a computer generated list with examiners and operators blinded to allocations. 30 patients in total were entered into the study, with 27 completers (14 test, 13 control)”

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Correspondence: &quot;...using a computer generated list with examiners and operators blinded to allocations&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Correspondence: &quot;...using a computer generated list with examiners and operators blinded to allocations&quot;  Comment: Unclear whether this refers to allocation concealment or blinding</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>Low risk</td>
<td>Unknown, although provided with a placebo rinse, so no reason to indicate they were aware of their arm allocation</td>
</tr>
</tbody>
</table>
| Blinding of clinical operator       | Unclear risk       | Correspondence: "...using a computer generated list with examiners and operators blinded to allocations"  Comment: Insufficient information. Unclear whether this refers to allocation con-
<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Low Risk</th>
<th>High Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>Per-protocol analysis: not all participants analysed in groups randomised to, regardless of intervention actually received</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td>27 of 30 completed the study, with no indication of reasons for drop-outs; despite this the rates are similar. Data presented by email for Gp A n = 14, Gp B n = 13</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Unknown until study published</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Unpublished data, and therefore without peer-review although study lead confirms intention to publish</td>
</tr>
</tbody>
</table>

**O’Connell 2008**

**Methods**

- **Trial design:** 2-arm, single-centre, parallel-design RCT
- **Location:** Brazil
- **Setting:** Not reported
- **Number of centres:** 1, University of Sao Paulo-Ribeirao Preto, Sao Paulo, Brazil
- **Recruitment period:** Not stated
- **Funding source:** Grant from Sao Paulo Research foundation (04/09844-8), National Council for Scientific and Technological Development (470638/2006) and a scholarship from Coordination for the Improvement of Graduated Personnel. Doxycycline was donated by Pfizer, Brazil

**Participants**

- **Inclusion criteria:** Type 2 DM diagnosed for >5 years and HbA1c >8%, at least 1 site with probing depth >5 mm, and 2 teeth with attachment loss >6 mm
- **Exclusion criteria:** The use of antibiotics or periodontal treatment in previous 6 months; smoking within past 5 years; pregnancy or lactation; major diabetic complications; concomitant medical therapy
- **Age at baseline:** Overall: mean 52.9 yrs (SD 7); Gp A: mean 53.5 yrs (SD 13.6); Gp B: mean 52.3 yrs (SD 6.3)
- **Sex (M:F):** Overall: M14:F16; Gp A M8:F7; Gp B M6:F9
- **Tobacco use:** Non-smokers, required by exclusion criteria
- **Alcohol consumption:** Not reported
- **Diabetes type:** All T2 DM
- **Duration since diabetes diagnosis:** >5 years
- **Metabolic control:** Poor mean HbA1c at baseline
  - Mean HbA1c at baseline: Gp A 10.7% (SD 2.0) 2.0; Gp B 11.8% (SD 1.6)
- **Antidiabetic therapy:** Not reported
- **Other medical conditions:** Unlikely as concomitant medical therapy is exclusion criterion
- **Other clinical investigations:** Suppuration, missing teeth, serum biomarkers
- **Number randomised:** 35
- **Number evaluated:** 30
### Interventions

**Comparison:** SRP + OHI + prophylaxis + doxycycline versus SRP + OHI + prophylaxis + placebo  
Gp A (n = 15): SRP (in 2-4 sessions within 24 to 36 hours, using hand instruments and ultrasonic device, under local anaesthesia) + OHI and prophylaxis (OHI and scale and polish delivered every 2 weeks for 3 months) + doxycycline (200 mg: 1 day prior to SRP, then 100 mg daily for 14 days)  
Gp B (n = 15): SRP + OHI + prophylaxis with placebo as above  
**Duration of follow-up:** 3 months

### Outcomes

**Primary:** HbA1c at baseline and 3 months  
**Secondary:** CAL, PPD, PI, BOP at baseline and 3 months

### Notes

**Sample size calculation:** Not reported  
**Data analysis:** Per-protocol  
**Adverse events:** Not reported  
**SES:** Not reported  
**HbA1c assessment method:** High pressure liquid chromatography (Labtest Sistemas para Diagnostico, Lagoa Santa, MG, Brazil)  
**Conflict of interests:** Authors declare no conflict of interests exist

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “Subjects were randomly assigned to two groups”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>Unclear risk</td>
<td>Quote: “double-masked, placebo-controlled study”</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>Unclear risk</td>
<td>Same operator performed SRP sessions. Not reported whether operator was blinded as part of “double-masked” study</td>
</tr>
</tbody>
</table>
| Incomplete outcome data (attrition bias)  | High risk          | Per-protocol analysis: not all participants analysed in groups randomised to, regardless of intervention actually received  
Quote: “Two subjects were eliminated because they did not finish the treatment phase, two subjects eliminated because they had to use an anticoagulant agent, and one subject died”  
Comment unclear which groups, and whether they could have obtained outcome data for subjects who did not finish treatment phase |
Selective reporting (reporting bias) | Unclear risk | All outcomes reported except adverse events
---|---|---
Other bias | Low risk | No other apparent biases

**Pradeep 2013**

**Methods**
- **Trial design:** 2-arm, single-centre, parallel-design RCT
- **Location:** India
- **Setting:** Hospital
- **Number of centres:** 1, outpatient section of Department of Periodontics, Government Dental College and Research Institute, Bangalore, India
- **Recruitment period:** January 2011 to September 2011
- **Funding source:** Not reported. States Simvastatin (SMV) sample was provided by Aurobindo Pharma, Hyderabad, Andhra Pradesh, India (www.aurobindo.com/)

**Participants**
- **Inclusion criteria:** Patients with well-controlled type 2 diabetes; with PD >5 mm or CAL >4 mm and vertical bone loss >3 mm; no history of periodontal therapy or use of antibiotics in prior 6 months; and with >20 teeth
- **Exclusion criteria:** Known systemic disease; known/suspected allergy to SMV; on systemic SMV/statin therapy; hyperlipidaemia or on a lipid-lowering diet; aggressive periodontitis; use of tobacco in any form; alcoholics; immunocompromised patients; pregnant or lactating; teeth with furcation defects, gingival recession, endodontic involvement or third molars
- **Age at baseline:** Overall: range 30-50 years; data not provided by group
- **Sex (M:F):** Overall: M20:F18; data not provided by group
- **Tobacco use:** Exclusion criteria prevented participation of patients who use any form of tobacco
- **Weight:** Not reported
- **BMI:** Not reported
- **Alcohol consumption:** Not reported
- **Diabetes type:** All T2 DM
- **Duration since diabetes diagnosis:** Not reported
- **Metabolic control:** Good mean HbA1c at baseline
  - Mean HbA1c at baseline: Gp A: 6.66 (SD 0.11); Gp B: 6.71 (SD 0.13)
  - Quote: “Patients with well-controlled type 2 diabetes were selected”
- **Antidiabetic therapy:** Not reported
- **Other investigations:** Complete bone defect fill; intrabony defect (IBD) fill
- **Other medical conditions:** Not reported
- **Number randomised:** 38 (Gp A n = 19 (36 sites); Gp B n = 19 (34 sites))
- **Number evaluated:** 35 (Gp A n = 17 (29 sites); Gp B n = 18 (29 sites))
- **Lost to follow-up:** 3 (Gp A n = 2; Gp B: n = 1)

**Interventions**
- **Comparison:** SRP + adjunctive statin gel + OHI versus SRP + adjunctive placebo gel + OHI
  - Gp A (n = 19): OHI, followed by SRP and then adjunctive local delivery of 1.2% SMV gel syringe-injected (by blunt cannula) into periodontal pockets
  - Gp B (n = 19): OHI, followed by SRP and then adjunctive local placement of placebo
Duration of follow-up: 9 months

Outcomes

| Primary: Change in HbA1c from baseline to 3, 6, and 9 months |
| Secondary: Change in PI, GI (reported as modified sulcus bleeding index (mSBI)), PD and CAL from baseline to 3, 6, and 9 months |

Notes

| Sample size calculation: Number of participants required unknown as calculation was performed for sites rather than patients in each group (90% power to detect mean differences between groups). Planned sample size was 60 sites (30 in each arm). After loss to follow-up, trial presents data for 29 sites in each arm |
| SES: Not reported |
| Data analysis: Assumed ITT |
| Adverse events: Quote: “All participants tolerated the drug well without any complications or adverse reactions to the drug. Soft tissues healed within normal limits, and no significant visual differences were noted” |
| HbA1c assessment method: Not reported |
| Conflict of interests: Authors declare no conflict of interests |

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Randomisation conducted by computer-generated random numbers table</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Randomisation process conducted by external statistical unit, and states investigators were neither involved in the randomisation process, nor aware of group assignment when assessing outcomes</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>Low risk</td>
<td>States participants masked to allocation, and only difference between intervention and control group delivery was use of a placebo gel</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>Analysis assumed to have been ITT, but not specifically reported 3 patients lost to follow-up, but clearly identified in patient flow diagram which arms they were from (Intervention n = 2; Control n = 1)</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>All specified outcomes (including adverse events) reported</td>
</tr>
</tbody>
</table>
Other bias | Low risk | No other apparent biases
---|---|---

### Raman 2014

**Methods**

- **Trial design:** 2-arm, multicentre, parallel-design RCT
- **Location:** Malaysia
- **Setting:** Hospital
- **Number of centres:** 2, patients recruited from outpatient Diabetes Clinic of the University of Malaya Medical Centre, then treated at Periodontology Clinic at the Faculty of Dentistry, University of Malaya
- **Recruitment period:** Recruitment period not explicit, although states screening and treatment from May 2010 - April 2011
- **Funding source:** 2 research grants from University of Malaya (P0027/2009B and RG/11HTM)

**Participants**

- **Inclusion criteria:** Moderate-advanced chronic periodontitis; at least 12 teeth; 5 or more > PD 5 mm or > and attachment loss 4 mm or > in at least 2 quadrants which bleed on probing
- **Exclusion criteria:** Systemic antibiotic use in prior 4 months; pregnancy; current smoker; cardiovascular/cerebrovascular event in prior 12 months; diabetes medication change during study; non-surgical periodontal therapy in prior 6 months; surgical periodontal therapy in prior 12 months
- **Age at baseline:** Overall 56.2 yrs (SD 8.1); Gp A: 57.7 yrs (SD 9.9); Gp B: 54.6 yrs (SD 6.2)
- **Sex (M:F):** Overall M20:F12; Gp A M11:F4; Gp B: M9:F8
- **Tobacco use:** Current smokers excluded from participation
- **Alcohol consumption:** Not reported
- **Diabetes type:** All type 2
- **Duration since diabetes diagnosis:** Overall: <7 yrs n = 7 (21.9%), 7-12 yrs n = 8 (25.0%), >12 yrs n = 17 (53.1%); Gp A: <7 yrs n = 4 (26.7%), 7-12 yrs n = 4 (26.7%), >12 yrs n = 7 (46.7%); Gp B: <7 yrs n = 3 (17.6%), 7-12 yrs n = 4 (23.5%), >12 yrs n = 10 (58.8%)
- **Metabolic control:** Fair mean HbA1c at baseline
  - Mean HbA1c at baseline: Gp A: 7.80 (SD 1.50); Gp B: 7.60 (SD 1.50)
- **Antidiabetic therapy:** Not reported fully. Only a quote: “All subjects who completed the study were on oral hypoglycaemic drugs”
- **Other medical conditions:** Not reported
- **Other clinical investigations:** Systemic hs-CRP, GBI
- **Number randomised:** 40
- **Number evaluated:** 32 (Gp A: n = 15; Gp B: n = 17)

**Interventions**

- **SRP + OHI (x 3) + adjunctive chlorhexidine mouthrinse versus OHI (x 3)**
  - Gp A (n = 20): Repeat OHI (modified Bass technique, soft-bristled toothbrush, compact-tuft toothbrush, interdental brush, floss (using TePe oral hygiene education set)) until PI <20%, followed by SRP (single visit, ultrasonic scaler, Gracey curettes) and 0.12% chlorhexidine mouthrinse (Hexipro, Evapharm, Kuala Lumpur, Malaysia) 3 x 15 ml p/d for 14 days. OHI repeated at each monthly visit
  - Gp B (n = 20): OHI (modified Bass technique, soft-bristled toothbrush, compact-tuft...
toothbrush, interdental brush, floss (using TePe oral hygiene education set)). OHI repeated at each monthly visit

**Duration of follow-up:** 3 months

| Outcomes | **Primary:** HbA1c at baseline and 3 months  
**Secondary:** PI, PPD, PAL (corresponds to CAL) at baseline, 2 months, and 3 months |
|---|---|

**Notes**

**Sample size calculation:** 30 required (15 per arm; 80% power). Accounting for attrition, recruited 40 (20 per arm). Results confirm arms were sufficiently powered after accounting for attrition. Quote: “This gave a within group analyses power of 80% for the NSPT group [Gp A] and 88% for the OHI group [Gp B]”

**Data analysis:** Per-protocol

**SES:** Ethnicity data provided. Overall: Malay n = 9 (28.1%); Chinese n = 8 (25%); Indian n = 6 (46.9%)

Gp A: Malay n = 5 (33.3%); Chinese n = 4 (26.7%); Indian n = 6 (40.0%)

Gp B: Malay n = 4 (23.5%); Chinese n = 4 (23.5%); Indian n = 9 (52.9%)

**Adverse events:** Not reported

**HbA1c assessment method:** Not reported. Assessed by private laboratory, using 15 ml venous blood

**Conflicts of interest:** Authors declare no conflict of interests

**Trial ID:** NCT01951547

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “All subjects were assigned via block randomisation to age matched NSPT and OHI groups. Following randomisation, baseline values for hs-CRP and HbA1c were obtained”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>States “not double-blinded.” Not reported further</td>
</tr>
</tbody>
</table>
| Incomplete outcome data (attrition bias)  
All outcomes | High risk | Per-protocol analysis: not all participants analysed in groups randomised to, regardless of intervention actually received  
Gp A: lost 5 patients. 2 due to medication change during study (exclusion criteria); 2 withdrew for unspecified reasons; and 1 unable to attend recall due to distance  
Gp B: lost 3 patients. 1 due to medication change during study; and 2 withdrew for unspecified reasons |
<table>
<thead>
<tr>
<th>Selective reporting (reporting bias)</th>
<th>Unclear risk</th>
<th>All outcomes fully reported on, except adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>Quote: &quot;...during the randomization of subjects, more participants with poor metabolic control were placed in the NSPT group. In the OHI group, there was equal distribution of participants with poor and good metabolic control&quot;</td>
</tr>
</tbody>
</table>

### Rocha 2001

**Methods**
- **Trial design:** 2-arm, single-centre, parallel-design RCT
- **Location:** Mexico
- **Setting:** Not reported
- **Number of centres:** 1
- **Recruitment period:** Not reported
- **Funding source:** Grant from Consejo Nacional de Ciencia y Tecnologia (CONACYT) SIIGO 19980202026

**Participants**
- **Inclusion criteria:** Patients aged 50-60 years with diagnosis of type 2 DM for a minimum of 5 years and established periodontitis, defined as probing depth >3 mm in at least 1 tooth. Patients did not have clinical evidence of complications of diabetes or systemic infections or other metabolic diseases. At least 6 teeth, gingival Index of 2-3 according to Silness and Loe, and gingival recession of 2-3 mm
- **Exclusion criteria:** Smoking; recent peptic or oesophageal disorders; used drugs to inhibit gastric secretion for more than 2 weeks in previous 6 months; chronic treatment with NSAIDs estrogens or glucocorticoids
- **Age at baseline:** Gp A mean 56 yrs (SD 3.5); Gp B mean 55 yrs (SD 3.6) (P = 0.22)
- **Sex (M:F):** M20:F20, Split by group not reported
- **Tobacco use:** Non-smokers only
- **Alcohol consumption:** Not reported
- **Diabetes type:** T2 DM
- **Duration since diabetes diagnosis:** >5 years, mean 10.9 years (5.8)
- **Metabolic control:** Poor mean HbA1c at baseline
  - Mean HbA1c at baseline: Gp A 11.9% (SD 3.2), Gp B 13.1% (SD 2.9) (P = 0.18)
- **Antidiabetic therapy:** Not reported
- **Other medical conditions:** None
- **Other clinical investigations:** Dental mobility, gingival recession, gingival bleeding
- **Number randomised:** 40
- **Number evaluated:** 40

**Interventions**
- **Comparison:** SRP + OHI + alendronate versus SRP + OHI + placebo
  - Gp A (n = 20): SRP (at baseline, by quadrant in 4 successive sessions) + OHI (instruction on mechanical toothbrushing and flossing) + alendronate 10 mg/daily (aminobisphosphonate)
  - Gp B (n = 20): SRP (at baseline, by quadrant in 4 successive sessions) + OHI (instruction on mechanical toothbrushing and flossing) + placebo capsules (1 capsule/daily; v
trivitamin 100 mg thiamine pyroxidine 50 mg cyanocobalamin 250 µg

**Duration of follow-up:** 6 months

Subjects assessed for plaque fortnightly during 6-month study period, when flossing technique reinforced for each arm

| Outcomes | Primary: | HbA1c (at baseline, and 6 months)  
Secondary: | PD, CAL (at baseline, and 6 months) |

| Notes | Sample size calculation: | Not reported  
Data analysis: | Assumed ITT  
SES: | Not reported  
HbA1c assessment method: | Cation-exchange chromatography (Sigma Chemical Co, St. Louis, Missouri, USA)  
Conflict of interests: | Not reported, however does state “the companies producing or marketing the medications under study were unaware of this work” |

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bias</td>
<td>Authors’ judgement</td>
<td>Support for judgement</td>
</tr>
</tbody>
</table>
| Random sequence generation (selection bias) | High risk | Quote: “...randomised double blind case control study”  
Comment: Method of sequence generation not described and likely to be quasi random. Sex and age matched pairs before randomisation to trial arms |
| Allocation concealment (selection bias) | High risk | Not reported |
| Blinding of participants | Low risk | Quote: “Both patients and the examiner were blind to the treatment group” |
| Blinding of clinical operator | Unclear risk | Blinding possible, but not reported |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Analysis assumed to have been ITT, but not specifically reported Withdrawals and drop-outs not mentioned but numbers included in outcome evaluation probably include all as degree of freedom for paired t-test is 19 |
| Selective reporting (reporting bias) | Unclear risk | Planned outcomes not clearly specified but expected outcomes reported. No adverse events data reported for alendronate |
| Other bias | Low risk | No other apparent biases |
### Methods

**Trial design:** 2-arm, single-centre, parallel-design RCT  
**Location:** Brazil  
**Setting:** Hospital  
**Number of centres:** 1, University Hospital Sao Paulo, Brazil  
**Recruitment period:** Not reported  
**Funding source:** Grants from CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brazilian Ministry of Education organisation to fund graduate education)  
, and FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo (São Paulo Research Foundation) - grant 2000/14108-8)

### Participants

**Inclusion criteria:** Type 2 diabetes and periodontal disease defined as probing depth of more than 5 mm at least 1 site; 2 teeth with more than 6 mm CAL  
**Exclusion criteria:** Antibiotics in the last 6 months, smoking, pregnant, insulin controlled or diagnosis of DM less than 5 years  
**Age at baseline:** Not reported  
**Sex (M:F):** Not reported  
**Tobacco use:** Specified exclusion  
**Alcohol consumption:** Not reported  
**Diabetes type:** T2 DM  
**Duration since diabetes diagnosis:** At least 5 years  
**Metabolic control:** Poor mean HbA1c at baseline  
Mean HbA1c at baseline: Gp A 9.5% (SD 2.4), Gp B 8.8% (SD 1.8)  
**Antidiabetic therapy:** Insulin users excluded from participation, no other detail reported except that "alterations in [...] diabetes control were recorded" - but again, data not reported  
**Other medical conditions:** Test group had more reported diabetic complications  
Cardiac complications (44% versus 6%) and hypertension (55% versus 40%)  
**Other clinical investigations:** FBG, RAL, percentage of surfaces exhibiting biofilm, and suppuration  
**Number randomised:** 30  
**Number evaluated:** Unclear, assumed 30. No information re: attrition

### Interventions

**Comparison:** SRP + OHI (x 7) + prophylaxis (x 6) + systemic amoxicillin/clavulanic acid versus SRP + OHI (x 7) + prophylaxis (x 6)  
Gp A (n = 15): SRP (2 sessions, within 24-36 hours; using standard curettes, an ultrasonic device and under local anaesthesia) + OHI (x 7; prior to baseline, and twice p/month for 3 months after SRP) + prophylaxis (x 6; twice p/month for 3 months after SRP) + systemic amoxicillin/clavulanic acid (given 24 hours prior to SRP, 875 mg bid for 14 days)  
Gp B (n = 15): SRP (2 sessions, within 24-36 hours; using standard curettes, an ultrasonic device and under local anaesthesia) + OHI (x 7; prior to baseline, and twice p/month for 3 months after SRP) + prophylaxis (x 6; twice p/month for 3 months after SRP)  
**Duration of study:** 3 months

### Outcomes

**Primary:** HbA1c (at baseline and 3 months)  
**Secondary:** PD, BOP (at baseline and 3 months)

### Notes

**Sample size calculation:** Not reported  
**Data analysis:** Assumed ITT
**Rodrigues 2003**  
*(Continued)*

<table>
<thead>
<tr>
<th></th>
<th><strong>HbA1c assessment method:</strong> High pressure liquid chromatography (Labtest Sistemas para Diagnostico, Lagoa Santa, MG, Brazil)</th>
<th><strong>SES:</strong> Not reported</th>
<th><strong>Conflict of interests:</strong> Not reported</th>
</tr>
</thead>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Confirmed in correspondence: &quot;...the groups were randomized in advance of the subject selection and then treated following the randomization table”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>No placebo tablets</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>Low risk</td>
<td>Confirmed in correspondence</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Analysis assumed to have been ITT, but not specifically reported. Attrition not reported. Unclear how many in each group at 3 months</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>No tabulated data, only extractable from core text of report. States alterations in diabetes control/antibiotic use were recorded, but not presented. No reporting of adverse events</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Participant characteristics not reported</td>
</tr>
</tbody>
</table>

**Santos 2009**

<table>
<thead>
<tr>
<th>Methods</th>
<th><strong>Trial design:</strong> 2-arm, single-centre, parallel-design RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Location:</strong></td>
<td>Brazil</td>
</tr>
<tr>
<td><strong>Setting:</strong></td>
<td>Hospital</td>
</tr>
<tr>
<td><strong>Number of centres:</strong></td>
<td>1, Periodontal Clinic of Guarulhos University, Brazil</td>
</tr>
<tr>
<td><strong>Recruitment period:</strong></td>
<td>Not reported</td>
</tr>
<tr>
<td><strong>Funding source:</strong></td>
<td>Not reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
<th><strong>Inclusion criteria:</strong> Participants aged 36-70 years with type 2 diabetes diagnosed within past 5 years and chronic periodontitis based on 1999 World Workshop Classification of Periodontal Disease; ≥30 years old with ≥15 standing teeth (excluding third molars and teeth with severe periodontitis and/or caries with an indication for surgical extraction); 30% of sites required to have ≥CAL of 5 mm at baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion criteria:</strong></td>
<td>Pregnancy; lactation; current smoking or smoking within the pre-</td>
</tr>
</tbody>
</table>
previous 5 years; periodontal or antibiotic therapy in the previous 6 months (including mouthrinses etc containing antimicrobials within the previous 2 months); any systemic condition affecting the progression of periodontal disease except DM; patients taking anti-inflammatory or immunosuppressive medications. Also excluded were people with periapical pathology, orthodontic treatment and those with multiple systemic diabetic complications.

**Age at baseline:** Gp A mean 52.3 yrs (SD 9.4); Gp B mean 53.0 yrs (SD 9.2)

**Sex (M:F):** Overall: M16:F20 (44%:56%). Gp A M8:F10; Gp B M8:F10

**Tobacco use:** Specified exclusion

**Alcohol consumption:** Not reported

**Diabetes type:** T2 DM

**Duration since diabetes diagnosis:** < 5 years

**Metabolic control:** Poor mean HbA1c at baseline

Mean HbA1c at baseline: Gp A: 9.10 (SD 2.10); Gp B: 9.20 (SD 1.90)

Classified in study as:

Poor (HbA1c 9%-12%) Gp A 11, Gp B 10

Better (HbA1c 4.8%-8.7%) Gp A 7, Gp B 8

**Antidiabetic therapy:** All in receipt of oral hypoglycaemic medications, insulin, diet or combination

**Other medical conditions:** None

**Other clinical investigations:** FBG, suppuration on probing (SUP)

**Number randomised:** 18

**Number evaluated:** 18

### Interventions

**Comparison:** Immediate SRP (24 hrs) + OHI (x 3) + prophylaxis (x 2) versus ongoing SRP (21 days) + OHI (x 3) + prophylaxis (x 2)

Gp A (n = 18): "Full-mouth" SRP (under local anaesthetic, completed in 2 sessions lasting 2 hours each, within 24 hours) + OHI (x 3: at baseline, 3 and 6 months; brushing technique instruction for soft manual toothbrush, dental floss, interdental brushes, and provision of branded toothpaste for duration of study period) + supportive prophylaxis (x 2: at 3 and 6 months, professional plaque control including abrasive sodium carbonate air-powder system)

Gp B (n = 18): "Partial" SRP (under local anaesthetic, completed in 4 sessions lasting 1 hour each, within a maximum of 21 days) + OHI (x 3: at baseline, 3 and 6 months; brushing technique instruction for soft manual toothbrush, dental floss, interdental brushes, and provision of branded toothpaste for duration of study period) + supportive prophylaxis (x 2: at 3 and 6 months, professional plaque control including abrasive sodium carbonate air-powder system)

**Duration of follow-up:** 6 months

### Outcomes

**Primary outcome:** HbA1c (at baseline, 3 and 6 months)

**Secondary outcomes:** PI, BOP, PD, CAL (at baseline, 3 and 6 months)

### Notes

**Sample size calculation:** "The ideal sample size to ensure adequate power for this clinical trial was calculated considering differences >1 mm for CAL and a standard deviation of 0.94 mm between groups in initially deep periodontal pockets (>6 mm). Based on these calculations, it was decided that 14 subjects per group were necessary to provide 80% power with a = 0.05"

**Data analysis:** ITT
### Santos 2009 (Continued)

<table>
<thead>
<tr>
<th>SES: Not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HbA1c assessment method:</strong> High pressure liquid chromatography</td>
</tr>
<tr>
<td><strong>Adverse events:</strong> No adverse events occurred</td>
</tr>
<tr>
<td><strong>Conflict of interests:</strong> Authors declare no conflict of interests exists</td>
</tr>
<tr>
<td><strong>Note:</strong> Clarification sought from authors whether Santos 2009 and 2012 were the same study. Author confirmed they are indeed 2 separate studies on different participants (the difference being the lack of data collection for GCF and biofilm in Santos 2009), but that unfortunately the studies were not registered at the time to be able to reference trial IDs</td>
</tr>
</tbody>
</table>

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Toss of a coin”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Allocation concealed but no methods described</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>Operative treatment differed between arms</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>All participants completed study. ITT analysis</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Pre-specified outcomes reported, including adverse events</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other apparent biases</td>
</tr>
</tbody>
</table>

### Santos 2012

#### Methods

- **Trial design:** 2-arm, single-centre, parallel-design RCT
- **Location:** Brazil
- **Setting:** Hospital
- **Number of centres:** 1, Guarulhos University, Sao Paulo
- **Recruitment period:** December 2007 until March 2009
- **Funding source:** Sao Paulo State Research Foundation (# 2008/09687-0; # 2008/04280-0)

#### Participants

- **Inclusion criteria:** Type 2 DM for at least the past 5 years and generalized chronic periodontitis. They were receiving supplementation with insulin, an appropriate dietary regimen and/or oral hypoglycaemic agents. All subjects were >30 years of age, had at least 15 teeth (excluding third molars and teeth indicated to exodontias) and had more than 30% of sites with a probing depth and CAL of >= 4 mm at baseline
- **Exclusion criteria:** Pregnancy; lactation; current smoking and smoking within the past 5 years; periodontal and/or antibiotic therapy in the previous 6 months; regular use
of mouthrinses containing antimicrobials in the preceding 2 months; other systemic condition that could affect the progression of periodontal disease; long-term treatment with anti-inflammatory and immunosuppressive medications; periapical pathology; orthodontic appliances and multiple systemic complications of DM

**Age at baseline:** Overall 42-67 years; Gp A mean 51.9 (SD) 7.8 years, Gp B mean 53.1 (SD) 8.1 years

**Sex (M:F):** Overall: M16:F18 (47%:53%). Gp A M9:F8; Gp B M7:F10

**Tobacco use:** Excluded

**Alcohol consumption:** Not reported

**Diabetes type:** T2 DM

**Duration since diabetes diagnosis:** >= 5 years

**Metabolic control:** Poor mean HbA1c at baseline

Mean HbA1c at baseline: Gp A: 9.40 (SD 2.50); Gp B: 8.90 (SD 2.20)

**Antidiabetic therapy:** All in receipt of oral hypoglycaemic medications, insulin, diet or combination

**Other medical conditions:** As stated in exclusion criteria

**Other clinical investigations:** SUP, FPG levels and measurements of cytokine- and osteoclastogenesis related factors (measured by gingival crevicular fluid)

**Number randomised:** 34

**Number evaluated:** 34

### Interventions

**Comparison:** Immediate SRP (24 hrs) + OHI (x 4) + prophylaxis (x 3) versus ongoing SRP (21 days) + OHI (x 4) + prophylaxis (x 3)

**Gp A (n = 17):** “Full-mouth” SRP (under local anaesthetic, completed in 2 sessions lasting 2 hours each, within 24 hours) + OHI (x 4: at baseline, 3, 6 and 9 months; brushing technique instruction for soft manual toothbrush, dental floss, interdental brushes, and provision of branded toothpaste for duration of study period) + supportive prophylaxis (x 3: at 3, 6 and 9 months; professional plaque control including abrasive sodium carbonate air-powder system)

**Gp B (n = 17):** “Partial” SRP (under local anaesthetic, completed in 4 sessions lasting 1 hour each, within a maximum of 21 days) + OHI (x 4: at baseline, 3, 6 and 9 months; brushing technique instruction for soft manual toothbrush, dental floss, interdental brushes, and provision of branded toothpaste for duration of study period) + supportive prophylaxis (x 3: at 3, 6 and 9 months; professional plaque control including abrasive sodium carbonate air-powder system)

**Duration of follow-up:** 12 months

### Outcomes

**Primary:** HbA1c (at baseline, 3, 6 and 12 months)

**Secondary:** CAL, PI, BOP, PPD (at baseline, 3, 6 and 12 months)

### Notes

**Sample size calculation:** Quote: “...differences of at least 1 mm for clinical attachment level and a standard deviation of 1 mm between groups in initially deep pockets (>= 7 mm). Based on these calculations, it was decided that 17 subjects per group would provide 80% power at a significance level of 5%”

**Data analysis:** ITT

**SES:** Quote: “the subjects included in the current investigation were predominantly from families of a low socioeconomic status who often lack financial, social and educational support and have inadequate or limited access to medical care”

**Adverse events:** No adverse events occurred
HbA1c assessment method: High pressure liquid chromatography
Conflict of interests: Not reported
Note: Clarification sought from authors whether Santos 2009 and 2012 were the same study. Author confirmed they are indeed 2 separate studies on different participants (the difference being the lack of data collection for GCF and biofilm in Santos 2009), but that unfortunately the studies were not registered at the time to be able to reference trial IDs

## Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “The subjects were randomly assigned, by tossing a coin (performed by the same assessor (P.M.D.))”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>No detail provided</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Number of treatment appointments differed between arms so not possible to blind participants</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>Operative treatment differed between arms</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>ITT analysis Quote: “There were no subject or site drop-outs during the study period. No adverse effects, such as fever and indisposition after treatment, were reported by any subject, and no changes in the category of treatment regimen for DM occurred during the study”</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Pre-specified outcomes reported, including adverse events</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other apparent biases</td>
</tr>
</tbody>
</table>

## Santos 2013

Methods
- **Trial design**: 2-arm, single-centre, parallel-design RCT
- **Location**: Brazil
- **Setting**: Hospital
- **Number of centres**: 1, Clinic of Guarulhos University
- **Recruitment period**: July 2008 - May 2010
- **Funding source**: Sao Paulo Research Foundation (#2008/09687-0 2008/11419-4)
**Participants**

**Inclusion criteria:** ≥ 35 years old; ≥ 15 teeth present after excluding third molars and teeth requiring exodontia due to advanced caries; diagnosis of generalised chronic periodontitis (Armitage 1999); concomitant PPD and CAL ≥ 4 mm in at least 30% of sites; presenting with T2 DM in the last 5 years; must be on insulin, diet controlled or oral hypoglycaemic agents

**Exclusion criteria:** Pregnancy, lactation, smokers or those that had smoked in last 5 years. SRP in last 12 months. Antimicrobial therapy in previous 6 months including those with medical conditions requiring antibiotic cover and use of antimicrobial mouthwashes in last 3 months. Medical conditions that affect the progress of periodontitis and long-term administration of anti-inflammatory and immunosuppressive medications. Allergy to CHX. Periapical pathology or wearing orthodontic appliances. Major complications of DM

**Age at baseline:** Gp A mean 50.3 yrs (SD 9.5); Gp B 53.9 yrs (SD 10.8)

**Sex (M:F):** Overall: M10:F28; Gp A M4:F15; Gp B M6:F13

**Tobacco use:** Excluded from study

**Alcohol consumption:** Not recorded

**Diabetes type:** Type 2 DM

**Duration since diabetes diagnosis:** Gp A mean 6.3 yrs (SD 0.8); Gp B mean 6.8 yrs (SD 1.1)

**Metabolic control:** Poor mean HbA1c at baseline

Mean HbA1c at baseline: Gp A 10.00% (SD 2.41); Gp B 10.4% (SD 2.9)

HbA1c > 8.0%: Gp A 15/19, Gp B 13/19

**Antidiabetic therapy:** All in receipt of oral hypoglycaemic medication, insulin, diet or combination

**Other clinical investigations:** FPG (mg/dl), SUP (%)

**Number randomised:** 38

**Number evaluated:** 3 months = 37, 6 months = 37, 12 months = 33

(Gp A: 2 lost to follow-up; Gp B: 3 lost to follow-up (1 excluded from analysis due to not attending 3-month assessment))

ITT analysis used for all results using 6-month data

**Interventions**

**Comparison:** SRP + FMD (CHX rinse x 60 days & CHX gel x 1) + OHI (x 4) + prophylaxis (x 3) versus SRP + placebo FMD (rinse x 60 days & gel x 1) + OHI (x 4) + prophylaxis (x 3)

Gp A (n = 19): SRP + FMD (full mouth disinfection with chlorhexidine digluconate (CHX) 0.12% rinse for 60 days, and CHX gel (1%, applied to irrigate all treated pockets 3 times, within 10 minutes)) + OHI (x 4: at baseline, 3, 6 and 9 months; brushing technique instruction for soft manual toothbrush, dental floss, interdental brushes, and provision of branded toothpaste for duration of study period) + supportive prophylaxis (x 3: at 3, 6 and 9 months; professional plaque control including abrasive sodium carbonate air-powder system and subgingival debridement)

Gp B (n = 19): SRP + placebo FMD (placebo rinse for 60 days, and placebo gel (1%, applied to irrigate all treated pockets 3 times, within 10 minutes: composed of aspartame, zinc acetate dehydrate, alcohol, colourant, flavouring, ascesulphame and purified water)) + OHI (x 4: at baseline, 3, 6 and 9 months; brushing technique instruction for soft manual toothbrush, dental floss, interdental brushes, and provision of branded toothpaste for duration of study period) + supportive prophylaxis (x 3: at 3, 6 and 9 months; professional plaque control including abrasive sodium carbonate air-powder system and subgingival debridement)
Duration of follow-up: 12 months

Outcomes

<table>
<thead>
<tr>
<th>Primary: HbA1c (at baseline, 3, 6 and 12 months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secondary: Periodontal parameters BOP (%), PPD (mm), CAL (mm) (at baseline, 3, 6 and 12 months)</td>
</tr>
</tbody>
</table>

Notes

Sample size calculation: A priori calculations showed a minimum participation of 32 at 80% power

Data analysis: ITT

SES: Not reported

Adverse events: Gp A: 89%; Gp B: 67% report taste perception change/dry mouth/staining

HbA1c assessment method: High pressure liquid chromatography

Conflict of interests: Authors declare no conflict of interests exists

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Code number given a number during enrolment visit. Assignment by computer generated table (PMD)</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>PMD allocated code bottles</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>Low risk</td>
<td>Placebo given to control group</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>Low risk</td>
<td>Both groups received similar mechanical therapy, and the operator did not identify the contents of the bottles at any time during the study</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>ITT analysis. All patients accounted for. 5 patients lost to follow-up. Similar rates, no concerns</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>All outcomes reported, including adverse events</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other apparent biases</td>
</tr>
</tbody>
</table>
Singh 2008

### Methods

<table>
<thead>
<tr>
<th>Trial design:</th>
<th>3-arm, single-centre, parallel-design RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location:</td>
<td>India</td>
</tr>
<tr>
<td>Setting:</td>
<td>Hospital</td>
</tr>
<tr>
<td>Number of centres:</td>
<td>1, Department of Periodontics, JSS Dental College, Mysore, India</td>
</tr>
<tr>
<td>Recruitment period:</td>
<td>Not reported</td>
</tr>
<tr>
<td>Funding source:</td>
<td>Quote: &quot;Source of support: Nil&quot;</td>
</tr>
</tbody>
</table>

### Participants

| Inclusion criteria: | ≥ 30 years old, either sex; T2 DM; moderate to advanced periodontitis (30% or > of examined teeth with ≥ 4 mm probing depth); absence of any major diabetic complications; no evidence of any systemic disease (other than diabetes) being a risk factor for periodontitis |
| Exclusion criteria: | Uncontrolled DM; periodontal treatment in prior 6 months; antibiotic administration in prior 3 months; <16 remaining natural teeth |
| Age at baseline: | Not reported |
| Sex (M:F): | Not reported |
| Tobacco use: | Not reported |
| Alcohol consumption: | Not reported |
| Diabetes type: | Type 2 DM |
| Duration since diabetes diagnosis: | Not reported |
| Metabolic control: | Fair mean HbA1c at baseline |
| Mean HbA1c at baseline: | Gp A: mean 7.9% (SD 0.7); Gp B mean 8.3% (SD 0.7); Gp C mean 8.08% (SD 0.7) |
| Antidiabetic therapy: | Not specifically reported. All in receipt of antidiabetic therapy but no indication what form ("Exclusion criteria: Patients with uncontrolled DM") |
| Other clinical investigations: | FPG, PPBG |
| Number randomised: | 45 |
| Number evaluated: | 45 |

### Interventions

| Comparison: SRP + OHI versus SRP + OHI + doxycycline versus no treatment |
| Gp A (n = 15): Full mouth SRP (under local anaesthesia) + OHI |
| Gp B (n = 15): Full mouth SRP + OHI + systemic doxycycline (200 mg on treatment day, followed by 100 mg p/d x 14 days) |
| Gp C (n = 15): No treatment |
| Note: Additionally "after oral examination the teeth with poor prognosis were extracted. " No indication which Gps or how many patients received extractions, or whether this may have affected treatment outcomes |
| Duration of follow-up: | 3 months |

### Outcomes

| Primary: | HbA1c (at baseline and 3 months) |
| Secondary: | PI, GI, PPD, CAL (at baseline and 3 months) |

### Notes

| Sample size calculation: | Not reported |
| Data analysis: | Assumed ITT |
| SES: | Not reported |
| Adverse events: | Quote: "None of the patients in our study experienced any adverse side effects with doxycycline" |
| HbA1c assessment method: | Liquid chromatography |
| Conflict of interests: | Authors declare no conflict of interests exists |
### Singh 2008  
(Continued)

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “They were randomly divided into three groups of 15 patients each” Comment: No further details</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Not possible, and no placebos used</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>Not reported, and unlikely to be possible due to differing treatments provided</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>No patients reported as lost to follow-up. Analysis assumed to have been ITT, but not specifically reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Planned outcomes reported for 3 months; however, assessed at 1 month and not reported. Furthermore, no adverse events reported other than for doxycycline use (Gp B) relating to SRP (Gps A+B) or no treatment (Gp C)</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No patient characteristics presented therefore unknown if baseline imbalances between groups. Also no indication of how many patients in each arm received tooth extractions as part of treatment protocol as wound healing may potentially affect results</td>
</tr>
</tbody>
</table>

#### Skaleric 2004

**Methods**
- **Trial design:** 2-arm, single-centre, parallel-design RCT
- **Location:** Slovenia
- **Setting:** Hospital
- **Number of centres:** 1, Diabetes Clinic University of Ljubljana
- **Recruitment period:** Not reported
- **Funding source:** Not reported

**Participants**
- **Inclusion criteria:** >21 years old; good general health; clinical diagnosis of periodontitis defined as 4 teeth in more than 2 quadrants with ≥5 mm periodontal pocketing, 2 of which had 6-9 mm pockets and BOP; uncontrolled or poorly controlled T1 DM as determined by HbA1c of 9%; stable dosage of angiotensin II (ACE/AII) inhibitors or any other hypotensive; stable oral antidiabetic medications in last 2 months; no major
control of dental infection (extraction, root canal therapy, local or systemic antibiotics)

**Exclusion criteria:** T2 DM. Pregnant, lactating or of child bearing potential and not using acceptable methods of birth control (hormonal, barrier or abstinence) and patients treated with medication known to affect periodontal status (eg phenytoin, calcium antagonists, Coumadin, cyclosporine, and NSAIDs) within 1 month of baseline visit. Presence of diabetes-related wounds and/or ulcers, requirement of prophylactic antibiotics, allergies to tetracyclines, steroid medications except for acute topical treatment. Use of systemic antibiotics within 3 months prior to enrolment, serum creatinine ≥1.9 mg/ml, laboratory values in excess of twice normal limit, and average baseline BP >160/100 limit. History of severe CVD within last 3 months, severe pulmonary disease, severe liver disease, ESRD (end stage renal disease), active malignancy, cerebral vascular disease, HIV, tuberculosis, hepatitis or other active infectious disease, drug or alcohol abuse, mental or cognitive deficiencies, or any condition which might require surgery during the course of the study and no major adverse events were reported

**Age at baseline:** Overall mean: 41.8 yrs (SD 7.5); Gp A mean 42.0 yrs (SD not reported) ; Gp B 41.6 yrs (SD not reported) (P = 0.98)

**Sex (M:F):** Overall: M10:F10; Gp A M5:F5; Gp B M5:F5 (P = 1)

**Tobacco use:** 10/20 Gp A 7, Gp B 3 (P = 0.18)

**Alcohol consumption:** Not reported

**Diabetes type:** Type 1 DM

**Duration since diabetes diagnosis:** <5 years: n = 4; >5 years: n = 16

**Metabolic control:** Poor mean HbA1c at baseline

Mean HbA1c at baseline: Gp A 9.11% (SD 0.93); Gp B 9.49% (SD 1.29)

**Antidiabetic therapy:** Not specifically reported, except for quotes: "Patients with type 2 non-insulin dependent diabetes were excluded from the study." "If patients were on additional oral antidiabetic medication, they had to be stable with no changes in the past two months."

**Other clinical investigations:** Sites with PD >5 mm

**Number randomised:** 20

**Number evaluated:** 20 at 3 months, 20 at 6 months

### Interventions

**Comparison:** SRP + minocycline (x 2) + supragingival prophylaxis versus SRP + supragingival prophylaxis

Gp A (n = 10): SRP (within 48 hrs of baseline; using hand curettes, ultrasonic instruments and local anaesthesia) + minocycline hydrochloride microspheres (1 mg; controlled release bioreabsorbable polymer, at baseline and 12 weeks; in pockets ≥5 mm after completion of SRP and bleeding subsided - participants instructed to avoid toothbrushing for 12 hrs, and flossing for 10 days post-treatment) + supragingival prophylaxis (at 12 weeks; full-mouth cleaning, for 20 min)

Gp B (n = 10): SRP (within 48 hrs of baseline; using hand curettes, ultrasonic instruments and local anaesthesia) + supragingival prophylaxis (at 12 weeks; full-mouth cleaning, for 20 min)

**Duration of follow-up:** 6 months

### Outcomes

**Primary:** HbA1c at baseline, 6 weeks, 12 weeks (3 months), 18 weeks, and 24 weeks (6 months)

**Secondary:** CAL, PD, PI, GI, at baseline, 12 weeks (3 months) and 24 weeks (6 months)
### Notes

- **Sample size calculation:** Not reported
- **Data analysis:** ITT
- **SES:** Not reported
- **HbA1c assessment method:** Not reported
- **Conflict of interests:** Not reported
- **Adverse events:** No major adverse events reported

Note: Use of antibacterial rinses, toothpastes (triclosan or 0.454% stannous fluoride) and irrigating devices were not allowed by patients during the study period

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Randomised by envelope. Inadequate description</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>Unclear risk</td>
<td>Described as single blinded but no description</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>All patients completed. ITT analysis</td>
</tr>
<tr>
<td>All outcomes</td>
<td>Low risk</td>
<td>All pre-stated outcomes reported although pockets &gt;5 mm were only described in baseline data. Adverse events also reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td></td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other apparent biases</td>
</tr>
</tbody>
</table>

### Sun 2011

#### Methods

- **Trial design:** 2-arm, single-centre, parallel-design RCT
- **Location:** China
- **Setting:** Hospital
- **Number of centres:** 1, Second Affiliated Hospital, College of Medicine, Zhejiang University, China
- **Recruitment period:** August 2008 to November 2010
- **Funding source:** Grants from public research organisations: Zhejiang Science and Technology Projects (2009C33168), Natural Science Foundation of Zhejiang Province (Y2100077), Zhejiang Education Committee Projects (Y201017607), National Natural Science Foundation of China (30872884) and Zhejiang Health Bureau Fund (2009A104)
## Participants

**Inclusion criteria:** Patients diagnosed with T2 DM at least 1 year prior to study; moderately poor glycaemic control (HbA1c between 7.5% and 9.5%); aged 70 years; BMI 19-26 kg/m² in women, BMI 20-27 kg/m² in men; no medication changes during the 3 months of study; not smoking; without severe complications, such as diabetic nephropathy, stroke, angina, myocardial infarction and so on. The diagnosis of periodontitis met the following conditions: at least 20 teeth, PD >5 mm, >30% teeth with attachment loss (AL) over 4 mm, or > 60% teeth with PD >4 mm and AL >3 mm; no periodontal treatment in the previous 6 months; no antibiotics or non-steroidal anti-inflammatory drugs administered in previous 3 months; no serious systemic diseases or complications

**Exclusion criteria:** Patients with systemic inflammatory diseases (rheumatoid arthritis, etc.), blood disease, liver damage, kidney disease or trauma

**Age at baseline:** Gp A mean 55.13 yrs (SD 11.16); Gp B mean 54.23 yrs (SD 10.85)

**Sex (M:F):** Overal: M67:F90; Gp A: M35:F47; Gp B: M32:F43

**Tobacco use:** Smokers excluded

**Alcohol consumption:** Not reported

**Diabetes type:** All T2 DM

**Duration since diabetes diagnosis:** >1 year

**Metabolic control:** Poor mean HbA1c at baseline

**Mean HbA1c at baseline:** Gp A: 8.75% (SD 0.67); Gp B: 8.70% (SD 0.65)

**Antidiabetic therapy:** Not reported, only study requirement for no medication changes during study period

**Other medical conditions:** None

**Other clinical investigations:** Sulcus bleeding index; fasting plasma glucose; triglycerides; total cholesterol; high-density lipoprotein cholesterol; low-density lipoprotein cholesterol; FINS, fasting insulin; homeostasis model assessment of insulin resistance; high-sensitivity C reactive protein; tumour necrosis factor; interleukin-6; adiponectin

**Number randomised:** 190

**Number evaluated:** 157

## Interventions

**Comparison:** SRP + OHI + antibiotics versus no intervention

**Gp A (n = 82 after removal of patients not completing the study):** OHI, full mouth scaling (supragingival and subgingival scaling), root planing, periodontal flap surgery when indicated, and extraction of hopeless teeth, restore of balanced occlusion. Antibiotics (tinidazole 1.0 g, bid, po and ampicillin 0.25 g, qid, po) were prescribed for 3 days before and after periodontal intervention. All periodontal interventions were performed by 1 periodontist

**Gp B (n = 75 after removal of patients not completing the study):** No periodontal treatment (no indication if OHI delivered)

**Duration of follow-up:** 3 months

## Outcomes

**Primary:** HbA1c at baseline and 3 months

**Secondary:** PD, CAL, BI, PI at baseline and 3 months

## Notes

**Sample size calculation:** Not reported

**Data analysis:** Per-protocol

**SES:** Not reported

**Adverse events:** Not reported

**HbA1c assessment method:** Immunoturbidimetry
Sun 2011  (Continued)

Conflict of interests: Authors declare no conflict of interests exists

Note: Not detailed anywhere how many were originally in each group
Quote: “A total of 33 patients did not finish the study. The reasons for dropping out included withdrawal due to personal reasons (such as sickness, no available time) (12 patients), later follow-up visit (21 patients, over 3 months). The data of these patients have been excluded from the data at the baseline (Table 1, 2)”

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “..patients were randomly divided into two Groups.” This is the only information reported. The study is not even described as being an RCT</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Quote: “study was not blinded”</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>Quote: “study was not blinded”</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>Per-protocol analysis: not all participants analysed in groups randomised to, regardless of intervention actually received All losses accounted for by rationale, but not indicated which arm withdrawals are from: personal reasons n = 12; postponed follow-up visit n = 21, over 3 months</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>All outcomes reported, except adverse events</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other apparent biases</td>
</tr>
</tbody>
</table>
### Methods

**Trial design:** 2-arm, multicentre, parallel-design RCT  
**Location:** Greece  
**Setting:** Hospital  
**Number of centres:** 2, undergraduate and postgraduate clinics of the Department of Preventive Dentistry, Periodontology and Implant Biology, Dental School, Aristotle University of Thessaloniki, Greece; Pathology Clinic, Hippokration Hospital, Aristotle University of Thessaloniki, Greece  
**Recruitment period:** Not reported  
**Funding source:** Procter and Gamble Hellas (Koulourides 2011 Award for Dental Research, Greece)

### Participants

**Inclusion criteria:**  
- >30 years; T2 DM (diagnosis at least 1 year prior to baseline); HbA1c <7.5% from at least 2 consecutive patient medical record values; absence of important diabetes-related comorbidities; moderate or advanced periodontitis; absence of other systemic diseases known to be risk factors for periodontitis; written consent; ability to attend recall visits  

**Exclusion criteria:**  
- T1 DM; antibiotics in prior 3 months; periodontal treatment in prior 6 months; smoking; infectious conditions (e.g. hepatitis, HIV); pregnant/lactating  

**Age at baseline:** Overall: 60.4 yrs (SD 9.1); Gp A: 62.9 yrs (SD 10.0); Gp B: 57.9 yrs (SD 8.2)  
**Sex (M/F):** Overall: M38:F28; Gp A: M18:F13; Gp B: M20:F15  
**Tobacco use:** Smokers excluded from participation in study  
**Alcohol consumption:** Not reported  
**Diabetes type:** All T2 DM  
**Duration since diabetes diagnosis:** Overall: 11.0 yrs (SD 5.8); Gp A: 11.8 yrs (SD 5.9); Gp B: 10.2 yrs (SD 5.7)  
**Metabolic control:** Good mean HbA1c at baseline  
**Mean HbA1c at baseline:** Mean HbA1c at baseline: 6.70% (SD 0.61); Gp B: 6.89% (SD 0.60)  
**Antidiabetic therapy:** Not reported  
**Other medical conditions:** Not specifically reported, although inclusion criteria specifies requirement for “Absence of important comorbidities due to diabetes”  
**Other investigations:** Gingival recession  
**Number randomised:** 70  
**Number evaluated:** 66 (Gp A: 31; Gp B: 35)

### Interventions

**Comparison:** SRP + OHI + adjunctive antimicrobial (doxycycline) versus SRP + OHI + placebo antimicrobial  
**Gp A (n = 35):** 2-week OHI pretreatment phase (resulting in <20% plaque for inclusion in trial), followed by SRP (2 sessions of supragingival Piezon ultrasonic instrumentation and subgingival hand instrumentation with Gracey curettes, under local anaesthetic), before randomisation to receive systemic doxycycline (21 days: 200 mg loading dose, followed by 100 mg for further 20 days) and subsequent OHI reinforcement after clinical assessments (patients provided with identical soft nylon multitufted Oral-B Indicator manual toothbrushes)  
**Gp B (n = 35):** 2-week OHI pretreatment phase (resulting in <20% plaque for inclusion in trial), followed by SRP (2 sessions of supragingival Piezon ultrasonic instrumentation and subgingival hand instrumentation with Gracey curettes, under local anaesthetic), before randomisation to receive systemic placebo (21 days: initial dose, followed by additional daily dose for further 20 days) and subsequent OHI reinforcement after clinical assessments (patients provided with identical soft nylon multitufted Oral-B Indicator manual toothbrushes).
---

**Tsiklis 2014 (Continued)**

| Outcomes | **Primary:** HbA1c at baseline, 3 and 6 months  
| | **Secondary:** PPD, CAL, BOP at baseline, 3 and 6 months  
| | **Duration of follow-up:** 6 months |

| Notes | **Sample size calculation:** 60 required (30 per arm; 0.05 significance (2-tailed test) with 99% power to detect CAL means difference of 1.13 mm SD 1.0 mm). Accounting for attrition, recruited 70 (35 per arm)  
| | **Data analysis:** Per-protocol  
| | **Adverse events:** Quote: “no major adverse effects were reported for both groups. Dizziness and difficulty to swallow was reported by one female participant in the control group (Gp B)”  
| | **SES:** Not reported  
| | **HbA1c assessment method:** A1CNow+ Multitest HbA1c system (Bayer HealthCare, Basel, Switzerland) in accordance with manufacturer instructions  
| | **Conflicts of interest:** Authors declare no conflict of interests  
| | **Trial ID:** Not reported |

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Randomization was generated using randomization software, (<a href="http://www.randomization.com">www.randomization.com</a>) and the randomization list was kept by one of the authors (LT) until patients were eligible for the study”</td>
</tr>
</tbody>
</table>
| Allocation concealment (selection bias) | High risk | Quote: “Upon completion of [mechanical] treatment, subjects were allocated [to receive antibiotic or placebo] in the two groups by one of the authors (DS) according to the randomization list kept by LT”  
| | | Comment: Inadequate concealment due to list held by author |
| Blinding of participants | Low risk | Quote: “Subjects in the test group were administered systemic doxycycline (200 mg as loading dose and 100 mg for 20 days), while patients in the control group were administered placebo with the same instructions” |
| Blinding of clinical operator | Low risk | Quote: “Neither therapists nor the examiner were aware of the treatment group” |
### Yun 2007

**Methods**
- **Trial design:** 2-arm, single-centre, parallel-design RCT
- **Location:** China
- **Setting:** Hospital
- **Number of centres:** 1, periodontal department of Guanghua College of Stomatology, Sun Yat-sen University, China
- **Recruitment period:** Not reported
- **Funding source:** Not reported

**Participants**
- **Inclusion criteria:** Patients with newly diagnosed type 2 diabetes and no history of another major illness, no antibiotics or other medications received for at least 3 previous months; at least 14 standing teeth, pocket probing depth was > 5 mm, but < 8 mm in at least 1 site in 4 teeth in at least 2 different quadrants; bleeding and/or suppuration on probing; no periodontal treatment for 6 months prior to baseline examination
- **Exclusion criteria:** Pregnancy or lactation
- **Age at baseline:** Gp A mean 53.41 (SD 2.42) years, Gp B mean 55.10 (SD 2.64) years
- **Sex (M:F):** Overall: M22:F24; Gp A: M10:F13; Gp B: M12:F11
- **Tobacco use:** Not reported
- **Alcohol consumption:** Not reported
- **Diabetes type:** T2 DM
- **Duration since diabetes diagnosis:** “newly diagnosed”
- **Metabolic control:** Fair mean HbA1c at baseline
- **Mean HbA1c at baseline:** Gp A 8.26% (SD 0.31); Gp B 8.22% (SD 0.45)
- **Antidiabetic therapy:** Not specifically reported.
- **Quote:** “These groups were well matched for oral hypoglycaemic medication, the proportion of patients prescribed diet control”
- **Other medical conditions:** No history of other major illness
- **Number randomised:** 46
- **Number evaluated:** 46

**Interventions**
- **Comparison:** SRP + OHI + doxycycline versus doxycycline alone
- **Gp A (n = 23):** Patients were treated weekly with 5 1-hour sessions on a weekly basis. First session OHI and supragingival scaling and polishing, then on subsequent sessions
OHI reinforced and SRP under topical anaesthesia on quadrant by quadrant basis. Doxycycline 100 mg/day for 14 days. Reassessed 8 weeks last session (3 months post-baseline)
Gp B (n = 23): Doxycycline 100 mg/day for 14 days. This group received periodontal treatment as above after the end of the study
**Duration of follow-up:** 4 months

**Outcomes**
- **Primary:** HbA1c (at baseline and 4 months)
- **Secondary:** BOP, PPD, CAL, PI (at baseline and 4 months)

**Notes**
- **Sample size calculation:** Not reported
- **Data analysis:** ITT
- **Adverse events:** Not reported
- **Conflict of interests:** Not reported
- **SES:** Not reported
- **HbA1c assessment method:** High pressure liquid chromatography

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “randomly divided”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Patients would know which group they were in</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>Not reported, but there do not seem to be any drop-outs. ITT analysis</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>All measured outcomes were reported, except adverse events</td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>Poorly reported</td>
</tr>
</tbody>
</table>
### Methods

**Trial design:** 2-arm, single-centre, parallel-design RCT  
**Location:** China  
**Setting:** Hospital  
**Number of centres:** 1, Hubei Provincial Govt Hospital, Hubei, China  
**Recruitment period:** July 2010 to May 2011  
**Funding source:** 11th 5-year National Science and Technology Support Project (2007BAI18B02)

### Participants

**Inclusion criteria:** Chronic periodontitis and had been diagnosed to have T2 DM for more than 1 year. A diagnosis of T2 DM should meet at least 1 of the following criteria: (1) postprandial plasma glucose 200 mg/dL (11.1 mmol/L); (2) fast plasma glucose (FPG) 126 mg/dL (7.0 mmol/L); (3) 2-hour oral glucose tolerance test 200 mg/dL (11.1 mmol/L). In addition, patients should have the following attributes: 35 to 80 years old; with at least 16 natural teeth; with at least 4 teeth with PPD = 5 mm, CAL = 4 mm, and BOP; distributed in 2 or more oral quadrants; and the HbA1c level within 3 months before recruitment should at least be 5.5%

**Exclusion criteria:** Accompanied with other systemic immune diseases; administered with antibiotics, immunomodulators, contraceptives, or any other form of hormone within the past 3 months; underwent modified diabetes treatment strategy within 3 months; had periodontal treatment within the past 12 months; needed extraction or endodontic treatment; smokes more than 4 cigarettes per day; pregnant or lactating women. Patients were dropped from the study if these conditions were met during the study course: diabetes treatment scheme was changed; drugs were systemically administered; patients could not revisit on time; participants were lost on follow-up

**Age at baseline:** Gp A mean 60.4 yrs (SD 9.77); Gp B mean 62.7 yrs (SD 10.7) (P = 0.377)

**Sex (M:F):** Overall: M31:F40; Gp A: M21:F28; Gp B: M10:F12 (P = 0.838)

**Tobacco use:** Overall: n = 18 (25%); Gp A: n = 12 (24%); Gp B: n = 6 (27%)

**Alcohol consumption:** Overall: n = 20 (28%); Gp A: n = 13 (27%); Gp B: n = 7 (32%)

**Diabetes type:** T2 DM

**Duration since diabetes diagnosis:** Gp A 8.63 yrs (SD 4.20); Gp B 7.29 yrs (SD 5.61) (P = 0.305)

**Metabolic control:** Fair mean HbA1c at baseline  
Mean HbA1c at baseline: Gp A 7.68% (SD 1.22); Gp B 7.38 (SD 1.30)

**Antidiabetic therapy:** All in receipt of oral hypoglycaemic medication, insulin or combination  
Overall: oral medication n = 55 (77%); insulin n = 41 (58%); Gp A: oral medication n = 40 (82%); insulin n = 30 (61%); Gp B: oral medication n = 15 (68%); insulin n = 11 (50%)

**Other medical conditions:** n/a

**Other clinical investigations:** FPG

**Number randomised:** 75; Gp A n = 50; Gp B n = 25

**Number evaluated:** 3 months n = 72; 6 months n = 71

### Interventions

**Comparison: SRP + OHI versus no intervention** (delayed ‘initial periodontal treatment’)

Gp A (n = 50): SRP (supra/subgingival scaling (Cavitron Bobcat Pro, Dentsply, USA); manual curettage (Hu-Friedy, USA)) + OHI (within 2 weeks of baseline examination)  
Gp B (n = 25): Delayed treatment  
Gp A subdivided at 3 months into Gp C (n = 25; SRP + OHI + “sub-enhanced root

---

Zhang 2013

109

Treatment of periodontal disease for glycaemic control in people with diabetes mellitus (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**Outcomes**

**Primary:** HbA1c (at baseline, 3 and 6 months)  
**Secondary:** BOP, PPD, CAL, PI (at baseline, 3 and 6 months)

**Notes**

**Sample size calculation:** Preliminary trial on 5 subjects per group SRP versus no treatment. A priori calculation at 80% power 20 in control and 40 in treatment group at 95% significance  
**Data analysis:** Per-protocol  
**Adverse events:** Not reported  
**Conflict of interests:** Not reported  
**HbA1c assessment method:** Ion exchange chromatography (Drew Scientific DS5, England)

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Pre-prepared randomisation in group A, B and C. No description of sequence generation</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Number coded-envelopes</td>
</tr>
<tr>
<td>Blinding of participants</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Blinding of clinical operator</td>
<td>High risk</td>
<td>Not possible</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>4 lost to follow-up: Gp A: 1 lost at evaluation 2 (3 months); Gp B: 2 lost at evaluation 2 (3 months), and 1 at evaluation 3 (6 months) Per-protocol analysis: not all participants analysed in groups randomised to, regardless of intervention actually received</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>HbA1c data presented inconsistently, adverse effects not reported, periodontal outcomes presented as graphs without data. Email to authors bounced</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other apparent biases</td>
</tr>
</tbody>
</table>

aPDT = antimicrobial photodynamic therapy; AL = attachment level; BI = bleeding index; bid = twice daily; BMI = body mass index; BOP = bleeding on probing; CAL = clinical attachment level; CHX = chlorhexidine; DM = diabetes mellitus; F = female; FMD =
full mouth disinfection; GI = gingival index; Gp = group; GR = gingival recession; ITT = intention-to-treat; M = male; NSAIDS = non-steroidal anti-inflammatory drugs; OHI = oral hygiene instruction; PD = probing depth; PI = plaque index; po = orally; PPD = probing pocket depth; qid = 4 times a day; RCT = randomised controlled trial; SD = standard deviation; SE = standard error; SES = socioeconomic status; SRP = scaling and root planing

### Characteristics of excluded studies  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Al-Mubarak 2002</td>
<td>Intervention (Waterpik, an irrigation device) is neither professionally-delivered, nor a periodontal therapy</td>
</tr>
<tr>
<td>Albrecht 1988</td>
<td>No HbA1c outcome reported. Study was not translated to English but advice sought from a Hungarian speaker on the content</td>
</tr>
<tr>
<td>Cinar 2014</td>
<td>Intervention (empowerment “health coaching”) is not a periodontal therapy</td>
</tr>
<tr>
<td>Gorbacheva 2010</td>
<td>Intervention (emoxypine succinate salt toothpaste) is neither professionally-delivered, nor a periodontal therapy. Comparator also a toothpaste</td>
</tr>
<tr>
<td>Hagiwara 2002</td>
<td>Study previously noted under ongoing studies (2010 version of this review); however, upon reinspection of abstract it clearly states non-diabetic control participants were included</td>
</tr>
<tr>
<td>Khader 2010</td>
<td>Use of a non-periodontal intervention: full-mouth tooth extraction for patients whose remaining teeth were deemed to be in a hopeless condition and indicated for extraction regardless</td>
</tr>
<tr>
<td>Llambés 2012</td>
<td>No HbA1c outcome measurement (only hs-CRP), and appears to be subset of included Llambés 2008 study (this second paper reporting hs-CRP separately from HbA1c data already reported in Llambés 2008)</td>
</tr>
<tr>
<td>Mansouri 2006</td>
<td>Follow-up was only 8 weeks</td>
</tr>
<tr>
<td>Munenaga 2013</td>
<td>Patients were able to self select to control arm</td>
</tr>
<tr>
<td>NCT01255254</td>
<td>Correspondence with trial investigator (May 2013) indicated trial was abandoned due to recruitment issues</td>
</tr>
<tr>
<td>Promsudthi 2005</td>
<td>Patients were able to self select to control arm</td>
</tr>
<tr>
<td>Taylor 2011</td>
<td>An error in the MEDLINE reference. This is a review</td>
</tr>
</tbody>
</table>

### Characteristics of studies awaiting assessment  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.*
### Al-Mubarak 2010

<table>
<thead>
<tr>
<th>Methods</th>
<th>RCT conducted in Saudi Arabia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>369 participants (T1DM and T2DM) randomised to 4 groups</td>
</tr>
<tr>
<td></td>
<td>346 participants completed (T1DM: n = 33; T2DM: n = 313)</td>
</tr>
<tr>
<td>Interventions</td>
<td><strong>Comparison: SRP + antimicrobial (doxycycline) versus SRP + placebo</strong></td>
</tr>
<tr>
<td></td>
<td>Gp 1: 1 x SRP session (baseline visit) + placebo tablets twice/day (at baseline for 3 months)</td>
</tr>
<tr>
<td></td>
<td>Gp 2: 1 x SRP session (baseline visit) + doxycycline hyclate (20 mg twice/day, at baseline for 3 months)</td>
</tr>
<tr>
<td></td>
<td>Gp 3: 2 x SRP session (baseline; 6 months) + placebo tablets twice/day (at baseline for 3 months; at 6-month visit for 3 months)</td>
</tr>
<tr>
<td></td>
<td>Gp 4: 2 x SRP session (baseline; 6 months) + doxycycline hyclate 20 mg twice/day (at baseline for 3 months; at 6-month visit for 3 months)</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Primary: HbA1c at 3, 6, 9 and 12 months</td>
</tr>
<tr>
<td></td>
<td>Secondary: BOP, CAL, GI, PI, PPD at 3, 6, 9 and 12 months</td>
</tr>
<tr>
<td></td>
<td>Duration: 12 months</td>
</tr>
<tr>
<td>Notes</td>
<td>International Standard Randomized Controlled Trial Number: ISRCTN-11742127</td>
</tr>
<tr>
<td></td>
<td>No indication patients had periodontitis, also would need control arm HbA1c data from the author to consider further. Awaiting reply from authors</td>
</tr>
</tbody>
</table>

### Botero 2013

<table>
<thead>
<tr>
<th>Methods</th>
<th>RCT conducted in Columbia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>105 patients (T1DM (n = 39) or T2DM (n= 63)) with moderate periodontitis</td>
</tr>
<tr>
<td>Interventions</td>
<td><strong>Comparison: Subgingival prophylaxis + antimicrobial (azithromycin) versus supragingival prophylaxis + antimicrobial (azithromycin) versus subgingival prophylaxis + placebo</strong></td>
</tr>
<tr>
<td></td>
<td>Gp A: Azithromycin 500 mg/day x 3 days + subgingival scaling</td>
</tr>
<tr>
<td></td>
<td>Gp B: Placebo 500 mg/day x 3 days + subgingival scaling</td>
</tr>
<tr>
<td></td>
<td>Gp C: Azithromycin 500 mg/day x 3 days + supragingival prophylaxis</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Primary: HbA1c at 3, 6 and 9 months</td>
</tr>
<tr>
<td></td>
<td>Secondary: CAL, PPD at 3, 6 and 9 months</td>
</tr>
<tr>
<td></td>
<td>Duration: 9 months</td>
</tr>
<tr>
<td>Notes</td>
<td>Poorly reported. Need further data (particularly need accurate HbA1c means/SDs, data re: statin use) from author to complete assessment. Awaiting reply from authors</td>
</tr>
</tbody>
</table>

### Chee 2006

<table>
<thead>
<tr>
<th>Methods</th>
<th>RCT conducted in Singapore</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>159 diabetic patients</td>
</tr>
</tbody>
</table>
### Chee 2006 (Continued)

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Comparison: SRP + OHI versus OHI versus no treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gp A</td>
<td>SRP + OHI</td>
</tr>
<tr>
<td>Gp B</td>
<td>OHI</td>
</tr>
<tr>
<td>Gp C</td>
<td>No treatment</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Primary: HbA1c (no indication of time points for recording)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Secondary: BOP, PI, PPD (no indication of time points for recording)</td>
</tr>
<tr>
<td></td>
<td>Duration: 9 months</td>
</tr>
</tbody>
</table>

| Notes         | No indication whether patients had diagnosed periodontitis. Poorly reported. Insufficient data to complete assessment. Several attempts to contact authors for further details proved unsuccessful |

### Lin 2012

<table>
<thead>
<tr>
<th>Methods</th>
<th>RCT conducted in Taiwan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>28 T2DM patients</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Comparison: SRP + antimicrobial (minocycline) versus SRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gp A</td>
<td>SRP (weekly quadrants undertaken over a month) + subgingival application of 2% minocycline gel</td>
</tr>
<tr>
<td>Gp B</td>
<td>SRP (weekly quadrants undertaken over a month)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Primary: HbA1c at 3, 6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Secondary: BOP, CAL at 3, 6 months</td>
</tr>
<tr>
<td></td>
<td>Duration: 6 months</td>
</tr>
</tbody>
</table>

| Notes         | No affirmation of diagnosed periodontitis. Also needed HbA1c data from author, but not provided in email response. Emailed again to request, but no further response received |

### Nassar 2014

<table>
<thead>
<tr>
<th>Methods</th>
<th>RCT conducted in Brazil</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>40 (80? inconsistent reporting) diabetic patients</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Comparison: SRP (x 1) + OHI (x 3) + maintenance therapy (x 3) versus antimicrobial (chlorhexidine x 1?) + OHI (x 3) + maintenance therapy (x 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gp A</td>
<td>SRP (at baseline) + OHI (x 3: baseline, 3 months, 6 months) + mechanical maintenance therapy ((small-headed, soft-bristled toothbrush + standard toothpaste) x 3: baseline, 3 months, 6 months)</td>
</tr>
<tr>
<td>Gp B</td>
<td>Antimicrobial (chlorhexidine) full-mouth disinfection (at baseline) + OHI (x 3: baseline, 3 months, 6 months) + mechanical maintenance therapy ((small-headed, soft-bristled toothbrush + standard toothpaste) x 3: baseline, 3 months, 6 months)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Primary: HbA1c at 3, 6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Secondary: BOP, CAL, PPD at 3, 6 months</td>
</tr>
<tr>
<td></td>
<td>Duration: 6 months</td>
</tr>
</tbody>
</table>
Notes
Poorly reported, particular clarification sought re: number of patients/randomisation/confirmed use of chlorhexidine (assumed from text). Awaiting response from authors.

BOP = bleeding on probing; CAL = clinical attachment level; GI = gingival index; Gp = group; OHI = oral hygiene instruction; PI = plaque index; PPD = probing pocket depth; RCT = randomised controlled trial; SD = standard deviation; SRP = scaling and root planing; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.

Characteristics of ongoing studies  [ordered by study ID]

ACTRN12605000260628

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Assessment of diabetes after periodontal treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>RCT</td>
</tr>
<tr>
<td>Participants</td>
<td>60 patients</td>
</tr>
<tr>
<td>Inclusion criteria:</td>
<td>Either sex; &gt;35 years old; able to give informed consent; random glucose &gt;200 mg/dL; at least 16 teeth; chronic periodontitis</td>
</tr>
<tr>
<td>Exclusion criteria:</td>
<td>Pregnancy; gross dental caries; requirement for antibiotic cover for dental treatment; anticoagulant therapy; other serious illness</td>
</tr>
<tr>
<td>Interventions</td>
<td><strong>Comparison: SRP + antimicrobial toothpaste (triclosan) versus no treatment + placebo toothpaste</strong></td>
</tr>
<tr>
<td></td>
<td>Gp A: “Periodontal treatment” + triclosan/fluoride toothpaste</td>
</tr>
<tr>
<td></td>
<td>Gp B: Triclosan/fluoride toothpaste + delayed “periodontal treatment”</td>
</tr>
<tr>
<td>Follow-up duration:</td>
<td>12 months</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Primary: HbA1c (recorded at baseline, 6 and 12 months)</td>
</tr>
<tr>
<td></td>
<td>Secondary: (Unspecified: assume periodontal parameters) “response to periodontal treatment” (recorded at baseline, 6 and 12 months)</td>
</tr>
<tr>
<td>Starting date</td>
<td>2005</td>
</tr>
<tr>
<td>Contact information</td>
<td>Mary Cullinan: <a href="mailto:m.cullinan@uq.edu.au">m.cullinan@uq.edu.au</a></td>
</tr>
<tr>
<td>Notes</td>
<td>Funding source: Australian Dental Research Fund and Colgate Palmolive Co USA</td>
</tr>
<tr>
<td></td>
<td>Dr Cullinan confirmed (February 2015), completed but not published. Not able to share results (unknown if analysed)</td>
</tr>
</tbody>
</table>
### ACTRN12605000340639

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>RMI adult oral health programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>RCT</td>
</tr>
<tr>
<td>Participants</td>
<td>60 patients</td>
</tr>
<tr>
<td>Inclusion criteria:</td>
<td>Either sex; &gt;35 years old; able to give informed consent; random glucose &gt;200 mg/dL; at least 16 teeth; chronic periodontitis</td>
</tr>
<tr>
<td>Exclusion criteria:</td>
<td>Pregnancy; requirement for antibiotic cover for dental treatment; anticoagulant therapy; other serious illness</td>
</tr>
</tbody>
</table>
| Interventions       | **Comparison: SRP + OHI + antimicrobial toothpaste (triclosan) versus SRP + OHI + placebo toothpaste**  
Gp A: SRP + OHI + triclosan/fluoride toothpaste  
Gp B: SRP + OHI + fluoride toothpaste (placebo)  
Follow-up duration: 12 months |
| Outcomes            | Primary: HbA1c (recorded at baseline, 6 and 12 months)  
Secondary: (Unspecified) “periodontal parameters” (recorded at baseline, 6 and 12 months) |
| Starting date       | 2005                            |
| Contact information | Mary Cullinan: m.cullinan@uq.edu.au |
| Notes               | Funding source: Colgate Palmolive Co USA  
Dr Cullinan confirmed (February 2015), completed but not published. Not able to share results (unknown if analysed) |

### IRCT2014082417587N7

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>The effect of non-surgical periodontal therapy plus doxycycline on HbA1c in patients with type 2 diabetes mellitus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>RCT</td>
</tr>
<tr>
<td>Participants</td>
<td>24 type 2 DM patients with chronic-moderate periodontitis</td>
</tr>
</tbody>
</table>
| Interventions       | **Comparison: SRP + OHI + antimicrobial (doxycycline) versus SRP + OHI + placebo antimicrobial**  
Gp A: SRP + OHI + antimicrobial (doxycycline: 100 mg/day x 15 days)  
Gp B: SRP + OHI + placebo antimicrobial (x 15 days)  
Follow-up duration: 3 months |
| Outcomes            | Primary: HbA1c (at 3 months)  
Secondary: BOP, CAL, PI, PPD (at 3 months) |
| Starting date       | September 2015                                                                                           |
| Contact information | Amirhossein Farahmand: perio-implant@hotmail.com                                                            |
| Notes               | Recruitment complete (September 2015)                                                                     |
### ISRCTN15334496

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Periodontal treatment for improving glycaemic control in diabetic patients: a randomised controlled trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial acronym</td>
<td>DIAPERIO</td>
</tr>
<tr>
<td>Trial ID</td>
<td>ISRCTN15334496</td>
</tr>
</tbody>
</table>

**Methods**

2-centre, single-blind RCT

**Participants**

150 people with type 1 and 2 DM and:
- be aged 18 years or older (male or female),
- be affiliated to a public health system,
- be diagnosed as having had type 1 or 2 diabetes for at least 1 year before V0,
- have a last known value of HbA1c, measured within 3 months prior V0, between 6.8% and 9.7%,
- have received stable antidiabetic therapy (no changes to diet, medication, dosage or formulation) during the 3 months preceding V0,
- have at least 6 natural permanent teeth,
- be available for all study visits over 3 months in the dental care departments (V1 to V6),
- be able to give their written informed consent

**Interventions**

**Comparison:** SRP + OHI + systemic antimicrobial (amoxicillin) + topical antimicrobial (chlorhexidine) versus no treatment

Gp A: SRP + OHI + systemic antimicrobial (500 mg amoxicillin tid for 7 days; or if contraindicated to beta-lactam antibiotics: 300 mg clindamycin bid for 7 days) + topical antimicrobial (chlorhexidine 0.12%)

Gp B: No treatment (delayed until 23 weeks, when receive Gp A’s allocated treatment)

**Outcomes**

Primary: HbA1c after 13 weeks
Secondary: Quality of life
Duration: 13 weeks

**Starting date** May 2009

**Contact information** Jean-Noel Vergnes: jn.vergnes@mcgill.ca

**Notes**

Protocol only
May 2013, email from JN Vergnes confirmed that this trial is still recruiting
Followed up December 2014, no response from author

### ISRCTN83229304

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Periodontitis and type 2 diabetes mellitus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial acronym</td>
<td>DRN211</td>
</tr>
</tbody>
</table>

**Methods**

Single centre RCT

**Participants**

280 patients
Inclusion criteria: Either sex; >18 years old; able to give consent; diagnosed type 2 DM; at least 15 teeth; signs of active moderate-severe periodontitis (>20 periodontal pockets, PPD >4 mm and BOP)
Exclusion criteria: Pregnancy; requirement for antibiotic cover for periodontal procedures; chronic treatment with phenytoin/cyclosporin; known HIV/hepatitis B or C/uncontrolled systemic disease; neoplasm
### Interventions

**Comparison:** “Intensive periodontal therapy” versus supragingival scaling and polishing  

- **Gp A:** “Intensive periodontal therapy”  
- **Gp B:** “Usual periodontal care (supragingival scaling and polishing)"  

**Follow-up duration:** 12 months

### Outcomes

Primary: HbA1c (recorded at baseline and 12 months)

### Starting date

2008

### Contact information

Jean Suvan: j.suvan@eastman.ucl.ac.uk

### Notes

Author confirmed (December 2014) data currently being analysed

---

#### NCT00016835

**Trial name or title**  

Treating periodontal infection: effects on glycaemic control in people with type 2 diabetes

**Methods**  

3-arm RCT

**Participants**  

45 type 2 DM patients with established periodontitis

**Interventions**

**Comparison:** Scaling + topical antimicrobial (povidone-iodine) + systemic antimicrobial (doxycycline) versus scaling + topical antimicrobial (povidone-iodine) + systemic antimicrobial (metronidazole) versus supragingival prophylaxis/calculus removal + placebo + delayed subgingival scaling + topical antimicrobial (povidone-iodine)  

- **Gp A:** Ultrasonic scaling with local anaesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation and an oral systemic antibiotic (doxycycline) at baseline  
- **Gp B:** Ultrasonic scaling with local anaesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation and an oral systemic antibiotic (metronidazole) at baseline  
- **Gp C:** Placebo and supragingival oral prophylaxis and ultrasonic removal of supragingival calculus with water irrigation at baseline, + subgingival ultrasonic scaling with povidone-iodine irrigation at 9 months

**Outcomes**

Primary: HbA1c. Others unknown  

**Duration:** 15 months

**Starting date**  

April 2001

**Contact information**  

George Taylor: gwt@umich.edu

**Notes**

Author (GT) previously supplied some information for 2010 review indicating that data had been collected and was awaiting analysis. Emailed Dr Taylor to check if trial completed/obtain unpublished results, but no response
### NCT01291875

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Periodontal treatment and metabolic control in type 2 diabetic patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>2-arm RCT</td>
</tr>
<tr>
<td>Participants</td>
<td>732 type 2 DM patients with severe periodontitis</td>
</tr>
<tr>
<td>Interventions</td>
<td><strong>Comparison: SRP versus mechanical debridement</strong></td>
</tr>
<tr>
<td></td>
<td>Gp A: SRP under local analgesia (depending on the severity in 1 session or 2 sessions within 2 days) + extraction of indicated hopeless teeth + additional SRP where necessary at follow-up</td>
</tr>
<tr>
<td></td>
<td>Gp B: “Supragingival biofilm control”: supragingival mechanical instrumentation/polishing using hand and machine driven (piezoelectric) instrumentation</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Primary: HbA1c (at 2, 6, 12 months). Others unknown</td>
</tr>
<tr>
<td>Starting date</td>
<td>February 2011</td>
</tr>
<tr>
<td>Contact information</td>
<td>Hilana Artese: <a href="mailto:hilanartese@gmail.com">hilanartese@gmail.com</a>; Giuseppe Romito: <a href="mailto:garomito@usp.br">garomito@usp.br</a></td>
</tr>
<tr>
<td>Notes</td>
<td>Emailed Drs Artese and Romito to check if trial completed/obtain unpublished results, but no response</td>
</tr>
</tbody>
</table>

### NCT01881074

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Periodontal treatment response in type II diabetic patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>2-arm RCT</td>
</tr>
<tr>
<td>Participants</td>
<td>68 type 2 DM patients</td>
</tr>
<tr>
<td>Interventions</td>
<td><strong>Comparison: Prophylaxis (x 6) + antimicrobial toothpaste (triclosan) versus prophylaxis (x 6) + placebo toothpaste</strong></td>
</tr>
<tr>
<td></td>
<td>Gp A: &quot;Dental cleaning&quot; (x 6: at baseline, 6 weeks, 3, 6, 9, and 12 months) + use of provided antimicrobial toothpaste (triclosan) (for full 12 months)</td>
</tr>
<tr>
<td></td>
<td>Gp B: “Dental cleaning” (x 6: at baseline, 6 weeks, 3, 6, 9, and 12 months) + use of provided placebo toothpaste (for full 12 months)</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Primary: HbA1c (at 3, 6, 12 months)</td>
</tr>
<tr>
<td></td>
<td>Secondary: CAL, PI, PPD (at 3, 6, 12 months)</td>
</tr>
<tr>
<td></td>
<td>Duration: 12 months</td>
</tr>
<tr>
<td>Starting date</td>
<td>June 2012</td>
</tr>
<tr>
<td>Contact information</td>
<td>Luciana Shaddox: <a href="mailto:ShaddoxResearch@dental.ufl.edu">ShaddoxResearch@dental.ufl.edu</a></td>
</tr>
<tr>
<td>Notes</td>
<td>Emailed Dr Shaddox to check if trial completed/obtain unpublished results, but no response</td>
</tr>
<tr>
<td></td>
<td>Collaborative study with Colgate-Palmolive</td>
</tr>
<tr>
<td></td>
<td>No indication of patients requiring diagnosis of periodontitis</td>
</tr>
</tbody>
</table>
### NCT01901926

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Periodontal treatment and glycaemic control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>RCT</td>
</tr>
<tr>
<td>Participants</td>
<td>184 type 2 DM patients with mild-moderate periodontitis</td>
</tr>
</tbody>
</table>
| Interventions       | **Comparison: SRP versus no treatment**  
                       Gp A: SRP  
                       Gp B: No treatment |
| Outcomes            | Primary: HbA1c (at 3, 6, 9 months)  
                       Secondary: BOP, CAL, PPD (at 3, 6, 9 months)  
                       Duration: 9 months |
| Starting date       | December 2012                              |
| Contact information | Salman Aziz: dr.salman_aziz@yahoo.com       |
| Notes               | Emailed Dr Aziz to check if trial completed/obtain unpublished results, but no response |

### NCT01904422

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Periodontal treatment in non-controlled type 2 diabetes mellitus patients (FONIS12I2106)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>2-arm RCT</td>
</tr>
<tr>
<td>Participants</td>
<td>100 type 2 DM patients</td>
</tr>
</tbody>
</table>
| Interventions       | **Comparison: Immediate treatment (SRP + additional mechanical therapy (prophylaxis) + OHI) versus ongoing treatment SRP + additional mechanical therapy (prophylaxis) + OHI**  
                       Gp A: Intensive treatment (2 sessions (left side, then right) in 24 hrs: SRP + OHI + supragingival and subgingival debridement)  
                       Gp B: Ongoing treatment (5 sessions: 1 quadrant p/w) over 5 weeks: SRP + OHI + supragingival and subgingival debridement |
| Outcomes            | Primary: HbA1c (at 3, 6 months)  
                       Secondary: BOP, CAL, PPD (at 3, 6 months)  
                       Duration: 6 months |
| Starting date       | March 2013                                                                                 |
| Contact information | Helia Morales: heliamorales@gmail.com                                                      |
| Notes               | No indication of patients requiring diagnosis of periodontitis  
                       Emailed Dr Morales to check if trial completed/obtain unpublished results, but no response |
**NCT01964833**

| Trial name or title | Combination of photodynamic therapy and periodontal treatment in patients with type 2 diabetes mellitus: randomised, double-blind clinical trial  
Trial acronym: PDTDMT2 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>RCT</td>
</tr>
</tbody>
</table>
| Participants        | 44 patients  
Inclusion criteria: Either sex; >18 years old; compensated type 2 DM or with adequate control based on the criteria of the Brazilian Society of Diabetes (SBD, 2012); chronic periodontitis (AAP, 2001); at least 15 teeth and at least 4 teeth with BOP and PPD >4 mm; under follow-up with an endocrinologist  
Exclusion criteria: Uncompensated diabetes, based on SBD criteria; smoking habit in 12 months prior to treatment; anaemia; active cancer; current pregnancy; history of antibiotic therapy in previous 6 months; history of anti-inflammatory therapy in previous 3 months; clotting disorder (use of anti-coagulant, presence of liver disease, thrombocytopenia and immunosuppression); currently undergoing orthodontic treatment |
| Interventions       | Comparison: SRP + OHI + aPDT versus SRP + OHI + placebo aPDT  
Gp A: SRP + OHI + aPDT  
Gp B: SRP + OHI + placebo aPDT  
Follow-up duration: 6 months |
| Outcomes            | Primary: HbA1c (recorded at baseline, 2 weeks, 1, 3 and 6 months)  
Secondary: CAL (recorded at baseline and 6 months)  
Duration: 6 months |
| Starting date       | 2013                                                                                                                             |
| Contact information | Cristiane Franca: cristiane321@gmail.com                                                                                         |
| Notes               | Author reports (December 2014) trial neither completed nor published, and encountered significant problems with following-up patients |

**U1111-1124-3635**

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Influence of periodontal treatment in periodontitis and diabetes control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>RCT</td>
</tr>
<tr>
<td>Participants</td>
<td>150 type 2 DM patients with chronic periodontitis</td>
</tr>
</tbody>
</table>
| Interventions       | Comparison: SRP versus ultrasonic debridement versus OHI  
Gp A: SRP  
Gp B: Ultrasonic debridement  
Gp C: OHI |
| Outcomes            | Primary: HbA1c  
Secondary: PI, PPD  
Duration: 6 months          |
Continued

<table>
<thead>
<tr>
<th>Starting date</th>
<th>August 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact information</td>
<td>Renata Cimões: <a href="mailto:renata.cimoes@globo.com">renata.cimoes@globo.com</a></td>
</tr>
<tr>
<td>Notes</td>
<td>Emailed to check if completed/unpublished results available: no response</td>
</tr>
</tbody>
</table>

aPDT = antimicrobial photodynamic therapy; bid = twice daily; BOP = bleeding on probing; CAL = clinical attachment level; DM = diabetes mellitus; Gp = group; OHI = oral hygiene instruction; PI = plaque index; PPD = probing pocket depth; RCT = randomised controlled trial; SRP = scaling and root planing; tid = 3 times a day
## DATA AND ANALYSES

### Comparison 1. Periodontal therapy versus no active intervention/usual care

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 HbA1c at 3-4 months</td>
<td>14</td>
<td>1499</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>-0.29 [-0.48, -0.10]</td>
</tr>
<tr>
<td>1.1 SRP</td>
<td>8</td>
<td>547</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>-0.41 [-0.73, -0.08]</td>
</tr>
<tr>
<td>1.2 SRP + antimicrobials</td>
<td>7</td>
<td>952</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>-0.18 [-0.39, 0.03]</td>
</tr>
<tr>
<td>2 HbA1c at 6 months</td>
<td>5</td>
<td>826</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>-0.02 [-0.20, 0.16]</td>
</tr>
<tr>
<td>2.1 SRP</td>
<td>3</td>
<td>263</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>-0.18 [-0.58, 0.22]</td>
</tr>
<tr>
<td>2.2 SRP + antimicrobials</td>
<td>2</td>
<td>563</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.02 [-0.18, 0.22]</td>
</tr>
</tbody>
</table>

### Comparison 2. Periodontal therapy versus alternative periodontal therapy

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 HbA1c at 3-4 months</td>
<td>21</td>
<td>Totals not selected</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.1 SRP vs alternative mechanical therapy</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
<td></td>
</tr>
<tr>
<td>1.2 SRP vs alternative SRP</td>
<td>3</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
<td></td>
</tr>
<tr>
<td>1.3 SRP + antimicrobial vs antimicrobial</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
<td></td>
</tr>
<tr>
<td>1.4 SRP + antimicrobial vs SRP</td>
<td>12</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
<td></td>
</tr>
<tr>
<td>1.5 SRP + antimicrobial (doxycycline) vs SRP + alternative antimicrobial</td>
<td>3</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
<td></td>
</tr>
<tr>
<td>1.6 SRP + combined antimicrobials vs SRP + single antimicrobial</td>
<td>3</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
<td></td>
</tr>
<tr>
<td>1.7 SRP + statin vs SRP</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
<td></td>
</tr>
<tr>
<td>2 HbA1c at 6 months</td>
<td>12</td>
<td>Totals not selected</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.1 SRP vs alternative mechanical therapy</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
<td></td>
</tr>
<tr>
<td>2.2 SRP vs alternative SRP</td>
<td>3</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
<td></td>
</tr>
<tr>
<td>2.3 SRP + antimicrobial vs SRP</td>
<td>5</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
<td></td>
</tr>
<tr>
<td>2.4 SRP + antimicrobial (doxycycline) vs SRP + alternative antimicrobial</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
<td></td>
</tr>
<tr>
<td>2.5 SRP + combined antimicrobials vs SRP + single antimicrobial</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
<td></td>
</tr>
</tbody>
</table>
2.6 SRP + bone modifier vs SRP  
Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]

2.7 SRP + statin vs SRP  
Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]

### Analysis 1.1. Comparison 1 Periodontal therapy versus no active intervention/usual care, Outcome 1 HbA1c at 3-4 months.

**Review:** Treatment of periodontal disease for glycaemic control in people with diabetes mellitus

**Comparison:** 1 Periodontal therapy versus no active intervention/usual care

**Outcome:** 1 HbA1c at 3-4 months

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>SRP</th>
<th>Usual care/no active treatment</th>
<th>N</th>
<th>Mean(SD)</th>
<th>N</th>
<th>Mean(SD)</th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen 2012 (1)</td>
<td>85</td>
<td>7.3658 (1.5076)</td>
<td>41</td>
<td>7.59 (1.54)</td>
<td>6.7%</td>
<td>-0.22 [ -0.79, 0.35 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gay 2014</td>
<td>66</td>
<td>8.4 (1.9)</td>
<td>60</td>
<td>8.1 (1.8)</td>
<td>5.8%</td>
<td>0.30 [ -0.35, 0.95 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kiran 2005</td>
<td>22</td>
<td>6.51 (0.8)</td>
<td>22</td>
<td>7.31 (2.08)</td>
<td>3.4%</td>
<td>-0.80 [ -1.73, 0.13 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kothiwale 2013</td>
<td>25</td>
<td>7.53 (0.4)</td>
<td>25</td>
<td>7.97 (0.64)</td>
<td>11.9%</td>
<td>-0.44 [ -0.74, -0.14 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Li 2011 (2)</td>
<td>41</td>
<td>7.3427 (1.2485)</td>
<td>25</td>
<td>7.54 (1.76)</td>
<td>4.4%</td>
<td>-0.20 [ -0.99, 0.59 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moeintaghavi 2012</td>
<td>22</td>
<td>7.41 (1.18)</td>
<td>18</td>
<td>8.97 (1.82)</td>
<td>3.1%</td>
<td>-1.56 [ -2.53, -0.59 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singh 2008</td>
<td>15</td>
<td>7.3 (0.6)</td>
<td>8</td>
<td>8.1 (0.7)</td>
<td>6.7%</td>
<td>0.30 [ -0.15, 0.77 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhang 2013</td>
<td>49</td>
<td>7.54 (1.13)</td>
<td>23</td>
<td>7.51 (1.64)</td>
<td>4.8%</td>
<td>0.03 [ -0.71, 0.77 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Subtotal (95% CI)** 325 222  
46.7 % -0.41 [-0.73, -0.08 ]

Heterogeneity: Tau² = 0.10; Chi² = 14.52, df = 7 (P = 0.04); I² =52%

Test for overall effect: Z = 2.48 (P = 0.013)

2 SRP + antimicrobials

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calbacho 2004</td>
<td>12</td>
<td>9.6 (3.2)</td>
<td>12</td>
<td>10.6 (2.2)</td>
<td>0.7%</td>
<td>1.00 [ -3.20, 1.20 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ergebretson 2013</td>
<td>257</td>
<td>7.7 (1.0223)</td>
<td>257</td>
<td>7.67 (1.0632)</td>
<td>14.4%</td>
<td>0.03 [ -0.15, 0.21 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jones 2007</td>
<td>74</td>
<td>9.22 (1.56)</td>
<td>80</td>
<td>9.58 (1.42)</td>
<td>8.3%</td>
<td>-0.36 [ -0.83, 0.11 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Katagiri 2009</td>
<td>32</td>
<td>7.04 (0.91)</td>
<td>17</td>
<td>6.89 (1.13)</td>
<td>6.0%</td>
<td>0.15 [ -0.47, 0.77 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raman 2014</td>
<td>15</td>
<td>7.1 (1.2)</td>
<td>17</td>
<td>7.1 (1.2)</td>
<td>4.0%</td>
<td>0.00 [ -0.83, 0.83 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singh 2008</td>
<td>15</td>
<td>7.5 (0.6)</td>
<td>7</td>
<td>8.1 (0.7)</td>
<td>6.3%</td>
<td>0.60 [ -1.20, 0.00 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sun 2011</td>
<td>82</td>
<td>8.25 (0.72)</td>
<td>75</td>
<td>8.56 (0.69)</td>
<td>13.6%</td>
<td>-0.31 [ -0.53, -0.09 ]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Subtotal (95% CI)** 487 465  
53.3 % -0.18 [-0.39, 0.03 ]

Heterogeneity: Tau² = 0.03; Chi² = 10.31, df = 6 (P = 0.11); I² =42%

Test for overall effect: Z = 1.68 (P = 0.092)

---

Treatments of periodontal disease for glycaemic control in people with diabetes mellitus (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(... continued)

(1) SRP + additional mechanical therapy

(2) Periodontal therapy described as “mechanical therapy”

### Analysis 1.2. Comparison 1 Periodontal therapy versus no active intervention/usual care, Outcome 2 HbA1c at 6 months.

#### Review: Treatment of periodontal disease for glycaemic control in people with diabetes mellitus

#### Comparison: 1 Periodontal therapy versus no active intervention/usual care

#### Outcome: 2 HbA1c at 6 months

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>SRP</th>
<th>Usual care/no active treatment</th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>N</td>
<td>N</td>
<td>IV,Random,95% CI</td>
<td>IV,Random,95% CI</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>812</td>
<td>687</td>
<td>100.0 % -0.29 [-0.48, -0.10]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.06; Chi² = 29.74, df = 14 (P = 0.01); I² = 53%

Test for overall effect: Z = 2.96 (P = 0.0030)

Test for subgroup differences: Chi² = 1.30, df = 1 (P = 0.25), I² = 23%

<table>
<thead>
<tr>
<th>(1) SRP + additional mechanical therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen 2012 (1) 85 7.0825 (1.3312) 41 7.38 (1.57) 10.4 % -0.30 [-0.86, 0.26]</td>
</tr>
<tr>
<td>Li 2011 (2) 41 7.1078 (1.2212) 25 7.48 (2.05) 4.1 % -0.37 [-1.26, 0.51]</td>
</tr>
<tr>
<td>Zhang 2013 49 7.51 (1.31) 22 7.35 (1.52) 6.0 % 0.16 [-0.57, 0.89]</td>
</tr>
</tbody>
</table>

Subtotal (95% CI) 175 88 20.6 % -0.18 [-0.58, 0.22]

Heterogeneity: Tau² = 0.00; Chi² = 1.18, df = 2 (P = 0.56); I² = 0.0%

Test for overall effect: Z = 0.88 (P = 0.38)

<table>
<thead>
<tr>
<th>(2) Periodontal therapy described as “mechanical therapy”</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 SRP + antimicrobials</td>
</tr>
<tr>
<td>Engebretson 2013 257 7.69 (1.267) 257 7.69 (1.267) 67.5 % 67.5 % 0.00 [-0.22, 0.22]</td>
</tr>
<tr>
<td>Katagiri 2009 32 7 (1) 47 6.85 (0.82) 47 6.85 (0.82) 11.9 % 0.15 [-0.37, 0.67]</td>
</tr>
</tbody>
</table>

Subtotal (95% CI) 289 274 79.4 % 0.02 [-0.18, 0.22]
### Analysis 2.1. Comparison 2 Periodontal therapy versus alternative periodontal therapy, Outcome 1 HbA1c at 3-4 months.

Review: Treatment of periodontal disease for glycaemic control in people with diabetes mellitus

Comparison: Periodontal therapy versus alternative periodontal therapy

Outcome: HbA1c at 3-4 months

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Periodontal therapy</th>
<th>Alternative periodontal therapy</th>
<th>Mean Difference</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 SRP vs alternative mechanical therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Koromantzos 2011 (1)</td>
<td>30 7.14 (0.54)</td>
<td>30 7.41 (0.48)</td>
<td>-0.27 [-0.53, -0.01]</td>
<td></td>
</tr>
<tr>
<td>2 SRP vs alternative SRP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen 2012 (2)</td>
<td>42 7.3 (1.5)</td>
<td>43 7.43 (1.53)</td>
<td>-0.13 [-0.77, 0.51]</td>
<td></td>
</tr>
<tr>
<td>Santos 2009 (3)</td>
<td>18 9.8 (2.3)</td>
<td>18 9.6 (2)</td>
<td>0.20 [-1.21, 1.61]</td>
<td></td>
</tr>
<tr>
<td>Santos 2012 (4)</td>
<td>17 10.1 (2.5)</td>
<td>17 9.3 (1.9)</td>
<td>0.80 [-0.69, 2.29]</td>
<td></td>
</tr>
<tr>
<td>3 SRP + antimicrobial vs antimicrobial</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yun 2007</td>
<td>23 7.49 (0.28)</td>
<td>23 7.64 (0.36)</td>
<td>-0.15 [-0.34, 0.04]</td>
<td></td>
</tr>
<tr>
<td>4 SRP + antimicrobial vs SRP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued...)

(1) SRP + additional mechanical therapy

(2) Periodontal therapy described as “mechanical therapy”
<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Periodontal therapy</th>
<th>Mean Difference</th>
<th>Mean</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Al-Zahrani 2009</td>
<td>30</td>
<td>0.03</td>
<td>-0.95, 1.01</td>
<td></td>
</tr>
<tr>
<td>Ergebretson 2011</td>
<td>30</td>
<td>-0.64</td>
<td>-1.67, 0.39</td>
<td></td>
</tr>
<tr>
<td>Gilowski 2012</td>
<td>17</td>
<td>0.10</td>
<td>-0.92, 1.12</td>
<td></td>
</tr>
<tr>
<td>Haerian Ardakani 2014</td>
<td>15</td>
<td>0.03</td>
<td>-0.23, 0.29</td>
<td></td>
</tr>
<tr>
<td>Miranda 2014</td>
<td>29</td>
<td>-0.64</td>
<td>-1.32, 0.64</td>
<td></td>
</tr>
<tr>
<td>NCT00801164</td>
<td>14</td>
<td>0.05</td>
<td>-0.31, 0.41</td>
<td></td>
</tr>
<tr>
<td>O'Connell 2008</td>
<td>15</td>
<td>0.50</td>
<td>-1.04, 2.04</td>
<td></td>
</tr>
<tr>
<td>Rodrigues 2003</td>
<td>15</td>
<td>1.60</td>
<td>0.52, 2.68</td>
<td></td>
</tr>
<tr>
<td>Santos 2013</td>
<td>18</td>
<td>-0.40</td>
<td>-2.22, 1.42</td>
<td></td>
</tr>
<tr>
<td>Singh 2008</td>
<td>15</td>
<td>0.26</td>
<td>-0.52, 1.04</td>
<td></td>
</tr>
<tr>
<td>Skaleric 2004</td>
<td>10</td>
<td>-0.43</td>
<td>-1.59, 0.73</td>
<td></td>
</tr>
<tr>
<td>Tsalkis 2014</td>
<td>31</td>
<td>-0.34</td>
<td>-0.73, 0.05</td>
<td></td>
</tr>
</tbody>
</table>

5 SRP + antimicrobial (doxycycline) vs SRP + alternative antimicrobial

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Periodontal therapy</th>
<th>Mean Difference</th>
<th>Mean</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Al-Zahrani 2009</td>
<td>15</td>
<td>-1.08</td>
<td>-2.78, 0.62</td>
<td></td>
</tr>
<tr>
<td>Ergebretson 2011</td>
<td>15 (5)</td>
<td>0.48</td>
<td>-0.47, 1.43</td>
<td></td>
</tr>
<tr>
<td>Grossi 1997</td>
<td>18</td>
<td>-1.10</td>
<td>-2.46, 0.26</td>
<td></td>
</tr>
</tbody>
</table>

6 SRP + combined antimicrobials vs SRP + single antimicrobial

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Periodontal therapy</th>
<th>Mean Difference</th>
<th>Mean</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grossi 1997</td>
<td>39</td>
<td>-0.14</td>
<td>-1.09, 0.80</td>
<td></td>
</tr>
<tr>
<td>Llamba 2008</td>
<td>30</td>
<td>0.26</td>
<td>-0.52, 1.04</td>
<td></td>
</tr>
<tr>
<td>Macedo 2014</td>
<td>15</td>
<td>-0.20</td>
<td>-0.95, 0.55</td>
<td></td>
</tr>
</tbody>
</table>

7 SRP + statin vs SRP

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Periodontal therapy</th>
<th>Mean Difference</th>
<th>Mean</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pradeep 2013</td>
<td>19</td>
<td>-0.04</td>
<td>-0.12, 0.04</td>
<td></td>
</tr>
</tbody>
</table>

(1) SRP + OHI vs. mechanical therapy (supragingival cleaning) + OHI
(2) SRP + subgingival debridement vs. SRP + supragingival debridement
(3) Immediate SRP + OHI + prophylaxis vs. ongoing SRP + OHI + prophylaxis
(4) Immediate SRP + OHI + prophylaxis (incl. subgingival debridement) vs. ongoing SRP + OHI + prophylaxis (incl. subgingival debridement)
(5) SRP + antimicrobial (doxycycline) vs. SRP + alternative ‘sub’ antimicrobial (doxycycline)
**Analysis 2.2. Comparison 2 Periodontal therapy versus alternative periodontal therapy, Outcome 2 HbA1c at 6 months.**

Review: Treatment of periodontal disease for glycaemic control in people with diabetes mellitus

Comparison: 2 Periodontal therapy versus alternative periodontal therapy

Outcome: 2 HbA1c at 6 months

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Periodontal therapy</th>
<th>Alternative periodontal therapy</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean(SD)</td>
<td>N Mean(SD)</td>
<td>IV,Random,95% CI</td>
<td>IV,Random,95% CI</td>
</tr>
<tr>
<td>1 SRP vs alternative mechanical therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Koromantzos 2011 (1)</td>
<td>30 7.16 (0.69)</td>
<td>30 7.47 (0.72)</td>
<td>-0.31 [-0.67, 0.05]</td>
<td></td>
</tr>
<tr>
<td>2 SRP vs alternative SRP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen 2012 (2)</td>
<td>42 7.09 (1.34)</td>
<td>43 6.87 (1.12)</td>
<td>0.22 [-0.31, 0.75]</td>
<td></td>
</tr>
<tr>
<td>Santos 2009 (3)</td>
<td>18 9.5 (1.9)</td>
<td>18 10.3 (2.6)</td>
<td>-0.80 [-2.29, 0.69]</td>
<td></td>
</tr>
<tr>
<td>Santos 2012 (4)</td>
<td>17 9.7 (2)</td>
<td>17 10.2 (2.9)</td>
<td>-0.50 [-2.17, 1.17]</td>
<td></td>
</tr>
<tr>
<td>3 SRP + antimicrobial vs SRP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miranda 2014</td>
<td>29 8.49 (2.17)</td>
<td>27 9.07 (1.69)</td>
<td>-0.58 [-1.59, 0.43]</td>
<td></td>
</tr>
<tr>
<td>NCT00801164</td>
<td>14 9.14 (0.47)</td>
<td>13 8.8 (0.49)</td>
<td>0.34 [-0.02, 0.70]</td>
<td></td>
</tr>
<tr>
<td>Santos 2013</td>
<td>19 9.9 (2.4)</td>
<td>18 9.6 (3.2)</td>
<td>0.30 [-1.53, 2.13]</td>
<td></td>
</tr>
<tr>
<td>Skaleric 2004</td>
<td>10 8.5 (0.6)</td>
<td>10 8.53 (0.75)</td>
<td>0.03 [-0.63, 0.57]</td>
<td></td>
</tr>
<tr>
<td>Tsalikis 2014</td>
<td>31 6.48 (0.71)</td>
<td>35 6.8 (0.87)</td>
<td>-0.32 [-0.70, 0.06]</td>
<td></td>
</tr>
<tr>
<td>4 SRP + antimicrobial (doxycycline) vs SRP + alternative antimicrobial</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grossi 1997</td>
<td>17 10.3 (2.2)</td>
<td>26 10.3 (2.1)</td>
<td>0.0 [-1.32, 1.32]</td>
<td></td>
</tr>
<tr>
<td>5 SRP + combined antimicrobials vs SRP + single antimicrobial</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grossi 1997</td>
<td>41 10.2073 (2.1693)</td>
<td>43 10.3 (2.14)</td>
<td>-0.09 [-1.01, 0.82]</td>
<td></td>
</tr>
<tr>
<td>6 SRP + bone modifier vs SRP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rocha 2001</td>
<td>20 9.4 (1.5)</td>
<td>20 10.8 (2.4)</td>
<td>-1.40 [-2.64, -0.16]</td>
<td></td>
</tr>
<tr>
<td>7 SRP + statin vs SRP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pradeep 2013</td>
<td>19 6.65 (0.12)</td>
<td>19 6.68 (0.13)</td>
<td>-0.03 [-0.11, 0.05]</td>
<td></td>
</tr>
</tbody>
</table>

(1) SRP + OH1 vs. mechanical therapy (supragingival cleaning) + OH1
(2) SRP + subgingival debridement vs. SRP + supragingival debridement
(3) Immediate SRP + OH1 + prophylaxis vs. ongoing SRP + OH1 + prophylaxis
(4) Immediate SRP + OH1 + prophylaxis (incl. subgingival debridement) vs. ongoing SRP + OH1 + prophylaxis (incl. subgingival debridement)
### ADDITIONAL TABLES

**Table 1. Diagnostic criteria (diabetes mellitus and periodontal disease)**

<table>
<thead>
<tr>
<th>Study</th>
<th>Diabetes assessment of patients for inclusion</th>
<th>Periodontitis assessment of patients for inclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Al-Zahrani 2009</td>
<td>Diagnosed with Type 2 DM</td>
<td>CAL ≥3 mm at ≥30% of sites</td>
</tr>
<tr>
<td>Calbacho 2005</td>
<td>Diagnosed with Type 2 DM</td>
<td>Quote: &quot;moderate chronic marginal periodontitis diagnosis&quot;</td>
</tr>
<tr>
<td>Chen 2012</td>
<td>Diagnosed with Type 2 DM for &gt;1 year</td>
<td>American Academy of Periodontology criteria, with a ≥1 mm mean CAL</td>
</tr>
<tr>
<td>Engebretson 2011</td>
<td>Diagnosed with Type 2 DM at least 6 months previously</td>
<td>CAL &gt;5 mm in at least 1 site in each jaw quadrant</td>
</tr>
<tr>
<td>Engebretson 2013</td>
<td>Diagnosed with Type 2 DM more than 3 months duration, an HbA1c value between 7.0% and less than 9.0% at screening</td>
<td>CAL and PPD of at least 5 mm in 2 or more quadrants of the mouth</td>
</tr>
<tr>
<td>Gay 2014</td>
<td>Diagnosed with Type 2 DM, HbA1c levels ≥6.5%; initial HbA1c values between 5.7%–6.5% were included if they were taking hypoglycaemic medications (n = 16)</td>
<td>Severe chronic periodontitis according to American Academy of Periodontology criteria</td>
</tr>
<tr>
<td>Gilowski 2012</td>
<td>Diagnosed with Type 2 DM</td>
<td>At least 4 non-adjacent sites with PD ≥4 mm</td>
</tr>
<tr>
<td>Grossi 1997</td>
<td>WHO criteria for designation as having DM</td>
<td>No periodontal inclusion criteria stated; mean PPD around 3.5 to 3.7 mm for all groups; CAL in the range 4.5 to 5 mm at baseline</td>
</tr>
<tr>
<td>Haerian Ardakani 2014</td>
<td>Diagnosed with Type 2 DM, HbA1c ≤7%</td>
<td>Chronic periodontitis with 3 regions probe depth &gt;4 mm and &lt;7 mm</td>
</tr>
<tr>
<td>Jones 2007</td>
<td>Statement that inclusion depended on a repeat HbA1c of &gt; or equal to 8.5%</td>
<td>Community Periodontal Index of Treatment Need (CPITN; Ainamo 1982) scores of ≥3 in at least 2 sextants</td>
</tr>
<tr>
<td>Katagiri 2009</td>
<td>Type 2 DM and HbA1c 6.5%-10.0%</td>
<td>At least 2 pocket sites with PPD ≥4 mm</td>
</tr>
<tr>
<td>Kiran 2005</td>
<td>Diabetes - participants under treatment for Type 2 DM with HbA1c in the range 6%-8%</td>
<td>Not reported</td>
</tr>
<tr>
<td>Koromantzos 2011</td>
<td>Type 2 DM and HbA1c levels from 7% to 10%</td>
<td>At least 8 sites with PPD ≥6 mm and 4 sites with CAL ≥5 mm, distributed in at least 2 different quadrants</td>
</tr>
<tr>
<td>Study</td>
<td>Diabetes Type and Duration</td>
<td>Diagnostic Criteria</td>
</tr>
<tr>
<td>-------------------</td>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Kothiwale 2013</td>
<td>Type 2 DM with a minimum duration of 2 years</td>
<td>CPI (community periodontal index: PPD $\geq$ 4 mm) and LA (loss of attachment: CAL $\geq$ 4 mm) indices (as stated in Peter 2007)</td>
</tr>
<tr>
<td>Li 2011</td>
<td>Type 2 DM</td>
<td>Not reported</td>
</tr>
<tr>
<td>Llambes 2008</td>
<td>Type 1 DM with severities defined by the American Diabetes Association criteria</td>
<td>At least 5 teeth with a site of PPD $\geq$ 5 mm and CAL $\geq$ 3 mm</td>
</tr>
<tr>
<td>Macedo 2014</td>
<td>Type 2 DM diagnosed for $\geq$ 5 years and HbA1c $&gt;7%$</td>
<td>At least 1 site with PPD $\geq$ 5 mm on each quadrant, and 2 teeth with CAL $\geq$ 6 mm</td>
</tr>
<tr>
<td>Madden 2008</td>
<td>Type 2 DM for $&gt;1$ year; HbA1c $&gt;7%$ but $&lt;13.11%$</td>
<td>Löe and Silness GI</td>
</tr>
<tr>
<td>Miranda 2014</td>
<td>Type 2 DM for $\geq$ 5 years; HbA1c levels $\geq$ 6.5% $\leq$ 11%</td>
<td>More than 30% of the sites with PPD and CAL $\geq$ 4 mm and a minimum of 6 teeth with at least 1 site with PPD and CAL $\geq$ 5 mm and BOP at baseline</td>
</tr>
<tr>
<td>Moeintaghavi 2012</td>
<td>Diagnosis of type 2 DM with glycated haemoglobin (HbA1c) values over 7%</td>
<td>American Academy of Periodontology criteria</td>
</tr>
<tr>
<td>NCT00801164</td>
<td>Self reported type 2 DM of more than 3 months duration; a current HbA1c value between 7.0% and 12%</td>
<td>Moderate to severe chronic periodontitis, defined by loss of clinical attachment of $&gt;5$ mm on 2 separate teeth</td>
</tr>
<tr>
<td>O’Connell 2008</td>
<td>Type 2 DM diagnosed for $\geq$ 5 years and HbA1c $&gt;8%$</td>
<td>At least 1 site with PD $\geq$ 5 mm and 2 teeth with CAL $\geq$ 6 mm</td>
</tr>
<tr>
<td>Pradeep 2013</td>
<td>Classed as type 2 DM based on the American Diabetic Association 2011 criteria</td>
<td>PD $\geq$ 5 mm or CAL $\geq$ 4 mm and vertical bone loss $\geq$ 3 mm</td>
</tr>
<tr>
<td>Raman 2014</td>
<td>Type 2 DM diagnosed at least 1 year prior to the study</td>
<td>PD 5 or more pockets of $\geq$ 5 mm and probing AL of $\geq$ 4 mm or more in at least 2 different quadrants which bled on probing</td>
</tr>
<tr>
<td>Rocha 2001</td>
<td>Type 2 DM for at least 5 years</td>
<td>PPD $\geq$ 3 mm in at least 1 tooth</td>
</tr>
<tr>
<td>Rodrigues 2003</td>
<td>Diagnosed with Type 2 DM</td>
<td>1 site and 2 teeth with $\geq$ 5 mm PPD and $\geq$ 6 mm CAL</td>
</tr>
<tr>
<td>Santos 2009</td>
<td>Type 2 DM within the past 5 years</td>
<td>$&gt;$30% of sites with PD and CAL $\geq$ 5 mm at baseline (based on the 1999 World Workshop for classification of Periodontal Diseases and Conditions)</td>
</tr>
<tr>
<td>Santos 2012</td>
<td>Type 2 DM for at least the past 5 years</td>
<td>$&gt;$30% of sites with PD and CAL $\geq$ 4 mm at baseline</td>
</tr>
<tr>
<td>Santos 2013</td>
<td>Type 2 DM for at least the past 5 years</td>
<td>$&gt;$30% of sites with PD and CAL $\geq$ 4 mm at baseline</td>
</tr>
</tbody>
</table>
Table 1. Diagnostic criteria (diabetes mellitus and periodontal disease)  

<table>
<thead>
<tr>
<th>Study Authors</th>
<th>Type of DM</th>
<th>Diagnostic Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Singh 2008</td>
<td>Type 2 DM</td>
<td>≥30% teeth PD and CAL ≥4 mm at baseline</td>
</tr>
<tr>
<td>Skaleric 2004</td>
<td>Type 1 DM &lt;5 years</td>
<td>4 teeth in at least 2 quadrants with ≥5 mm PD</td>
</tr>
<tr>
<td>Sun 2011</td>
<td>Type 2 DM for over a year; HbA1c: 7.5%-9.5%</td>
<td>≥20 teeth, probing depth &gt;5 mm, more than 30% teeth with attachment loss &gt;4 mm, or over 60% teeth with PD &gt;4 mm and AL &gt;3 mm</td>
</tr>
<tr>
<td>Tsalikis 2014</td>
<td>Type 2 DM, diagnosed at least 1 year before baseline examination; at least 2 consecutive values of HbA1c &lt;7.5% as assessed by the patients' medical records</td>
<td>6 pockets &gt;5 mm and CAL &gt;3 mm with radiographic bone loss</td>
</tr>
<tr>
<td>Yun 2007</td>
<td>Newly diagnosed Type 2 DM</td>
<td>Periodontal - PPD &gt; or equal to 5 mm but &lt;8 mm in 1 site in 4 teeth or 2 different quadrants. No indication of CAL or alveolar bone loss</td>
</tr>
<tr>
<td>Zhang 2013</td>
<td>Type 2 DM for &gt;1 year; HbA1c level within 3 months before recruitment should at least be 5.5%</td>
<td>At least 4 teeth with PPD ≥5 mm, CAL ≥4 mm, and BOP, distributed in 2 or more oral quadrants</td>
</tr>
</tbody>
</table>

Study authors’ inclusion criteria for diabetes and periodontal disease  
AL = attachment loss; BOP = bleeding on probing; CAL = clinical attachment level; DM = diabetes mellitus; GI = gingival index; PD = pocket depth; PPD = probing pocket depth; WHO = World Health Organization

Table 2. Diabetic control at baseline (HbA1c threshold for participants)

- 4 studies (11%) had the broadest defined inclusion thresholds ranging at least a 4% difference in HbA1c levels (Madden 2008 (fair-poor: 7.0%-13.11%); NCT00801164 (fair-poor: 7.0%-12.0%); Miranda 2014 (good-poor: 6.5%-11.0%); Katagiri 2009 (good-poor: 6.5%-10.0%))
- 4 studies (11%) ranged a defined 2%-3% difference in HbA1c levels (Kiran 2005 (good-fair: 6.0%-8.0%); Engebretson 2013 (fair-poor: 7.0%-9.0%); Sun 2011 (fair-poor: 7.5%-9.5%); Koromantzos 2011 (fair-poor: 7.0%-10.0%))
- 3 studies (8%) only included participants within the threshold (good: <7.5%) for controlled diabetes (Gay 2014 (patients in receipt of diabetic treatment (79%) - good: 5.7%-6.5%; patients not receiving diabetic treatment (21%) - good-poor: >6.5%); Haerian Ardakani 2014 (<7.0%); Tsalikis 2014 (<7.5%))
- 1 study (3%) included patients with HbA1c levels >5.5% (good: Zhang 2013) without a defined upper threshold limit for inclusion
- 2 studies (8%) included patients with HbA1c levels >7.0% (fair-poor: Macedo 2014; Moeintaghavi 2012) without a defined upper threshold limit for inclusion
- 2 studies (6%) only included patients with uncontrolled HbA1c levels (Jones 2007 (poor: >8.5%); Skaleric 2004 (poor: >9.0%)) without a defined upper threshold limit for inclusion
Table 2. Diabetic control at baseline (HbA1c threshold for participants)  (Continued)

- 19 trials (53%) did not report their patient inclusion criteria for HbA1c levels (Al-Zahrani 2009; Calbacho 2004; Chen 2012; Engebretson 2011; Gilowski 2012; Grossi 1997; Kothiwale 2013; Li 2011; Llambés 2008; O’Connell 2008; Pradeep 2013; Raman 2014; Rocha 2001; Rodrigues 2003; Santos 2009; Santos 2012; Santos 2013; Singh 2008; Yun 2007)

Table 3. Types of antidiabetic therapy in included trials

- In five studies (17%), all patients were reported to be in receipt of oral hypoglycaemic medication, insulin, controlled diet or combination treatment (Gilowski 2012; Kiran 2005; Santos 2009; Santos 2012; Santos 2013)

- All patients were in receipt of oral hypoglycaemic medication, insulin, or combination treatment (no diet component) in 3 studies (9%) (Jones 2007; Koromantzos 2011; Li 2011)

- In Engebretson 2013 (3%), all except 11 patients (2% of 514 participants) were in receipt of oral hypoglycaemic medications, insulin, or combination treatment (no diet component)

- In 2 studies (6%), all patients were in receipt of oral hypoglycaemic medication, insulin, or controlled diet (no combination treatment) (Chen 2012; Katagiri 2009)

- 2 trials' patients used oral hypoglycaemic medication or insulin (no controlled diet or combination therapy) (Al-Zahrani 2009; Engebretson 2011)

- In 1 study (3%), all patients were in receipt of oral hypoglycaemic medication, insulin, or combination treatment (no diet component) (Zhang 2013)

- In 1 study, all patients used oral hypoglycaemic medication, but some also used insulin (no further details provided, except that insulin use was stratified to each group) (Grossi 1997)

- 4 studies’ (11%) patients only used oral hypoglycaemic medication to control their diabetes (Calbacho 2004; Kothiwale 2013; Miranda 2014; Moeintaghavi 2012)

- In 1 study (Llambés 2008), all patients solely used insulin to control their diabetes

- Singh 2008 only included patients in receipt of antidiabetic therapy but gave no indication what form

- Gay 2014 (3%) only reports that all except 26 patients (21% of 126 participants) were in receipt of “diabetic treatment” without further description

- 13 studies (39%) did not report use of antidiabetic therapy use (Haerian Ardakani 2014; Macedo 2014; Madden 2008; NCT00801164; O’Connell 2008; Pradeep 2013; Raman 2014; Rocha 2001; Rodrigues 2003 (excluded insulin users, but no other detail); Skaleric 2004 (excluded non-insulin users, but no other detail); Sun 2011; Tsalikis 2014; Yun 2007 (only that groups were well matched for oral hypoglycaemic medication and diet control - no further detail))
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Pre-intervention</th>
<th>Change in diabetic therapy during study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Al-Zahrani 2009</td>
<td>All (seemingly) in receipt of oral hypoglycaemic medication (Overall: 72%) or insulin (Overall: 28%; Gp A: 20%; Gp B: 29%; Gp C: 36% (P = 0.64))</td>
<td>Quote: “None of the participants reported a change in the types or doses of their medications during the study period”</td>
</tr>
<tr>
<td>Calbacho 2005</td>
<td>All in receipt of oral hypoglycaemic medication only</td>
<td>Authors report in correspondence that no variation of antidiabetic therapy occurred during the study</td>
</tr>
<tr>
<td>Chen 2012</td>
<td>All in receipt of oral hypoglycaemic medication (Gp A: 38; Gp B: 35; Gp C: 36), insulin (Gp A: 4; Gp B: 5; Gp C: 4), or diet (Gp A: 0; Gp B: 3; Gp C: 1) (P = 0.574)</td>
<td>Not reported</td>
</tr>
<tr>
<td>Engebretson 2011</td>
<td>Inclusion criteria required all patients to be in receipt of stable dosage of oral hypoglycaemic medications or insulin</td>
<td>Study confirms use of medications remained constant during study period</td>
</tr>
<tr>
<td>Engebretson 2013</td>
<td>All except 11 patients (2% of 514 participants) were in receipt of oral hypoglycaemic medication (Overall: 47%; Gp A: 46%; Gp B: 49%), insulin (Overall: 16%; Gp A: 16%; Gp B: 16%), or combination treatment (Overall: 35%; Gp A: 37%; Gp B: 33%)</td>
<td>Quote: “Of the 462 participants with medication data available at all study visits, 128 of 233 (55%) in the treatment group and 137 of 229 (60%) in the control group had no protocol-defined changes in diabetes medications during the study”</td>
</tr>
<tr>
<td>Gay 2014</td>
<td>All except 26 patients (21% of 126 participants) were in receipt of “diabetic treatment” (Gp A: 79%; Gp B: 80%) without further description Of diabetic treatment recipients, 21 patients were on insulin therapy: Gp A: 21% (n = 14); Gp B: 12% (n = 7)</td>
<td>Quote: “About 18 test and 13 control subjects had changes in their medications during the 4-month trial” No indication whether these numbers reflect baseline patients (Gp A: 66; Gp B: 60) or analysed patients (Gp A: 48; Gp B: 42)</td>
</tr>
<tr>
<td>Gilowski 2012</td>
<td>Quote: “All patients received optimal diabetic treatment including diet regimen, insulin supplementation, and/or oral hypoglycaemic drugs”</td>
<td>Not reported</td>
</tr>
<tr>
<td>Grossi 1997</td>
<td>All in receipt of oral hypoglycaemic medication Also states groups were stratified by insulin use, but no further detail provided</td>
<td>Dose and type of medication monitored. Most changes were to other oral agents (not described in detail). 2 people each in 2 arms (Gp C, and Gp E) were changed to insulin therapy. Similar results found when people whose treatment had been changed were excluded (but actual data not given)</td>
</tr>
<tr>
<td>Study</td>
<td>Changes in therapy</td>
<td>Notes</td>
</tr>
<tr>
<td>------------------------------</td>
<td>----------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Haerian Ardakani 2014</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
<tr>
<td>Jones 2007</td>
<td>Pattern of treatment similar in both groups (x² = 50.89, P = 0.64) for proportions receiving insulin, insulin and oral hypoglycaemic, oral hypoglycaemic alone</td>
<td>Participants in the usual care group were twice as likely (20% versus 11%, P &lt; 0.12) to increase insulin from baseline to 4 months and less likely to decrease insulin (1% versus 6%, P &lt; 0.21)</td>
</tr>
<tr>
<td>Katagiri 2009</td>
<td>All in receipt of oral hypoglycaemic medication, insulin, or diet Diet: Overall: n = 3; Gp A: n = 1; Gp B: n = 2 Oral hypoglycaemic medication: Overall: n = 27; Gp A: n = 15; Gp B: n = 12 Insulin: Overall: n = 19; Gp A: n = 16; Gp B: n = 3</td>
<td>Quote: “The doses and kinds of anti-diabetic drugs, including oral hypoglycaemic drugs and insulin injections and methods of diet and exercise were not changed to assess the real effects of periodontal treatment on blood glucose control”</td>
</tr>
<tr>
<td>Kiran 2005</td>
<td>All in receipt of oral hypoglycaemic medication (Gp A: 64%; Gp B: 72%), insulin (Gp A: 9%; Gp B: 9%), diet (Gp A: 9%; Gp B: 5%) or combination (Gp A: 18%; Gp B: 14%)</td>
<td>Quote: “No change in the medication or diet was made for both groups during the study period”</td>
</tr>
<tr>
<td>Koromantzos 2011</td>
<td>All in receipt of oral hypoglycaemic medication, insulin or both Insulin: Gp A n = 12 (40%); Gp B n = 7 (23.3%) OHA: Gp A n = 21 (70%); Gp B n = 27 (90%)</td>
<td>Quote: “Over the course of the study, no oral medication changes were performed, while a similar number of [Gp A] and [Gp B] participants increased their insulin dosages [four (13.3%) for [Gp A] and three (10.0%) for [Gp B] participants. Our of the seven patients that increased their insulin dosages, five (three in [Gp A] and two in [Gp B]) were patients that were lost to follow-up”</td>
</tr>
<tr>
<td>Kothiwale 2013</td>
<td>Quote (re: procedure): “The medical therapy for diabetes, diet and physical therapy was unchanged throughout the course of the study as monitored by the physician”</td>
<td>No changes reported, but also not anticipated due to protocol instruction not to change antidiabetic therapy during the course of the study</td>
</tr>
<tr>
<td>Li 2011</td>
<td>Gp A (oral hypoglycaemic agents: 77.3%/insulin injection: 27.3%); Gp B (78.9%/21.1%); Gp C (76%/16%)</td>
<td>Not identified by translation</td>
</tr>
<tr>
<td>Llambés 2008</td>
<td>All in receipt of insulin Quote: “They were told not to change their diet, exercise, or insulin dose unless absolutely necessary and to inform investigators if any change occurred”</td>
<td>Quote: “Insulin doses were quite stable in both groups. 18 patients from group 1 and 20 patients from group 2 did not change their insulin dose during the clinical investigation. 12 patients changed insulin doses in group 1, but half of them had a variation of less than 3 units a day. In group 2, 10 patients modified insulin doses during the study, and 8 of them had changes of less than 3 units a day”</td>
</tr>
<tr>
<td>Macedo 2014</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
</tbody>
</table>
Table 4. Changes in antidiabetic therapy during study period  (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Changes in Therapy</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Madden 2008</td>
<td>Not reported</td>
<td>Quote: “Of the 42 remaining subjects who completed the study, 15 had their diabetes medications changed at the advice of their physicians (Gp n=9; Gp B n=6). There were 27 subjects who did not have diabetic medication changes”</td>
</tr>
<tr>
<td>Miranda 2014</td>
<td>Not reported</td>
<td>Quote: “all subjects included in this study reported to be under metformin or glibenclamide treatment. In addition, two subjects per group also reported to be under insulin supplementation”</td>
</tr>
<tr>
<td>Moeintaghavi 2012</td>
<td>All in receipt of oral hypoglycaemic medications (no insulin) Inclusion criteria specifies patients “blood sugar controlled with glibenclamide and metformin, without insulin administration”</td>
<td>Quote: “our study as a prerequisite included only patients who did not have any change in their diabetic control regimen during the 3-month study period” No further detail, assumed no changes</td>
</tr>
<tr>
<td>NCT00801164</td>
<td>Not reported</td>
<td>Unknown due to study not yet having been published</td>
</tr>
<tr>
<td>O’Connell 2008</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
<tr>
<td>Pradeep 2013</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
<tr>
<td>Raman 2014</td>
<td>Not reported</td>
<td>Quote: “2 of the 5 subjects from [Gp A] who did not complete the study had their diabetic medication changed during the course of the study and had to be excluded...For [Gp B], 1 subject had his medications for Type 2 diabetes changed”</td>
</tr>
<tr>
<td>Rocha 2001</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
<tr>
<td>Rodrigues 2003</td>
<td>Insulin users excluded from participation, no other detail reported</td>
<td>Quote: “alterations in ... diabetes control were recorded” - however, data not reported</td>
</tr>
<tr>
<td>Santos 2009</td>
<td>All in receipt of oral hypoglycaemic medication, insulin, diet or combination Diet: Overall: n = 6; Gp A: n = 2; Gp B: n = 4 Diet + insulin: Overall: n = 5; Gp A: n = 3; Gp B: n = 2 Diet + OHA: Overall: n = 21; Gp A: n = 11; Gp B: n = 10 Diet + OHA + insulin: Overall: n = 4; Gp A: n = 2; Gp B: n = 2</td>
<td>Quote: “To assess the effects of the periodontal treatments on metabolic control, no changes in the medication or diet were made during the study period (6 months)”</td>
</tr>
<tr>
<td>Santos 2012</td>
<td>All in receipt of oral hypoglycaemic medication, insulin, diet or combination Diet: Overall: n = 6; Gp A: n = 3; Gp B: n = 3</td>
<td>Quote: “no changes in the category of treatment regimen for DM occurred during the study”</td>
</tr>
</tbody>
</table>
Table 4. Changes in antidiabetic therapy during study period  

<table>
<thead>
<tr>
<th>Study</th>
<th>Changes in antidiabetic therapy</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Santos 2013</td>
<td>Diet + insulin: Overall: n = 3; Gp A: n = 1; Gp B: n = 2</td>
<td>Quote: &quot;subjects reported no changes in the category of DM treatment regimen during the study&quot;</td>
</tr>
<tr>
<td></td>
<td>Diet + OHA: Overall: n = 23; Gp A: n = 12; Gp B: n = 11</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diet + OHA + insulin: Overall: n = 2; Gp A: n = 1; Gp B: n = 1</td>
<td></td>
</tr>
<tr>
<td>Singh 2008</td>
<td>All in receipt of oral hypoglycaemic medication, insulin, diet or combination</td>
<td>Quote: &quot;No change in the medication or diet was made for the patients. None of the patients received any additional guidance for managing their diabetic status&quot;</td>
</tr>
<tr>
<td></td>
<td>Diet: Overall: n = 1; Gp A: n = 1; Gp B: n = 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diet + insulin: Overall: n = 5; Gp A: n = 1; Gp B: n = 4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diet + OHA: Overall: n = 28; Gp A: n = 14; Gp B: n = 14</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diet + OHA + insulin: Overall: n = 4; Gp A: n = 3; Gp B: n = 1</td>
<td></td>
</tr>
<tr>
<td>Skaleric 2004</td>
<td>Not specifically reported. &quot;Patients with type 2 non-insulin dependent diabetes were excluded from the study&quot;</td>
<td>Quote: &quot;Insulin dosage was adjusted according to the routine procedure for blood glucose self management.... made at the discretion of the diabetologist&quot; - however, data not reported</td>
</tr>
<tr>
<td>Sun 2011</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
<tr>
<td>Tsalikis 2014</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
<tr>
<td>Yun 2007</td>
<td>Not specifically reported. Quote: &quot;These groups were well matched for ..., oral hypoglycemic medication, the proportion of patients prescribed diet control&quot;</td>
<td>Not reported</td>
</tr>
<tr>
<td>Zhang 2013</td>
<td>All in receipt of oral hypoglycaemic medication, insulin or combination</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Overall: oral medication n = 55 (77%); insulin n = 41 (58%); Gp A: oral medication n = 40 (82%); insulin n = 30 (61%); Gp B: oral medication n = 15 (68%); insulin n = 11 (50%)</td>
<td>Not reported</td>
</tr>
</tbody>
</table>
Table 5. Periodontal therapies compared in included studies

<table>
<thead>
<tr>
<th>Comparison 1: Periodontal therapy vs no active intervention/usual care (n = 9)</th>
<th>Subgroup 1.1: SRP (n = 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>● SRP + OHI + additional mechanical therapy vs no active intervention (Chen 2012 (3 of 3 arms: Gps A+B combined vs Gp C))</td>
</tr>
<tr>
<td></td>
<td>● SRP vs OHI (Gay 2014)</td>
</tr>
<tr>
<td></td>
<td>● SRP + OHI vs no active intervention (Kiran 2005; Kothiwale 2013; Singh 2008 (2 of 3 arms: Gp A vs Gp C); Zhang 2013)</td>
</tr>
<tr>
<td></td>
<td>● Periodontal therapy described as “mechanical therapy” vs OHI (Li 2011 (3 of 3 arms: Gps A+B combined vs Gp C))</td>
</tr>
<tr>
<td></td>
<td>● SRP vs no active intervention (Moeintaghavi 2012)</td>
</tr>
<tr>
<td>Subgroup 1.2: SRP + antimicrobials (n = 4)</td>
<td>● SRP + antimicrobial (doxycycline) vs OHI (Calbacho 2004)</td>
</tr>
<tr>
<td></td>
<td>● SRP + OHI + antimicrobial vs OHI (Engebretson 2013; Katagiri 2009; Raman 2014)</td>
</tr>
<tr>
<td></td>
<td>● SRP + OHI + antimicrobial (doxycycline) + antimicrobial (chlorhexidine) vs usual treatment (Jones 2007)</td>
</tr>
<tr>
<td></td>
<td>● SRP + OHI + antimicrobial vs no active intervention (Singh 2008 (2 of 3 arms: Gp B vs Gp C); Sun 2011)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comparison 2: Periodontal therapy vs alternative periodontal therapy (n = 26)</th>
<th>Subgroup 2.1: SRP vs alternative mechanical therapy (n = 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>● SRP + OHI vs mechanical therapy (supragingival cleaning) + OHI (Koromantzos 2011)</td>
</tr>
<tr>
<td>Subgroup 2.2: SRP vs alternative SRP (n = 3)</td>
<td>● SRP + OHI + additional mechanical therapy (subgingival cleaning) vs SRP + OHI + additional mechanical therapy (supragingival cleaning) (Chen 2012 (2 of 3 arms: Gp A vs Gp B))</td>
</tr>
<tr>
<td></td>
<td>● Immediate SRP + OHI + additional mechanical therapy (prophylaxis) vs ongoing SRP + OHI + additional mechanical therapy (prophylaxis) (Santos 2009)</td>
</tr>
<tr>
<td></td>
<td>● Immediate SRP + OHI + additional mechanical therapy (prophylaxis incl. subgingival debridement) vs ongoing SRP + OHI + additional mechanical therapy (prophylaxis incl. subgingival debridement) (Santos 2012)</td>
</tr>
<tr>
<td>Subgroup 2.3: SRP + antimicrobial vs antimicrobial (n = 1)</td>
<td>● SRP + OHI + antimicrobial (doxycycline) vs antimicrobial (doxycycline) (Yun 2007)</td>
</tr>
<tr>
<td>Subgroup 2.4: SRP + antimicrobial vs SRP (n = 12)</td>
<td>● SRP + OHI + antimicrobials vs SRP + OHI (Al-Zahrani 2009 (3 of 3 arms: Gps B (doxycycline) + C (antimicrobial photodynamic therapy (aPDT)) combined vs Gp A))</td>
</tr>
<tr>
<td></td>
<td>● SRP + OHI + antimicrobial (subantimicrobial doxycycline) vs SRP + OHI (Gilowski 2012)</td>
</tr>
</tbody>
</table>

Treatment of periodontal disease for glycaemic control in people with diabetes mellitus (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 5. Periodontal therapies compared in included studies  
(Continued)

- SRP + OHI + antimicrobial (chlorhexidine) vs SRP + OHI (Madden 2008)
- SRP + OHI + antimicrobial (metronidazole) vs SRP + OHI (Miranda 2014)
- SRP + OHI + antimicrobial (doxycycline) vs SRP + OHI (Singh 2008 (2 of 3 arms: Gp B vs Gp A); Tsaliks 2014)
- SRP + antimicrobials (doxycycline) vs SRP (Engebretson 2011 (3 of 3 arms: Gps A (sub antimicrobial doxycycline) + B (doxycycline combined vs Gp C))
- SRP + antimicrobial (tetracycline) vs SRP (Haerian Ardakani 2014)
- SRP + antimicrobial (iodine) vs SRP (NCT00801164)
- SRP + OHI + additional mechanical therapy (scale and polish) + antimicrobial (doxycycline) vs SRP + OHI + additional mechanical therapy (scale and polish) (O’Connell 2008)
- SRP + OHI + additional mechanical therapy (prophylaxis) + antimicrobial (amoxicillin) vs SRP + OHI + additional mechanical therapy (prophylaxis) (Rodrigues 2003)
- SRP + OHI + antimicrobial (chlorhexidine) + additional mechanical therapy (prophylaxis incl. subgingival debridement) vs SRP + OHI + additional mechanical therapy (prophylaxis incl. subgingival debridement) (Santos 2013)
- SRP + additional mechanical therapy (supragingival prophylaxis) + antimicrobial (minocycline) vs SRP + additional mechanical therapy (supragingival prophylaxis) (Skaleric 2004)

Subgroup 2.5: SRP + antimicrobial (doxycycline) vs SRP + alternative antimicrobial (n = 3)
- SRP + OHI + antimicrobial (doxycycline) vs SRP + OHI + alternative antimicrobial (aPDT) (Al-Zahrani 2009 (2 of 3 arms: Gp B vs Gp C))
- SRP + antimicrobial (doxycycline) vs SRP + alternative ‘sub-’ antimicrobial (doxycycline) (Engebretson 2011 (2 of 3 arms: Gp A vs Gp B))
- SRP + antimicrobial (doxycycline) vs SRP + alternative antimicrobial (chlorhexidine) (Grossi 1997 (2 of 5 arms: Gp A vs Gp D))

Subgroup 2.6: SRP + combined antimicrobials vs SRP + single antimicrobial (n = 4)
- SRP + antimicrobial (chlorhexidine) + additional antimicrobial (doxycycline) vs SRP + antimicrobial (chlorhexidine) (Grossi 1997 (2 of 5 arms: Gp B vs Gp D))
- SRP + antimicrobial (doxycycline) + additional antimicrobial (iodine) vs SRP + antimicrobial (doxycycline) (Grossi 1997 (2 of 5 arms: Gp C vs Gp A))
- SRP + OHI + antimicrobial (1: chlorhexidine rinse) + antimicrobial (2: systemic doxycycline) vs SRP + OHI + antimicrobial (1: chlorhexidine rinse) (Llambés 2008)
Table 5. Periodontal therapies compared in included studies (Continued)

- SRP + OHI + antimicrobial (1: doxycycline) + antimicrobial (2: aPDT) vs SRP + OHI + antimicrobial (1: doxycycline) (Macedo 2014)

N.B. In analysis, Grossi 1997 estimate is presented combined effect from Gps B + C vs Gps A + D to use maximum data

Subgroup 2.7: SRP + bone modifier vs SRP (n = 1)
- SRP + OHI + bone modifier (aminobisphosphonate) vs SRP + OHI (Rocha 2001)

Subgroup 2.8: SRP + statin vs SRP (n = 1)
- SRP + OHI + statin (simvastatin) vs SRP + OHI (Pradeep 2013)

aPDT = antimicrobial photodynamic therapy; OHI = oral hygiene instruction; SRP = scaling and root planing; vs = versus

Table 6. Secondary outcomes: Comparison 1. Periodontal therapy versus no active intervention/usual care

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Time point</th>
<th>Number of studies</th>
<th>Control group weighted mean</th>
<th>Mean difference (IV, 95% CI; P value)</th>
<th>Heterogeneity (P value; I²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BOP</td>
<td>3-4 months</td>
<td>4</td>
<td>0.059</td>
<td>-0.16, 95% CI -0.21 to -0.10 (Random); P &lt; 0.00001</td>
<td>(P = 0.06); I² = 59%</td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>3</td>
<td>0.004</td>
<td>-0.14, 95% CI -0.17 to -0.10 (Random); P &lt; 0.00001</td>
<td>(P = 0.26); I² = 25%</td>
</tr>
<tr>
<td>CAL</td>
<td>3-4 months</td>
<td>8</td>
<td>1.534</td>
<td>-0.25, 95% CI -0.45 to -0.05 (Random); P = 0.01</td>
<td>(P = 0.0005); I² = 73%</td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>5</td>
<td>1.308</td>
<td>-0.41, 95% CI -0.71 to -0.11 (Random); P = 0.008</td>
<td>(P &lt; 0.0001); I² = 85%</td>
</tr>
<tr>
<td>GI</td>
<td>3-4 months</td>
<td>4</td>
<td>0.182</td>
<td>-0.54, 95% CI -0.80 to -0.27 (Random); P &lt; 0.0001</td>
<td>(P &lt; 0.0003); I² = 84%</td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>1</td>
<td>1.3</td>
<td>-0.30, 95% CI -0.41 to -0.19 (Fixed); P &lt; 0.00001</td>
<td>n/a</td>
</tr>
<tr>
<td>PI</td>
<td>3-4 months</td>
<td>7</td>
<td>1.566</td>
<td>-0.57, 95% CI -0.79 to -0.35 (Random); P &lt; 0.00001</td>
<td>(P &lt; 0.00001); I² = 88%</td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>2</td>
<td>0.390</td>
<td>-0.41 (-0.51 to -0.30) (Fixed); P &lt; 0.00001</td>
<td>(P = 0.09); I² = 66%</td>
</tr>
</tbody>
</table>
Table 6. Secondary outcomes: Comparison 1. Periodontal therapy versus no active intervention/usual care  
(Continued)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Time point</th>
<th>Subgroup</th>
<th>Pooled number of studies</th>
<th>Single studies (unsuitable for pooling)</th>
<th>Control group mean (weighted mean where pooled)</th>
<th>Mean difference (IV, 95% CI; P value)</th>
<th>Heterogeneity (P value; I²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPD</td>
<td>3-4 months</td>
<td>9</td>
<td>1.303</td>
<td></td>
<td>-0.40, 95% CI -0.62 to -0.18 (Random); P &lt; 0.0004</td>
<td>(P &lt; 0.000001); I² = 88%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>4</td>
<td>0.364</td>
<td></td>
<td>-0.34, 95% CI -0.44 to -0.25 (Random); P &lt; 0.00001</td>
<td>(P = 0.23); I² = 30%</td>
<td></td>
</tr>
</tbody>
</table>

BOP = bleeding on probing; CAL = clinical attachment level; CI = confidence interval; GI = gingival index; PI = plaque index; PPD = probing pocket depth

Table 7. Secondary outcomes: Comparison 2. Periodontal therapy versus alternative periodontal therapy

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Time point</th>
<th>Subgroup</th>
<th>Pooled number of studies</th>
<th>Single studies (unsuitable for pooling)</th>
<th>Control group mean (weighted mean where pooled)</th>
<th>Mean difference (IV, 95% CI; P value)</th>
<th>Heterogeneity (P value; I²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BOP</td>
<td>3-4 months</td>
<td>SRP vs alternative mechanical therapy</td>
<td>n/a</td>
<td>Koromantzos 2011</td>
<td>0.597</td>
<td>-0.22 (-0.34, -0.11); P = 0.0001</td>
<td>n/a</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n/a</td>
<td>Chen 2012</td>
<td>0.121</td>
<td>0.01 (-0.03, 0.05); P = 0.53</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Santos 2009</td>
<td>0.119</td>
<td>-0.03 (-0.09, 0.03); P = 0.33</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Santos 2012</td>
<td>0.109</td>
<td>-0.02 (-0.09, 0.04); P = 0.44</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>SRP vs alternative SRP</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SRP + antimicrobial vs SRP</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SRP + antimicrobial vs antimicrobial</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SRP + combined antimicrobials vs SRP + single antimicrobial</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>SRP vs alternative mechanical therapy</td>
<td>n/a</td>
<td>Koromantzos 2011</td>
<td>0.617</td>
<td>-0.24 (-0.35, -0.13); P &lt; 0.0001</td>
<td>n/a</td>
</tr>
<tr>
<td>Comparison</td>
<td>Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>--------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP vs alternative SRP</td>
<td>Chen 2012²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.02 (-0.25, 0.29); P = 0.89</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Santos 2009 ³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.114</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-0.03 (-0.11, 0.04); P = 0.38</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Santos 2012 ⁴</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.102</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-0.03 (-0.11, 0.04); P = 0.37</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + antimicrobial vs SRP</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.116</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.02 (-0.03, 0.07) (Fixed); P = 0.46</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(P = 0.45); I² = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Santos 2009 ³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-0.30 (-0.76, 0.16); P = 0.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Santos 2012 ⁴</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-0.40 (-0.87, 0.07); P = 0.10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + antimicrobial vs SRP</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.51</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-0.23 (-0.48, 0.03) (Random); P = 0.08</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(P = 0.37); I² = 8%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + antimicrobial vs antimicrobial</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yun 2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-0.09 (-0.41, 0.23); P = 0.58</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + antimicrobial (doxycycline) vs SRP + alternative antimicrobial</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grossi 1997⁵</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-0.30 (-0.83, 0.23); P = 0.27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + combined antimicrobials vs SRP + single antimicrobial</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grossi 1997⁶</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-0.13 (-0.45, 0.19); P = 0.42</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Macedo 2014⁷</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.79</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.06 (-0.49, 0.61); P = 0.83</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + statin vs SRP</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pradeep 2013</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5.31</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-1.38 (-1.92, -0.84); P &lt; 0.00001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 months</td>
<td>SRP vs alternative SRP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chen 2012²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.55</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.65 (0.14, 1.16); P = 0.01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Santos 2009 ³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-0.30 (-0.80, 0.20); P = 0.24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 7. Secondary outcomes: Comparison 2. Periodontal therapy versus alternative periodontal therapy  (Continued)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Study</th>
<th>Months</th>
<th>Overview</th>
<th>Effect Size</th>
<th>95% CI</th>
<th>P-value</th>
<th>I²</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRP + antimicrobial vs SRP</td>
<td>Santos 2012</td>
<td>3</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + antimicrobial (doxycycline) vs SRP + alternative antimicrobial</td>
<td>Grossi 1997</td>
<td>4.3</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + combined antimicrobials vs SRP + single antimicrobial</td>
<td>Grossi 1997</td>
<td>4.1</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + bone modifier vs SRP</td>
<td>Rocha 2001</td>
<td>5.2</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + statin vs SRP</td>
<td>Pradeep 2013</td>
<td>4.93</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GI 3–4 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP vs alternative mechanical therapy</td>
<td>Koromantzos 2011</td>
<td>0.562</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + antimicrobial vs SRP</td>
<td></td>
<td>3</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + antimicrobial (doxycycline) vs SRP + alternative antimicrobial</td>
<td>Grossi 1997</td>
<td>0.43</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + combined antimicrobials vs SRP + single antimicrobial</td>
<td>Grossi 1997</td>
<td>0.45</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP + statin vs SRP</td>
<td>Pradeep 2013</td>
<td>1.69</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 months</td>
<td>SRP vs alternative mechanical therapy</td>
<td>n/a</td>
<td>Koromantzos 2011</td>
<td>0.547</td>
<td>-0.32 (-0.40, -0.23); P &lt; 0.0001</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------------</td>
<td>-----</td>
<td>------------------</td>
<td>------</td>
<td>-----------------------------</td>
<td>-----</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + antimicrobial vs SRP</td>
<td>n/a</td>
<td>Skaleric 2004</td>
<td>0.76</td>
<td>-0.16 (-0.40, 0.08); P = 0.20</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + antimicrobial (doxycycline) vs SRP + alternative antimicrobial</td>
<td>n/a</td>
<td>Grossi 1997 5</td>
<td>0.317</td>
<td>-0.00 (-0.12, 0.11); P = 0.94</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + combined antimicrobials vs SRP + single antimicrobial</td>
<td>n/a</td>
<td>Grossi 1997 6</td>
<td>0.392</td>
<td>-0.05 (-0.12, 0.03); P = 0.22</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + statin vs SRP</td>
<td>n/a</td>
<td>Pradeep 2013</td>
<td>1.71</td>
<td>-0.46 (-0.57, -0.35); P &lt; 0.0001</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Santos 2009 3</td>
<td>0.262</td>
<td>0.08 (-0.07, 0.22); P = 0.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Santos 2012 4</td>
<td>0.293</td>
<td>-0.00 (-0.14, 0.14); P = 0.99</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + antimicrobial vs SRP</td>
<td>7</td>
<td>n/a</td>
<td>0.538</td>
<td>0.02 (-0.02, 0.06) (Random); P = 0.39</td>
<td>(P = 0.80); I² = 0%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + antimicrobial vs antimicrobial</td>
<td>n/a</td>
<td>Yun 2007</td>
<td>0.304</td>
<td>-0.15 (-0.15, -0.14); P &lt; 0.0001</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + antimicrobial (doxycycline) vs SRP + alternative antimicrobial</td>
<td>n/a</td>
<td>Grossi 1997 5</td>
<td>0.611</td>
<td>-0.02 (-0.16, 0.12); P = 0.75</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + combined antimicrobials vs SRP + single antimicrobial</td>
<td>n/a</td>
<td>Grossi 1997 6</td>
<td>0.602</td>
<td>-0.04 (-0.13, 0.05); P = 0.43</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Intervention</td>
<td>Outcome</td>
<td>Author(s)</td>
<td>Effect Size</td>
<td>95% CI</td>
<td>p-Value</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>---------</td>
<td>-----------</td>
<td>-------------</td>
<td>--------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + statin vs SRP</td>
<td>n/a</td>
<td>Pradeep 2013</td>
<td>1.12</td>
<td>-0.07 (-0.25, 0.11)</td>
<td>P = 0.45</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP vs alternative SRP</td>
<td>n/a</td>
<td>Chen 2012</td>
<td>0.4</td>
<td>0.05 (-0.07, 0.17)</td>
<td>P = 0.40</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Santos 2009</td>
<td>0.262</td>
<td>0.08 (-0.05, 0.21)</td>
<td>P = 0.24</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Santos 2012</td>
<td>0.27</td>
<td>0.02 (-0.09, 0.14)</td>
<td>P = 0.71</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + antimicrobial vs SRP</td>
<td>2</td>
<td>n/a</td>
<td>0.488</td>
<td>0.09 (0.00, 0.18) (Fixed); P = 0.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + antimicrobial (doxycycline) vs SRP + alternative antimicrobial</td>
<td>n/a</td>
<td>Grossi 1997</td>
<td>0.509</td>
<td>-0.06 (-0.19, 0.07)</td>
<td>P = 0.38</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + combined antimicrobials vs SRP + single antimicrobial</td>
<td>n/a</td>
<td>Grossi 1997</td>
<td>0.487</td>
<td>0.01 (-0.08, 0.10)</td>
<td>P = 0.89</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + antimicrobial vs SRP</td>
<td>9</td>
<td>n/a</td>
<td>2.857</td>
<td>-0.11 (-0.28, 0.05) (Random); P = 0.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + antimicrobial vs antimicrobial</td>
<td>n/a</td>
<td>Yun 2007</td>
<td>3.61</td>
<td>-0.19 (-0.29, -0.09); P = 0.0003</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SRP + antimicrobial (doxycycline) vs SRP + alternative</td>
<td>n/a</td>
<td>Grossi 1997</td>
<td>2.9</td>
<td>0.00 (-0.27, 0.27); P = 1.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 7. Secondary outcomes: Comparison 2. Periodontal therapy versus alternative periodontal therapy  (Continued)

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Study</th>
<th>Year</th>
<th>Effect</th>
<th>95% CI</th>
<th>P value</th>
<th>Effect Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRP + combined antimicrobial vs SRP</td>
<td>Grossi 1997</td>
<td>6</td>
<td>n/a</td>
<td>2.9</td>
<td>-0.20 (-0.37, -0.03); P = 0.02</td>
<td>n/a</td>
</tr>
<tr>
<td></td>
<td>Macedo 2014</td>
<td>7</td>
<td>1.92</td>
<td>-0.10 (-0.43, 0.23); P = 0.55</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>SRP + statin vs SRP</td>
<td>Pradeep 2013</td>
<td>6.38</td>
<td>n/a</td>
<td>-0.86 (-1.42, -0.30); P = 0.003</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>6 months</td>
<td>SRP vs alternative SRP</td>
<td>Chen 2012</td>
<td>2.1</td>
<td>0.08 (-0.11, 0.27); P = 0.40</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Santos 2009</td>
<td>3</td>
<td>2.8</td>
<td>-0.20 (-0.47, 0.07); P = 0.15</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Santos 2012</td>
<td>4</td>
<td>2.7</td>
<td>0.00 (-0.45, 0.45); P = 1.00</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>SRP + antimicrobial vs SRP</td>
<td>n/a</td>
<td>3</td>
<td>2.712</td>
<td>-0.14 (-0.32, 0.05) (Fixed); P = 0.15</td>
<td>(P = 0.006); I² = 80%</td>
<td></td>
</tr>
<tr>
<td>SRP + antimicrobial (doxycycline) vs SRP + alternative antimicrobial</td>
<td>Grossi 1997</td>
<td>5</td>
<td>n/a</td>
<td>2.8</td>
<td>0.00 (-0.27, 0.27); P = 1.00</td>
<td>n/a</td>
</tr>
<tr>
<td>SRP + combined antimicrobials vs SRP + single antimicrobial</td>
<td>Grossi 1997</td>
<td>6</td>
<td>n/a</td>
<td>2.8</td>
<td>-0.15 (-0.34, 0.03); P = 0.10</td>
<td>n/a</td>
</tr>
<tr>
<td>SRP + bone modifier vs SRP</td>
<td>Rocha 2001</td>
<td>3.1</td>
<td>n/a</td>
<td>-0.30 (-0.74, 0.14); P = 0.18</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>SRP + statin vs SRP</td>
<td>Pradeep 2013</td>
<td>6.17</td>
<td>n/a</td>
<td>-1.65 (-2.26, -1.04); P &lt; 0.00001</td>
<td>n/a</td>
<td></td>
</tr>
</tbody>
</table>

BOP = bleeding on probing; CAL = clinical attachment level; CI = confidence interval; GI = gingival index; OHI = oral hygiene instruction; PI = plaque index; PPD = probing pocket depth; SRP = scaling and root planing; vs = versus

1 SRP + OHI vs mechanical therapy (supragingival cleaning) + OHI
2 SRP + subgingival debridement vs SRP + supragingival debridement
3 Immediate SRP + OHI + prophylaxis vs ongoing SRP + OHI + prophylaxis
Immediate SRP + OHI + prophylaxis (incl. subgingival debridement) vs ongoing SRP + OHI + prophylaxis (incl. subgingival debridement)

(Gp A) SRP + water rinse + doxycycline (100 mg daily for 14 days) vs (Gp D) SRP + chlorhexidine (0.12%) + placebo (daily for 14 days)

(Gp B) SRP + chlorhexidine (0.12%) + doxycycline (100 mg daily for 14 days) + (Gp C) SRP + iodine (0.05% povidone iodine) + doxycycline (100 mg daily for 14 days) vs (Gp A) SRP + water rinse + doxycycline (100 mg daily for 14 days) + (Gp D) SRP + chlorhexidine (0.12%) + placebo (daily for 14 days)

SRP + doxycycline (100 mg daily for 14 days) + antimicrobial photodynamic therapy + OHI (x 7) vs SRP + doxycycline (100 mg daily for 14 days) + OHI (x 7)

**APPENDICES**

**Appendix 1. Search strategies**

**The Cochrane Oral Health Group Trials Register search strategy**

From April 2013, searches of the Cochrane Oral Health Group Trials Register were carried out in the Cochrane Register of Studies using the search strategy below:

#1 (diabet* or IDDM OR DMI OR MODY OR DM2 OR NIDDM OR IIDM):ti,ab
#2 periodont*:ti,ab
#3 (#1 and #2) AND (INREGISTER)

Previous searches of the Cochrane Oral Health Group Trials Register were carried out using the Procite software and the search strategy below:

((diabet* or IDDM OR DMI OR MODY OR DM2 OR NIDDM OR IIDM)and periodont*)

**The Cochrane Central Register of Controlled Trials (CENTRAL) search strategy**

#1 MeSH descriptor DIABETES MELLITUS explode all trees
#2 (diabet* in Abstract or diabet* in Record Title)
#3 (dka in All Text or iddm in All Text)
#4 (dmi in Record Title or dmi in Abstract)
#5 (mody in All Text or dm2 in All Text or niddm in All Text)
#6 (iidm in Record Title or iidm in Abstract)
#7 insulin* next secret* next dysfunc* in All Text
#8 (insulin* next resist* in Record Title or insulin* next resist* in Abstract)
#9 ((impaired next glucose next tolerance in All Text or glucose next intoleran* in All Text or insulin* next resist* in Record Title)
and (DM in Record Title or DM in Abstract or DM2 in Record Title or DM2 in Abstract))
#10 ((juvenile* in All Text or child* in All Text or keto* in All Text or labil* in All Text or brittl* in All Text or “early onset” in All Text)
and (diabetes in All Text or DM in All Text or DM1 in All Text))
#11 ("keto* prone" in All Text near/6 diabet* in All Text) or (autoimmun* in All Text near/6 diabet* in All Text) or ("auto immun*” in All Text near/6 diabet* in All Text) or ("sudden onset” in All Text near/6 diabet* in All Text))
#12 (keto* in All Text and (resist* in All Text near/6 diabet* in All Text)) or (nonketo* in All Text near/6 diabet* in All Text) or (non in All Text and (keto* in All Text near/6 diabet* in All Text)) or (adult* in All Text and (onset in All Text near/6 diabet* in All Text)) or (matur* in All Text and (onset in All Text near/6 diabet* in All Text) or (late* in All Text and (onset in All Text near/6 diabet* in All Text)) or (slow* in All Text and (onset in All Text near/6 diabet* in All Text)) or (stabl* in All Text near/6 diabet* in All Text))
#13 MeSH descriptor INSULIN RESISTANCE explode all trees
MEDLINE via OVID search strategy

1. exp Diabetes Mellitus/
2. diabet$.ab,ti.
3. (DKA or IDDM).mp. or DM1.ab,ti. [mp=title, original title, abstract, name of substance word, subject heading word]
4. (MODY or DM2 or NIDDM).mp. or IIIDM.ti,ab. [mp=title, original title, abstract, name of substance word, subject heading word]
5. insulin$ secret$.dysfunc$.ti,ab.
6. insulin$ resist$.ti,ab.
7. ((impaired glucose tolerance or glucose intoleran$ or insulin$ resist$) and (DM or DM2)).ti,ab.
8. insulin$ depend$.mp. or insulin?depend$.ti,ab. [mp=title, original title, abstract, name of substance word, subject heading word]
9. (non insulin$ depend$ or noninsulin$ depend$. or non insulin$ depend$).mp. or non insulin$ depend$.ti,ab. [mp=title, original title, abstract, name of substance word, subject heading word]
10. ("typ$ 1" or typ$ I) adj6 DM).ti,ab.
11. ("typ$ 2" or typ$ II) adj6 DM).ti,ab.
12. ((juvenil$ or child$ or keto$ or labi$ or brittl$ or earl$ onset) adj6 (DM or DM1)).ti,ab.
13. (keto$ prone or autoimmun$ or auto immun$. or sudden onset) adj6 (DM or DM1)).ti,ab.
14. (keto$ resist$ or non keto$ or adult$ onset or matur$ onset or late$ onset or slow onset or stabl$) adj6 (DM or DM2)).ti,ab.
15. exp Insulin Resistance/
16. (insulin$ defic$ adj6 (absolut$ or relativ$)).ti,ab.
17. metabolic$ syndrom$.ti,ab.
18. (syndrom$ X not (fragil$ X or X linked)).ti,ab.
19. (plurimetabolic$ syndrom$ or plurimetabolic$ syndrom$).ti,ab.
20. or/1-19
21. exp Periodontics/
22. exp Periodontal Diseases/
23. exp Preventive Dentistry/
24. exp Dental Care for Chronically Ill/
25. periodont$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
26. Surgical Flaps/
27. surgical flap$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
28. (26 or 27) and periodont$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
29. exp Dental Prophylaxis/
30. (scale$ adj4 polish$).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
31. (scaling adj4 polish$).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
32. ((root$ adj4 planing) or (root$ adj4 plan$)).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
33. (gingivitis or gingiv$a$).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
34. ((tooth adj6 scaling) or (teeth adj6 scaling) or (dental adj6 scaling)).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
35. (((tooth adj6 scale$) or teeth) adj6 scale$).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
36. (((oral adj3 prophylaxis) or dental) adj3 prophylaxis).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
37. Oral Hygiene/
38. Oral Health/
39. (oral hygien$ or oral health$).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
40. or/21-25
41. or/28-40
42. or/40-41
43. 20 and 42
The above subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of the Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10

EMBASE via OVID search strategy
1. exp Diabetes Mellitus/
2. diabet$.ab,ti.
3. (DKA or IDDM).mp. or DMI.ab,ti. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]
4. (MODY or DM2 or NIDDM).mp. or IIDM.ti,ab. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]
5. insulin$ secret$.ti,ab.
6. insulin$ resist$.ti,ab.
7. ((impaired glucose tolerance or glucose intolerance or insulin$ resist$) and (DM or DM2)).ti,ab.

Treatment of periodontal disease for glycaemic control in people with diabetes mellitus (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
8. insulin$ depend$.mp. or insulin?depend$.ti,ab.
9. (non insulin$ depend$ or nonisulin$ depend$.mp. or non insulin?depend$).ti,ab.
10. ("typ$ 1" or typ$ I) adj6 DM).ti,ab.
11. ("typ$ 2" or typ$ II) adj6 DM).ti,ab.
12. ((juvenil$ or child$ or keto$ or labil$ or brittl$ or earl$ onset) adj6 (DM or DM1)).ti,ab.
13. ((keto$ prone or autoimmun$ or auto immun$ or sudden onset) adj6 (DM or DM1)).ti,ab.
14. ((keto$ resist$ or nonketo$ or non keto$ or adult$ onset or matur$ onset or late$ onset or slow onset or stabl$) adj6 (DM or DM2)).ti,ab.
15. exp Insulin Resistance/
16. (insulin$ defic$ adj6 (absolut$ or relativ$)).ti,ab.
17. metabolic$ syndrom$.ti,ab.
18. (syndrom$ X not (fragil$ X or X linked)).ti,ab.
19. (plurimetabolic$ syndrom$ or pluri metabolic$ syndrom$).ti,ab.
20. or/1-19
21. exp Periodontics/
22. exp Periodontal Disease/
23. exp Preventive Dentistry/
24. Dental Care.mp. and Chronic$ ill$
25. periodont$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]
27. exp Dental Prophylaxis/
28. (scale$ adj4 polish$).mp.
29. (scaling adj4 polish$).mp.
30. ((root$ adj4 planing) or (root$ adj4 plan$)).mp.
31. (gingivitis or gingiva$).mp.
32. ((tooth adj6 scaling) or (teeth adj6 scaling) or (dental adj6 scaling)).mp.
33. (((tooth adj6 scale$) or teeth) adj6 scale$).mp.
34. (((oral adj3 prophylaxis) or dental) adj3 prophylaxis).mp.
35. Mouth Hygiene/
36. (oral hygien$ or oral health$).mp.
37. or/21-36
38. 20 and 37

The above subject search was linked to the Cochrane Oral Health Group filter for identifying randomised controlled trials in EMBASE via OVID:
1. random$.ti,ab.
2. factorial$.ti,ab.
3. (crossover$ or cross over$ or cross-over$).ti,ab.
4. placebo$.ti,ab.
5. (doub$ adj blind$).ti,ab.
6. (singl$ adj blind$).ti,ab.
7. assign$.ti,ab.
8. allocate$.ti,ab.
9. volunteer$.ti,ab.
10. CROSSOVER PROCEDURE.sh.
11. DOUBLE-BLIND PROCEDURE.sh.
12. RANDOMIZED CONTROLLED TRIAL.sh.
13. SINGLE BLIND PROCEDURE.sh.
14. or/1-13
15. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
16. 14 NOT 15
CINAHL via EBSCO search strategy

S1 MH "DIABETES MELLITUS+
S2 TI diabet*
S3 AB diabet*
S4 DKA or IDDM or TI DMI or AB DMI
S5 MODY or DM2 or NIDDM or TI IDDM or AB IDDM
S6 TI insulin* secret* dysfunc* or AB insulin* secret* dysfunc*
S7 TI insulin* resist* or AB insulin* resist*
S8 impaired glucose tolerance or glucose intoleran* or insulin* resist*
S9 TI DM or AB DM or TI DM2 or AB DM2
S10 S9 and S8
S11 insulin* depend* or AB insulin* depend* or TI insulin* depend*
S12 non insulin* depend* or nonisulin* depend* or non insulin* depend*
S13 "typ* 1" or "typ* I"
S14 TI DM or AB DM
S15 S14 and S13
S16 "typ* 2" or "typ* II"
S17 S16 and S14
S18 TI DM or AB DM or TI DM1 or AB DM1
S19 juvenil* or child* or keto* or labil* or brittl* or "earl* onset"
S20 S19 and S18
S21 keto* prone or autoimmun* or auto immun* or "sudden onset"
S22 S21 and S18
S23 keto resist* or nonketo* or non keto* or "adult* onset" or matur* or "late* onset" or "slow onset" or stabl*
S24 S23 and S18
S25 MH INSULIN RESISTANCE
S26 insulin* defic*
S27 TI metabolic* syndrom* or AB metabolic* syndrom*
S28 syndrom* X not ( fragil* X or X linked )
S29 TI plurimetabolic* syndrom* or AB plurimetabolic* syndrom* or TI pluri metabolic* syndrom* or AB pluri metabolic* syndrom*
S30 S29 or S28 or S27 or S26 or S25 or S24 or S22 or S20 or S17 or S15 or S12 or S11 or S10 or S7 or S6 or S5 or S4 or S3 or S2 or S1
S31 MH PERIODONTICS or MH PERIODONTAL DISEASES or MH PREVENTIVE DENTISTRY or MH DENTAL CARE FOR CHRONICALLY ILL
S32 periodont*
S33 MH SURGICAL FLAPS or surgical flap*
S34 S33 and S32
S35 MH DENTAL PROPHYLAXIS
S36 scale or scaling and polish
S37 root and plan*
S38 gingivitis or gingiva*
S39 (tooth or teeth or dental) and scal*
S40 (oral or dental) and prophylaxis
S41 MH ORAL HYGIENE or oral hygien* or oral health*
S42 S41 or S40 or S39 or S38 or S37 or S36 or S35 or S34 or S32 or S31
S43 S42 and S30

The above subject search was linked to the Cochrane Oral Health Group filter for identifying controlled trials in CINAHL:
S1 MH Random Assignment
S2 MH Single-blind studies
S3 MH double-blind studies
S4 MH triple-blind studies
S5 MH crossover design

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S6 MH factorial design
S7 multicentre study or multicenter study or multi-centre study or multi-center study
S8 TI random or AB random
S9 TI latin square or AB latin square
S10 TI crossover or AB crossover or TI cross-over or AB cross-over
S11 MH placebos
S12 (singl* or doubl* or trebl* or tripl*) and (blind* or mask*)
S13 MH clinical trials
S14 placebo*
S15 clinical and trial
S16 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15

**LILACS via BIREME Virtual Health Library search strategy**
diabet$ [Palavras]
and periodont$ [Palavras]
The above subject search was linked to the Brazilian Cochrane Centre filter for identifying randomised controlled trials in LILACS:
((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CONTROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw clinic$)) AND NOT ((CT ANIMALS OR MH ANIMALS OR CT RABBITS OR CT MICE OR MH RATS OR MH PRIMATES OR MH DOGS OR MH RABBITS OR MH SWINE) AND NOT (CT HUMAN AND CT ANIMALS)) [Palavras]

**ZETOC Conference Proceedings search strategy**
diabet* AND periodont*

**ISI Web of Knowledge Conference Proceedings search strategy**
diabet* AND periodont*

**US National Institutes of Health Trials Registry (ClinicalTrials.gov) and WHO International Clinical Trials Registry Platform search strategy**
periodontal AND diabetes

**WHAT’S NEW**
Last assessed as up-to-date: 31 December 2014.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 November</td>
<td>New citation required but conclusions have not changed</td>
<td>Review now contains 35 included studies. The previous version (2010) had 7 included studies. New authors involved</td>
</tr>
<tr>
<td>5 November</td>
<td>New search has been performed</td>
<td>Search run up to December 2014</td>
</tr>
</tbody>
</table>
CONTRIBUTIONS OF AUTHORS

Conception/design of the review: Terry C Simpson (TS).
Co-ordination of the review: Jo C Weldon (JW).

Writing the protocol: TS, Ian Needleman (IN), Sarah H Wild (SW), David R Moles (DM), Susan Furness (SF), Edward Mills (EM).
Developing search strategy: Sylvia Bickley (Cochrane OHG), TS.
Running electronic searches: Anne Littlewood (Cochrane OHG).

Communication with authors and organisations: TS, JW, SF, Helen V Worthington (HW).
Screening titles, abstracts and full text papers: TS, SF, HW, JW, Zipporah Iheozor-Ejiofor (ZIE).
Arbiter for inclusion/exclusion of papers: ZIE.
Extracting data: TS, SF, HW, JW, ZIE, IN, DM, Brian Stevenson (BS).
Appraising quality/risk of bias: ZIE, JW.
Inputting numerical data: JW, HW.
Analysis of data: HW, JW.
Risk of bias analysis: ZIE, JW.
Interpretation of data: HW, JW.
Summary of findings tables: ZIE, JW.
Writing the review: TS, JW, ZIE, SF, HW.

2015 update

Edward Mills was not able to be involved in this update. Susan Furness, Zipporah Iheozor-Ejiofor, Brian Stevenson and Jo Weldon were added to the review team.

DECLARATIONS OF INTEREST

Terry C Simpson (TS): none known.

Jo Weldon (JW): none known. JW is salaried member of staff of the Cochrane Oral Health Group.

Helen V Worthington (HW): none known. HW is Co-ordinating Editor of the Cochrane Oral Health Group.

Ian Needleman (IN): none known. IN is an Editor with the Cochrane Oral Health Group.

Sarah H Wild (SW): none known.

David R Moles (DM): none known.

Brian Stevenson (BS): none known.

Susan Furness (SF): none known. SF is an Editor with the Cochrane Oral Health Group.

Zipporah Iheozor-Ejiofor (ZIE): none known. ZIE is salaried member of staff and an Editor with the Cochrane Oral Health Group.
SOURCES OF SUPPORT

Internal sources

• School of Dentistry, The University of Manchester, UK.
• Manchester Academic Health Sciences Centre (MAHSC), UK.
The Cochrane Oral Health Group is supported by MAHSC and the NIHR Manchester Biomedical Research Centre

External sources

• National Institute for Health Research (NIHR), UK.
This project was supported by the NIHR, via Cochrane Infrastructure funding to the Cochrane Oral Health Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health
• Cochrane Oral Health Group Global Alliance, Other.
Through our Global Alliance (http://ohg.cochrane.org/partnerships-alliances), the Cochrane Oral Health Group has received support from: British Association for the Study of Community Dentistry, UK; British Association of Oral Surgeons, UK; British Orthodontic Society, UK; British Society of Paediatric Dentistry, UK; British Society of Periodontology, UK; Canadian Dental Hygienists Association, Canada; Mayo Clinic, USA; National Center for Dental Hygiene Research & Practice, USA; New York University College of Dentistry, USA; and Royal College of Surgeons of Edinburgh, UK

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

For the 2015 update the following amendments have been made to the published protocol for this review.

• The original second objective (to identify whether further research is required in this area and if so, to identify the important research questions and appropriate study designs) and third objective (to investigate the various combinations of therapies used in treating periodontal disease in people with diabetes mellitus) have been removed as they are considered to be consequences of the outcome of the review.

• Periodontal treatment has been defined broadly to include any professionally-delivered intervention designed to reduce periodontal disease, and the criteria for types of interventions amended accordingly.

• Fructosamine has been deleted as an outcome measure because HbA1c is considered a more reliable and widely used measure of glycaemic control. Fructosamine (glycolated albumin) may be used as an indicator of glycaemic control over the previous 2 to 3 weeks in individuals who have atypical haemoglobin (eg sickle cell disease or thalassaemia), which does not form HbA1c.

• The previously vague secondary outcome ‘oral hygiene’ has been reworded as ‘plaque indices.’

• Trials where participants have metabolic syndrome are specifically excluded from this review.

• Diagnostic assessment criteria for diabetes mellitus are now clearly stated.

• Periodontal outcome assessment was removed as a risk of bias domain, as it was agreed that the addition of periodontal outcome assessment misdirected attention from the primary focus (glycaemic control) of this review.
INDEX TERMS

Medical Subject Headings (MeSH)
Dental Scaling; Diabetes Mellitus, Type 1 [*blood]; Diabetes Mellitus, Type 2 [*blood]; Hemoglobin A, Glycosylated [metabolism]; Hyperglycemia [blood; *therapy]; Oral Hygiene; Periodontal Diseases [blood; *therapy]; Randomized Controlled Trials as Topic; Root Planing

MeSH check words
Humans